
<html lang="en"     class="pb-page"  data-request-id="4d2a013d-9aa3-43a6-b9e5-cbd5e80266a4"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2014.57.issue-14;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/jm401719n;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Therapeutic Melting Pot of Never in Mitosis Gene A Related Kinase 2 (Nek2): A Perspective on Nek2 as an Oncology Target and Recent Advancements in Nek2 Small Molecule Inhibition" /></meta><meta name="dc.Creator" content="Brendan  Frett" /></meta><meta name="dc.Creator" content="Robert V.  Brown" /></meta><meta name="dc.Creator" content="Mingliang  Ma" /></meta><meta name="dc.Creator" content="Wenhao  Hu" /></meta><meta name="dc.Creator" content="Haiyong  Han" /></meta><meta name="dc.Creator" content="Hong-yu  Li" /></meta><meta name="dc.Description" content="The global incidence of cancer is on the rise, and within the next decade, the disease is expected to become the leading cause of death worldwide. Forthcoming strategies used to treat cancers focus..." /></meta><meta name="Description" content="The global incidence of cancer is on the rise, and within the next decade, the disease is expected to become the leading cause of death worldwide. Forthcoming strategies used to treat cancers focus..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 25, 2014" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm401719n" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2014 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm401719n" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm401719n" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm401719n" /></link>
        
    
    

<title>Therapeutic Melting Pot of Never in Mitosis Gene A Related Kinase 2 (Nek2): A Perspective on Nek2 as an Oncology Target and Recent Advancements in Nek2 Small Molecule Inhibition | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm401719n" /></meta><meta property="og:title" content="Therapeutic Melting Pot of Never in Mitosis Gene A Related Kinase 2 (Nek2): A Perspective on Nek2 as an Oncology Target and Recent Advancements in Nek2 Small Molecule Inhibition" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0009.jpeg" /></meta><meta property="og:description" content="The global incidence of cancer is on the rise, and within the next decade, the disease is expected to become the leading cause of death worldwide. Forthcoming strategies used to treat cancers focus on the design and implementation of multidrug therapies to target complementary cancer specific pathways. A more direct means by which this multitargeted approach can be achieved is by identifying and targeting interpathway regulatory factors. Recent advances in understanding Nek2 (NIMA related kinase 2) biology suggest that the kinase potentially represents a multifaceted therapeutic target. In this regard, pharmacologic modulation of Nek2 with a single agent may effect several mechanisms important for tumor growth, survival, progression, and metastasis. We herein review the development of Nek2 as an oncology target and provide a succinct chronology of drug discovery campaigns focused on targeting Nek2." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm401719n"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm401719n">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm401719n&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm401719n&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm401719n&amp;href=/doi/10.1021/jm401719n" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2014</span><span class="cit-fg-volume">, 57</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 5835-5844</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/57/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/jm4017625" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Therapeutic Melting Pot of Never in Mitosis Gene A Related Kinase 2 (Nek2): A Perspective on Nek2 as an Oncology Target and Recent Advancements in Nek2 Small Molecule Inhibition</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brendan++Frett">Brendan Frett</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Robert+V.++Brown">Robert V. Brown</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mingliang++Ma">Mingliang Ma</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Wenhao++Hu">Wenhao Hu</a></span><span class="author-xref-symbol author-aff-symbol"><sup>⊥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Haiyong++Han">Haiyong Han</a></span><span class="author-xref-symbol author-aff-symbol"><sup>#</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong-yu++Li">Hong-yu Li</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">†</span> <span class="aff-text">Department of Pharmacoloy and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona 85721, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">‡</span> <span class="aff-text">BIO5 Oro Valley, The University of Arizona, 1580 Hanley Boulevard, Oro Valley, Arizona 85737, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">§</span> <span class="aff-text">The University of Arizona Cancer Center, 1515 N. Campbell Avenue, Tucson, Arizona 85724, United States</span></div><div class="aff-info" id="aff4"><span class="aff-symbol">∥</span> <span class="aff-text">BIO5, The University of Arizona, 1657 E. Helen Street, Tucson, Arizona 85721, United States</span></div><div class="aff-info" id="aff5"><span class="aff-symbol">⊥</span> <span class="aff-text">Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, East China Normal University, Shanghai, 200241, China</span></div><div class="aff-info" id="aff6"><span class="aff-symbol">#</span> <span class="aff-text">Clincial Translational Research Division, Translational Genomics Research Institute, 445 N. Fifth Street, Phoenix, Arizona 85004, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 520-626-0083. E-mail: <a href="/cdn-cgi/l/email-protection#a4cccbcac3ddd1c8cde4d4ccc5d6c9c5c7dd8ac5d6cddecbcac58ac1c0d1"><span class="__cf_email__" data-cfemail="a8c0c7c6cfd1ddc4c1e8d8c0c9dac5c9cbd186c9dac1d2c7c6c986cdccdd">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm401719n&amp;href=/doi/10.1021%2Fjm401719n" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2014</span></span><span class="cit-volume">, 57</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 5835–5844</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 11, 2014</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>7 November 2013</li><li><span class="item_label"><b>Published</b> online</span>25 February 2014</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 July 2014</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm401719n" title="DOI URL">https://doi.org/10.1021/jm401719n</a></div><div class="article_header-article-copyright"><strong>Copyright © 2014 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5835%26pageCount%3D10%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBrendan%2BFrett%252C%2BRobert%2BV.%2BBrown%252C%2BMingliang%2BMa%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D57%26issueNum%3D14%26contentID%3Djm401719n%26title%3DTherapeutic%2BMelting%2BPot%2Bof%2BNever%2Bin%2BMitosis%2BGene%2BA%2BRelated%2BKinase%2B2%2B%2528Nek2%2529%253A%2BA%2BPerspective%2Bon%2BNek2%2Bas%2Ban%2BOncology%2BTarget%2Band%2BRecent%2BAdvancements%2Bin%2BNek2%2BSmall%2BMolecule%2BInhibition%26numPages%3D10%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5844%26publicationDate%3DJuly%2B2014">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm401719n"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2091</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">12</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm401719n" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Therapeutic Melting Pot of Never in Mitosis Gene A Related Kinase 2 (Nek2): A Perspective on Nek2 as an Oncology Target and Recent Advancements in Nek2 Small Molecule Inhibition&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Brendan&quot;,&quot;last_name&quot;:&quot;Frett&quot;},{&quot;first_name&quot;:&quot;Robert&quot;,&quot;last_name&quot;:&quot;V. Brown&quot;},{&quot;first_name&quot;:&quot;Mingliang&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Wenhao&quot;,&quot;last_name&quot;:&quot;Hu&quot;},{&quot;first_name&quot;:&quot;Haiyong&quot;,&quot;last_name&quot;:&quot;Han&quot;},{&quot;first_name&quot;:&quot;Hong-yu&quot;,&quot;last_name&quot;:&quot;Li&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2014&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;25&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;57&quot;,&quot;pages&quot;:&quot;5835-5844&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm401719n&quot;},&quot;abstract&quot;:&quot;The global incidence of cancer is on the rise, and within the next decade, the disease is expected to become the leading cause of death worldwide. Forthcoming strategies used to treat cancers focus on the design and implementation of multidrug therapies to target complementary cancer specific pathways. A more direct means by which this multitargeted approach can be achieved is by identifying and targeting interpathway regulatory factors. Recent advances in understanding Nek2 (NIMA related kinase 2) biology suggest that the kinase potentially represents a multifaceted therapeutic target. In this regard, pharmacologic modulation of Nek2 with a single agent may effect several mechanisms important for tumor growth, survival, progression, and metastasis. We herein review the development of Nek2 as an oncology target and provide a succinct chronology of drug discovery campaigns focused on targeting Nek2.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401719n&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401719n" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401719n&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401719n" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm401719n&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401719n" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm401719n&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm401719n&amp;href=/doi/10.1021/jm401719n" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm401719n" /></input><a href="/doi/pdf/10.1021/jm401719n" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm401719n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm401719n%26sid%3Dliteratum%253Aachs%26pmid%3D24517277%26genre%3Darticle%26aulast%3DFrett%26date%3D2014%26atitle%3DTherapeutic%2BMelting%2BPot%2Bof%2BNever%2Bin%2BMitosis%2BGene%2BA%2BRelated%2BKinase%2B2%2B%2528Nek2%2529%253A%2BA%2BPerspective%2Bon%2BNek2%2Bas%2Ban%2BOncology%2BTarget%2Band%2BRecent%2BAdvancements%2Bin%2BNek2%2BSmall%2BMolecule%2BInhibition%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D57%26issue%3D14%26spage%3D5835%26epage%3D5844%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=290782" title="Chemotherapy">Chemotherapy</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/57/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jmcmar.2014.57.issue-14/production/jmcmar.2014.57.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0009.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The global incidence of cancer is on the rise, and within the next decade, the disease is expected to become the leading cause of death worldwide. Forthcoming strategies used to treat cancers focus on the design and implementation of multidrug therapies to target complementary cancer specific pathways. A more direct means by which this multitargeted approach can be achieved is by identifying and targeting interpathway regulatory factors. Recent advances in understanding Nek2 (NIMA related kinase 2) biology suggest that the kinase potentially represents a multifaceted therapeutic target. In this regard, pharmacologic modulation of Nek2 with a single agent may effect several mechanisms important for tumor growth, survival, progression, and metastasis. We herein review the development of Nek2 as an oncology target and provide a succinct chronology of drug discovery campaigns focused on targeting Nek2.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div id="ac_i2" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i2"> </h2><div class="NLM_p">In the next two decades, global cancer incidence is expected to double from 12.7 million cases in 2008 to an estimated 21.4 million by 2030.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a> Many clinical therapies predate the 40+ year war on cancer, and modern therapeutics often have limited efficacy in aggressive drug refractory malignancies. Additional complicating factors, such as aberrant activity of undruggable oncogenic factors, further burden the success of treatment. Personalized medicine has been implemented to more efficiently and effectively diagnose and treat disease. However, the era of personalized medicine is in its infancy, and without the discovery of novel targets and therapeutics the challenges of successfully tackling a surge in cancer incidence are enormous. To meet the projected demand, innovative methods for treating cancers must be investigated.</div><div class="NLM_p">Current drugs used for the treatment of cancer fall into one of two main classes, chemotherapy or targeted therapy, based on target specificity. Chemotherapy comprises three main drug types: antimetabolites,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> alkylating agents,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and cell cycle inhibitors.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5, 6)</a> Though chemotherapy remains the dominant therapy in the clinical setting, design of new chemotherapies represent an outdated approach for identifying more effective anticancer drugs. Moreover, because of the heterogeneous nature of tumors,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> chemotherapies select for and promote drug refractory malignancies.</div><div class="NLM_p">The enhanced understanding of cancer biology has given rise to the second class of cancer therapies termed targeted therapeutics.<a onclick="showRef(event, 'ref8 ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref8 ref9 ref10">(8-10)</a> Targeted therapeutics are designed to specifically act on aberrant cancer signaling pathways that are unique to a particular tumor. Multiple generations of inhibitors have achieved profound target specificity effectively limiting off target toxicities. The success of target-based therapeutics was believed to eliminate the need for nonspecific agents; however, to date, this therapeutic goal remains unmet. Akin to chemotherapies, the targeted therapeutic class suffers from transient clinical efficacy, as treatment selects for drug refractory malignancies.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11, 12)</a></div><div class="NLM_p">The evolution of drugs for the treatment of cancer has begun to produce more successes in large part due to the combination of both therapeutic classes. On the basis of these successes, a variety of therapeutic combinations were investigated for the treatment of pervasive malignancies.<a onclick="showRef(event, 'ref13 ref14 ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16">(13-16)</a> Drug–drug interaction complications from this treatment strategy can produce undesirable toxicity.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Toxicity issues from drug–drug interactions have caused a push for the discovery and development of novel therapeutics that can bridge the two main drug classes. The goal of identifying one agent that can produce the benefit of combination therapy without the liability of a drug–drug interaction will require strategic analysis of molecular signaling pathways to identify key interpathway regulatory factors as drug targets.</div><div class="NLM_p last">Recent advances in understanding the biology of Nek2 (NIMA related kinase 2), a serine/threonine kinase, suggest that its pharmacological inhibition has multifaceted therapeutic potential in bridging targeted and nontargeted avenues of chemotherapy. Nek2 is involved in regulating four independent mechanisms of tumor biology: (1) cell-cycle regulation, (2) cell survival, (3) chemosensitization, and (4) metastasis. Many solid tumors overexpress Nek2,<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18-20)</a> and Nek2 RNAi inhibition results in decreased proliferation in numerous cancer models.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21, 22)</a> Additionally, overexpression of Nek2 promotes active Akt,<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a> a potent and critical oncogene for a variety of malignancies (reviewed by Vivanco et al.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a>). By contributing to aberrant Akt activity, Nek2 represents a novel target for blocking a variety of tumor-specific pathways.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a> Furthermore, recent studies have demonstrated that inhibition of Nek2 has an important role in chemoresensitization of drug refractory tumors by down-regulating the expression of ABC (ATP binding cassette) efflux transporters.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The ABC family of efflux transporters has been extensively studied, as increased expression of ABCs causes chemoresistance and inhibition results in chemoresensitization (reviewed by Gottesman et al.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a>). Nek2 has also been implemented in up-regulation Wnt/Wg signaling, altering cell adhesion markers, increasing Jnk (c-Jun N-terminal kinase) activity, and altering β-catenin signaling, which can increase tumor migration, metastasis, and survival.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Cumulatively, these findings identify the Nek2 kinase as an oncology target that is uniquely positioned in tumor biology such that blocking Nek2 can integrate the effects of both targeted and nontargeted treatment avenues. Herein, we review the development of Nek2 as an oncology target and associated inhibitor discovery campaigns.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Nek2 Overview</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87444" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87444" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The Nek family of serine/threonine kinases is essential for normal mitosis and cell cycle regulation.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27, 28)</a> The first characterized member of the Nek family was never in mitosis <i>Aspergillus</i> (NIMA) from the species <i>Aspergillus nidulans</i>, which has shown importance in cell division.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> The closest related mammalian isoform to NIMA is Nek2.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> In mammals, Nek2 is responsible for initiating centrosomal separation at the G2/M stage of the cell cycle.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> To accomplish separation, Nek2 phosphorylates β-catenin,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> ninein-like protein (NIP),<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> and centrosomal Nek2-associated protein 1 (C-Nap1).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Because of the very specific role in cell cycle progression, Nek2 is tightly regulated at the transcriptional and post-translational levels. Specifically, Nek2 is expressed during the S and G2 phases of the cell cycle, and at the post-translational level activity is modulated by protein phosphatase 1 (PP1).<a onclick="showRef(event, 'ref24 ref29 ref34'); return false;" href="javascript:void(0);" class="ref ref24 ref29 ref34">(24, 29, 34)</a> Interestingly, PP1 is also a critical regulator of Akt.<a onclick="showRef(event, 'ref24 ref29 ref34'); return false;" href="javascript:void(0);" class="ref ref24 ref29 ref34">(24, 29, 34)</a> In malignancies, elevated levels of Nek2 result in centrosomal separation, which can lead to chromosomal instability (CIN), tumor promotion, and progression.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> From a regulatory standpoint, elevated levels of Nek2 overwhelm the endogenous regulatory capacity of PP1, resulting in aberrant activity of Akt.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Conceptually, overexpressing Nek2 in normal cells can lead to a tumorigenic intracellular environment.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Nek2 and Cancer</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51433" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51433" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The contributions of aberrant Nek2 activity to the development and maintenance of an oncogenic phenotype have only been resolved in the past decade. The first report of aberrant expression of Nek2 in cancer came from a gene expression array querying over 1700 cancer associated genes expressed in pediatric solid tumors.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> In this study, Nek2 and factors that promote Nek2 activity were found to be co-up-regulated in a rare form of cancer called Ewing’s sarcoma.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> On the basis of the findings, aberrant Nek2 activity was correlated to the development and progression of Ewing’s sarcoma. Further investigation in follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) identified a significant elevation of Nek2 levels at both the transcriptional and protein level.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Seminal findings from the study indicate that aberrant expression and activity of Nek2 drive the progression and transformation of lymphomas that ultimately produce a more aggressive disease.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> A hallmark of lymphomas is aneuploidy and chromosomal rearrangement,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(37)</a> though speculative, aberrant Nek2 activity likely contributes to the defining characteristics of lymphoma. Significantly, Hayward and colleagues later defined a role for Nek2 in driving aneuploidy and centrosome amplification in human breast epithelial cells.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> Gene expression analysis identified elevated levels of Nek2 transcripts in a variety of malignancies that harbor genetic abnormalities such as leukemia, cervical, ovarian, breast, and prostate cancers. In solid tumors, up-regulated Nek2 was identified in both primary and metastatic lesions, suggesting that up-regulation can be an early oncogenic event that leads to promotion and progression of disease.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><div class="NLM_p">Early studies investigating the therapeutic value of targeting Nek2 utilized RNAi in cholangiocarcinoma, a rare inoperable cancer of the liver.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(38)</a> RNAi was utilized to specifically target and attenuate aberrantly expressed Nek2 in primary cultures of the tumor as well as primary human fibroblasts.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(38)</a> These studies demonstrated that Nek2 targeted therapies have selectivity for cancer, as suppressed proliferation relative to Nek2 RNAi was only observed in the cholangiocarcinoma.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(38)</a> In a similar RNAi based study, the efficacy of Nek2 targeted therapy was investigated in xenograft models of breast cancer using triple negative, MDA-MB-231, or estrogen receptor (ER) positive MCF7 breast cancer cell lines.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(39)</a> Inhibition of Nek2 by RNAi resulted in a statistically significant response in xenografts of both MDA-MB-231 and MCF7.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(39)</a> Results indicated that targeting Nek2 in breast cancer displays efficacy in reducing tumor growth independent of ER status. Another study identified that Nek2 is important for tumor growth at both primary and secondary breast cancer sites and depletion of Nek2 caused cell death from excessive aneuploidy.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(40)</a> Further, Nek2 was found to be important for driving the growth of breast cancer metastases in the lung.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(40)</a> The findings suggest that blocking oncogenic Nek2 in vivo is efficacious at reducing the proliferation of Nek2 mutant tumors and validates Nek2 as an oncogene.</div><div class="NLM_p last">In another study, deliberate overexpression of Nek2 in <i>Drosophila melanogaster</i> led to an up-regulation in Wnt/Wg signaling and an alteration in Rho1, Rac1, and E-cadherin cell migration markers.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Also, there was an increase in the activation of the Akt and Jnk pathways, which can promote growth and survival.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> β-Catenin levels were found to be reduced at the cell–cell adherens junction complexes with increased signaling around the nucleus, indicative of an invasive phenotype.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> As such, Nek2 was found to be important in the process of tumor migration, metastasis, and survival.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Nek2 enables tumor progression beyond promoting chromosomal instability (CIN) through the activation of a variety of tumor enabling pathways.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i5">Nek2 and Drug Resistance</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77705" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77705" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Drug efflux is an extensive, complicating factor that limits the therapeutic window for many cancer therapeutics and plays an essential role in increasing drug resistance in a variety of malignancies.<a onclick="showRef(event, 'ref1 ref2 ref24 ref42 ref43 ref44 ref45 ref46'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref24 ref42 ref43 ref44 ref45 ref46">(1, 2, 24, 41-45)</a> The Nek2 kinase has been identified as a critical player in increasing drug resistance by causing an increase in ABC mediated drug efflux.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Studies using RNAi to knock down Nek2 transcripts have linked the kinase to ABC expression and chemoresensitization.<a onclick="showRef(event, 'ref24 ref42'); return false;" href="javascript:void(0);" class="ref ref24 ref42">(24, 41)</a> Specifically, overexpression of Nek2 in the ARP-1 multiple myeloma cell line causes reduced efficacy of bortezomib, doxorubicin, and etoposide.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Zhou et al. demonstrated chemoresensitization to chemotherapies using tet-inducible Nek2 RNAi in a xenograft model system.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Seminal findings demonstrate Nek2 RNAi resensitizes ARP-1 cells to the aforementioned chemotherapies.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Similarly, knocking down Nek2 by RNAi resensitizes the breast cancer cell lines MDA-MB-231 and MDA-MB-468 to doxorubicin and paclitaxel.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(41)</a></div><div class="NLM_p">The proposed mechanism for Nek2 induced drug resistance relies on the deregulation of the phosphatase, PP1. Nek2 contains a binding domain for PP1, which dephosphorylates the activated form of Nek2 to control catalytic activity.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(46)</a> PP1 is also responsible for regulating Akt by dephosphorylating Akt at Thr-450.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(47)</a> As levels of Nek2 rise, the regulatory capacity of PP1 is overcome by an excess of activated Nek2, which results in aberrant activation of Akt, leading to an up-regulation in expression of ABC genes (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>). Supporting evidence for the proposed Nek2-PP1-Akt regulatory model comes from Nek2 inhibition studies that show diminished transcripts and protein levels for both multidrug resistance-associated protein 1 (ABCC1) and breast cancer resistant protein (ABCG2).<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> The proposed Nek2-PP1-Akt regulatory model implicates the kinase in driving drug resistance. Moreover, evidence presented in these studies suggests that blocking the Nek2 oncogene can restore and enhance chemotherapy efficacy.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Protein phosphatase 1 (PP1) signaling axis regulates both Nek2 and Akt in a normal cell. (B) In a tumor environment, increased Nek2 expression disrupts the PP1 signaling axis, leading to more active Akt, which drives ABC mediated drug resistance.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">Nek2: Therapeutic Impact and Implications</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72425" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72425" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Nek2 has been preliminarily validated as a fruitful drug target for effecting oncogenic pathways that drive cell division, Akt regulation, ABC mediated drug resistance, and metastasis in a diverse set of solid and liquid tumors (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref20 ref23 ref24 ref36 ref38 ref39 ref40 ref41 ref42 ref49'); return false;" href="javascript:void(0);" class="ref ref20 ref23 ref24 ref36 ref38 ref39 ref40 ref41 ref42 ref49">(20, 23, 24, 36, 37-41, 48)</a> A majority of all studies have been completed with RNAi knockdown or Nek2 knockin models. RNAi based studies do not necessarily recapitulate the effects observed with small molecule inhibition. Extensive Nek2 target validation utilizing biological models has provided incentive for the development of selective Nek2 small molecules. The small molecules can serve as a tool to further define Nek2 biology and to progress Nek2 as a therapeutic target.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Aberrant Nek2 activity causes an increase in Akt activity, cell division, drug resistance, and metastasis. Inhibiting the Nek2 oncogene can block Akt, reduce tumor cell proliferation, increase chemotherapy sensitivity, and lower the rate of metastasis. Crystal structure data were obtained from Westood et al.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i7">Nek2 Inhibitor Design and Development</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16186" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16186" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The concept of targeting Nek2 for chemotherapy treatment is a relatively new idea, since the role of Nek2 in tumor biology has only recently been described.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Development of the first Nek2 inhibitor relied on the modification of sunitinib (SU11652, <b>1</b>)<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(49, 50)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>A), which is a pan tyrosine kinase inhibitor with market approval for renal cell carcinomas (RCC) and gastrointestinal stromal tumors (GISTs). Design of the Nek2 inhibitor was geared toward the modification of compound <b>1</b> into an irreversible inhibitor through the strategic introduction of an electrophilic moiety (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(50)</a> Inhibitors were constructed to covalently engage a cysteine residue adjacent to the hinge of the kinase, which dramatically increased inhibitor potency (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>B).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(50)</a> Only 11 kinases in the kinome are known to have a cysteine residue in a similar location,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(50)</a> and this suggested a possible fine-tuning of activity to yield highly selective Nek2 inhibitors.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Evolution from compound <b>1</b> to compound <b>3</b>, a Nek2 selective irreversible inhibitor. (B) (1) Design strategy of a selective Nek2 covalent inhibitor and (2) compound <b>3</b> computationally modeled in the Nek2 kinase. The alkyne moiety is in proximity to Cys22 for covalent modification of Nek2. The imidazole moiety provides Nek2 selectivity. Computational binding experiments were completed using AutoDock Vina,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(58)</a> and the Nek2 crystal structure was obtained from Innocenti et al.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(55)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The most potent Nek2 covalent inhibitor identified, compound <b>2</b><a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(50)</a> (IC<sub>50</sub> < 6 nM), had no selectivity for cyclin dependent kinase 1 (Cdk1), and as such, cells treated rapidly exited mitosis.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(50)</a> The lack of selectivity obscures biological effects, and therefore, further design strategies were employed to mitigate selectivity issues. Compound design was improved by strategically introducing an ethyl and methyl group and changing the alkylating moiety to generate compound <b>3</b><a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(50)</a> that had >25 times selectivity against Cdk1. The selective compound <b>3</b> was >130 times less active on Nek2 (IC<sub>50</sub> = 770 nM) (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). Compound <b>3</b> was able to acutely inhibit Nek2 in vitro without significantly impacting chromosome congression, the spindle assembly checkpoint, bipolar spindle assembly, and mitotic entry.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(50)</a> Therefore, compound <b>3</b> was selective for Nek2 and did not have substantial activity on other cell-cycle kinases.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(50)</a> Because of the selectivity profile, compound <b>3</b> possesses characteristics that are useful for determining the biological roles of Nek2.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(50)</a> Identification of small molecule tools with limited off target activity will be required for progressing Nek2 target validation beyond RNAi knockdown experiments.</div><div class="NLM_p">Noncovalent Nek2 inhibition has been achieved with compound <b>4</b>,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(51)</a> a predecessor to the GlaxoSmithKline polo-like kinase inhibitor (Plk1) GSK461364 (<b>4a)</b><a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(51)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a> and Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>C).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(51)</a> The compound displayed excellent activity in colon (COLO205, IC<sub>50</sub> = 5 nM), lung (A549, IC<sub>50</sub> = 11 nM), breast (MX-1, IC<sub>50</sub> = 9 nM), and ovarian (SKOV-3, IC<sub>50</sub> = 11 nM) tumor cell lines.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(51)</a> Although the inhibitor achieved activity on Nek2 (IC<sub>50</sub> = 21 nM), inhibition was greater on Plk1 (IC<sub>50</sub> = 2 nM).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(51)</a> Because of the selectivity issue, the amount of efficacy originating from inhibiting Nek2 could not be identified. In a phase I clinical trial, compound <b>4a</b> caused a high incidence (20%) of venous thromboembolism (VTE), and no phase II data exist on compound <b>4a</b>.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(52)</a> Hence, Plk1 activity is likely not well tolerated in patients, despite prolonging stable disease in 15% of individuals on the study.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(52)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Development of compound <b>8</b> from compound <b>4</b> and HTS hit <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In another example of Nek2 inhibitor design, high throughput screening (HTS) identified a pyrazine-based scaffold <b>5</b><a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(53)</a> with Nek2 inhibitory activity (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(53)</a> Diversification efforts off the HTS hit commenced, and a nonliner Nek2 structure–activity relationship (SAR) was identified. Further SAR based studies identified the pyrazine moiety as the warhead of the compound. Molecular modeling revealed that the pyrazine forms two hydrogen bonds on the hinge of Nek2.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(53)</a> Further optimization of the pyrazine scaffold proceeded resulting in compounds that bound to a novel, inactive form of Nek2.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(53)</a> Specifically, compound <b>7</b><a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(53)</a> promoted a Nek2 conformational change where Tyr70 was recruited to a hydrogen bond network with the carboxylic acid moiety of the compound (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>). Presumably, this unique attribute is related to the flexibility of the compound as other more rigid compounds do not adopt similar binding modalities.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(53)</a> As such, the conformational change was not identified with compound <b>9</b><a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(53)</a> because of the rigidity of the structure (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(53)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Induced Nek2 conformational change. Adapted from Whelligan et al.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(53)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Despite the novelty of an induced-fit binding mode, strong geometric constraints at the ATP binding site (Phe148 and Met86) further complicate Nek2 inhibitor design.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(53)</a> Therefore, the majority of inhibitors based on the pyrazine scaffold had micromolar activity, while low nanomolar activity was never achieved.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(53)</a> Interestingly, the Nek2 ATP binding site has shared functionality with Plk1, which enables Nek2 chemotypes to have activity on Plk1 creating a problematic situation for selectivity (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(53)</a></div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Nek2 (orange) and Plk1 (blue) 3D structure alignment. Key residues within the ATP binding pocket have been highlighted. Arg136 on Plk1 provides an avenue for the development of Nek2 selective inhibitors. The structure alignment was completed with CLICK: Topology Independent Comparison of Biomolecular 3D Structures. The Nek2 crystal structure was obtained from Innocenti et al.,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(55)</a> and the Plk1 crystal structure was obtained from Nie et al.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(59)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To identify a potent, Plk1 selective Nek2 inhibitor, work shifted back to compound <b>4</b> in an effort to abrogate the Plk1 profile.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(54)</a> Compound <b>4</b> has a thiophene linker bridging the hinge heterocycle with the amide and chiral ether (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Remarkably, simply substituting the thiophene linker to a benzene linker significantly reduced activity on Plk1.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(54)</a> Exclusive Nek2 selectivity was achieved by moving the solubilizing group on the benzimidazole to the 5 position, yielding compound <b>6</b><a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(54)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a> and Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>D).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(54)</a> The strategic placement of the solubilizing group at the 5 position of benzimidazole creates Nek2 specificity relative to Plk1 because of steric clash with Plk1-Arg136, a bulky amino acid residue not encountered at the same position in Nek2 (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>).<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(54)</a> Therefore, by a change of the thiophene linker to benzene and the benzimidazole substitution to the 5 position, compounds with upward of 150 times selectivity for Nek2 were generated. Unlike the pyrazine-based scaffold, Nek2 inhibitors derived from benzimidazole achieved submicromolar activity and have a high degree of Nek2 selectivity.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(54)</a></div><div class="NLM_p">Perhaps the most successful campaign to develop a selective Nek2 inhibitor relied on the combination of the pyrazine scaffold with the benzimidazole scaffold to generate the hybrid compound <b>8</b><a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(55)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). Through SAR studies, an aminopyridine warhead was found to be superior to pyrazine, and the phenyl ring was substituted for an alkene to lower the molecular weight of the final compound.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(55)</a> Therefore, optimal Nek2 potency and selectivity were achieved with a significant optimization in ligand efficiency (IC<sub>50</sub> = 22 nM, >100 times Plk1 selectivity). Against a panel of cell cycle kinases and other important kinases, there was good selectivity for Nek2.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(55)</a> However, compound <b>8</b> had only 3 times Nek2 selectivity against GSK3β (glycogen synthase 3β), yet the narrow selectivity window was found to be acceptable because of good global kinase selectivity.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(55)</a> Like Plk1, GSK3β should be of similar concern for the design and development of future selective Nek2 inhibitors. Potent, selective compounds were progressed into cell-based assays, and the compounds were evaluated for Nek2 inhibition by monitoring the amount of C-Nap1 (centrosomal Nek2-associated protein 1) phosphorylation. Nek2 phosphorylates C-Nap1 to induce centrosome separation,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> and the lead inhibitor blocked Nek2 activity on C-Nap1 with submicromolar activity (IC<sub>50</sub> = 0.8 μM).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(55)</a> The activity further translated into growth inhibition observed in a panel of cancer cell lines: US02 (GI<sub>50</sub> = 0.48–2.92 μM), MDA-MB-231 (GI<sub>50</sub> = 0.95–7.25 μM), HeLa (GI<sub>50</sub> = 0.14–1.20 μM), and MCF7 (GI<sub>50</sub> = 0.22–5.42 μM).<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(55)</a> The developed inhibitors were able to preliminarily support RNAi knockdown studies by exhibiting activity in a variety of tumor cell lines. Because of the selectivity and potency of compound <b>8</b>, the compound was found to serve as an efficient tool to further define Nek2 biology.</div><div class="NLM_p">In a novel, orthogonal approach to identify a Nek2 inhibitor, epidermal growth factor receptor (EGFR) inhibitors, such as pelitinib (EKB-569, <b>10</b>)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> and neratinib (HKI-272, <b>11</b>)<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>), were found to have activity on the Nek2 kinase.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Compound <b>10</b> achieved a 661 nM IC<sub>50</sub> value on Nek2, while compound <b>11</b> achieved a 274 nM IC<sub>50</sub>.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> On EGFR, compounds <b>10</b> and <b>11</b> have IC<sub>50</sub> values of 38.5 <a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(56)</a> and 92 nM,<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(57)</a> respectively. Because Nek2 can promote metastasis by cooperating with mitogen-activated protein kinase (MAPK) and EGFR singling,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> identifying an inhibitor to simultaneously block the EGFR/MAPK cascade as well as Nek2 activity represents an innovative approach to targeting cancers where EGFR and Nek2 are both driving disease progression.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> By use of compound <b>10</b>, the inhibitor was found to block a Nek2 dependent increase in cytosolic β-catenin (nonmetastatic phenotype) and block Jnk signaling. Compound <b>10</b> also partially restored normal function of cell migration markers and reduced cell migratory phenotypes.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Lapatinib, an EGFR inhibitor without strong Nek2 activity, did not have a significant impact on Nek2 driven phenotypes.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The study displayed that simultaneous inhibition of Nek2 and EGFR synergize to increase efficacy in Nek2/EGFR driven tumors.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> The full extent of the synergy and dual inhibition on other receptor tyrosine kinases (RTKs) needs to be further investigated to better establish an understanding of Nek2/RTK interplay.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Novel Nek2/EGFR dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Proposed four-part Nek2 selective pharmacophore, composed of (1) solubilizing group, (2) hinge warhead, (3) aryl linker, and (4) glycine pocket moiety. (B) Crystal structure of compound <b>11</b> bound to the Nek2 kinase.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(55)</a> Key residues within the ATP active site are highlighted. (C) Computational binding of compound <b>4</b> with Nek2. (D) Computational binding of compound <b>6</b> with Nek2. (E) Molecular landscape of the Nek2 kinase. Crucial regions have been highlighted to aid in the design of future inhibitors. Computational binding experiments were completed using AutoDock Vina,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(58)</a> and the Nek2 crystal structure was obtained from Innocenti et al.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(55)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Considerable development on small molecules that can inhibit Nek2 has been completed. Both kinase selectivity and Nek2 potency were achieved by optimizing regions of compound <b>4</b> for Nek2 activity. In general, a selective Nek2 noncovalent pharmacophore is composed of four different regions: (1) solubilizing group, (2) hinge warhead, (3) aryl linker, and (4) glycine pocket moiety (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>A). Also, key areas of the Nek2 kinase can be strategically exploited to develop potent and selective inhibitors (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>B–E). Significant work has been completed to improve Nek2 activity at the biochemical level,<a onclick="showRef(event, 'ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref54 ref55 ref56">(53-55)</a> yet thoroughly validating RNAi knockdown studies with selective Nek2 inhibitors still needs much investigation. The inhibitors can be used to further define Nek2 biology and to evaluate Nek2 as a realistic therapeutic target. Also, a Nek2 inhibitor has yet to be evaluated for chemosensitization properties, which has been recently identified as an important aspect to Nek2 biology.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Because of the oncogene synergy observed between Nek2 and RTK signaling,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> dual inhibition of Nek2/RTK needs further investigation to fully determine therapeutic relevance.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">Nek2 Future Direction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47133" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47133" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">The basis for Nek2 as a therapeutic target has been preliminarily evaluated through RNAi knockdown studies and Nek2 knockin models.<a onclick="showRef(event, 'ref23 ref24 ref39 ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref23 ref24 ref39 ref40 ref41 ref42">(23, 24, 38-41)</a> Initial research suggests that the inhibition of Nek2 causes selective cytotoxicity, Akt regulation, reversal of ABC mediated drug resistance, and a decrease in metastasis. Although Nek2 drug discovery and development efforts have been limited, potent and selective inhibitors have been generated.<a onclick="showRef(event, 'ref51 ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref51 ref54 ref55 ref56">(50, 53-55)</a> Nek2 inhibitors are in the early stages of development and have primarily been used as selective, molecular probes to further define Nek2 biology. Also, dual Nek2/RTK inhibition represents a novel avenue for therapeutic investigation.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> At present, selective Nek2 inhibitors can be utilized to identify the therapeutic relevance of Akt regulation and the possibility of obstructing ABC mediated drug resistance. Moreover, down-regulating Nek2 demonstrates great potential to elicit inhibitory effects on aberrant Akt signaling; yet, the biological effects of Nek2 inhibitors on the Akt signaling axis remain largely unexplored. As is evident, many important questions surrounding Nek2 biology remain unanswered. With a Nek2 inhibitor, there is a possibility to impact therapeutic outcomes for Nek2 positive cancers and address the forecasted surge in cancer incidence, yet the biology surrounding the kinase needs to be further defined to fully evaluate therapeutic relevance.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/jm401719n" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50045" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50045" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong-yu Li</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacoloy and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona 85721, United States</span>; 
    <span class="hlFld-Affiliation affiliation">BIO5
Oro Valley, The University of Arizona, 1580 Hanley Boulevard, Oro Valley, Arizona 85737, United States</span>; 
    <span class="hlFld-Affiliation affiliation">The
University of Arizona Cancer Center, 1515 N. Campbell Avenue, Tucson, Arizona 85724, United
States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#cba3a4a5acb2bea7a28bbba3aab9a6aaa8b2e5aab9a2b1a4a5aae5aeafbe"><span class="__cf_email__" data-cfemail="caa2a5a4adb3bfa6a38abaa2abb8a7aba9b3e4abb8a3b0a5a4abe4afaebf">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brendan Frett</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacoloy and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona 85721, United States</span>; 
    <span class="hlFld-Affiliation affiliation">BIO5
Oro Valley, The University of Arizona, 1580 Hanley Boulevard, Oro Valley, Arizona 85737, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Robert V. Brown</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacoloy and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona 85721, United States</span>; 
    <span class="hlFld-Affiliation affiliation">The
University of Arizona Cancer Center, 1515 N. Campbell Avenue, Tucson, Arizona 85724, United
States</span>; 
    <span class="hlFld-Affiliation affiliation">BIO5, The University of Arizona, 1657 E. Helen Street, Tucson, Arizona 85721, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingliang Ma</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, East China Normal University, Shanghai, 200241, China</span>; 
    <span class="hlFld-Affiliation affiliation">Department
of Pharmacoloy and Toxicology, College of Pharmacy, The University of Arizona, Tucson, Arizona 85721, United States</span>; 
    <span class="hlFld-Affiliation affiliation">BIO5
Oro Valley, The University of Arizona, 1580 Hanley Boulevard, Oro Valley, Arizona 85737, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenhao Hu</span> - <span class="hlFld-Affiliation affiliation">Shanghai
Engineering Research Center of Molecular Therapeutics and New Drug
Development, East China Normal University, Shanghai, 200241, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haiyong Han</span> - <span class="hlFld-Affiliation affiliation">Clincial
Translational Research Division, Translational
Genomics Research Institute, 445 N. Fifth Street, Phoenix, Arizona 85004, United
States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_76232" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_76232" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Brendan Frett</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=BIO-d2704e994-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Brendan Frett</b> is currently pursuing a Ph.D. degree in the Drug Discovery and Development program at the University of Arizona under the advisement of Professor Hong-yu Li. He has a strong interest in small molecule inhibitors for novel oncology-related targets. His dissertation has focused on identifying a novel clinical candidate and multiple advanced leads. His expertise is in the development and synthesis of druglike compounds, the development of biological assays for high-throughput compound screening, computational modeling, inhibitor design, and the discovery of unique synthetic methodologies.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Robert V. Brown</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=BIO-d2704e999-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Robert V. Brown</b> is currently pursuing a Ph.D. in Pharmaceutical Sciences with a minor in Cancer Biology under the tutelage of Professor Lawrence L. Hurley at University of Arizona. His research focuses on the discovery and development of novel therapeutic targets for the treatment of human disease. To these ends, his dissertation focuses on the characterization and molecular targeting of transcriptionally induced, sequence dependent DNA secondary structures known as G-quadruplex(es) and iMotif(s) for modulating aberrant oncogene transcription. His expertise is in the focused characterization and analytics of drug–target interactions and the design/development of low-/mid-/high-throughput biochemical and cell-based assays for screening compounds.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Mingliang Ma</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=BIO-d2704e1004-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Mingliang Ma</b> is currently an Associate Professor at Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, East China Normal University, China, and also a Visiting Scholar in Professor Hong-yu Li’s laboratory in the College of Pharmacy at the University of Arizona. He obtained his Ph.D. degree in physiology from East China Normal University, under the supervision of Professor Ke Wen and Kang Zhao in 2008. His current research interests are in drug discovery and self-assembly in supramolecular chemistry.</p></figure></div><div class="bio" rid="ath5"><figure id="ath5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Haiyong Han</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=BIO-d2704e1009-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Wenhao Hu</b> is currently a Professor and Head of Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, East China Normal University, China. He received his Ph.D. from Hong Kong Polytechnic University and was a postdoctoral fellow at the University of Arizona with Professor Michael P. Doyle. He worked as a medicinal chemist at Genesoft Pharmaceutical in South San Francisco and as a process chemist at Bristol-Myers Squibb in New Jersey. His research interests include synthetic methodology, MCRs, medicinal, and process chemistry.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Wenhao Hu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=BIO-d2704e1014-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Haiyong Han</b> is currently an Associate Professor in the Clinical Translational Research Division at the Translational Genomics Research Institute (TGen), Phoenix, Arizona. His research involves the identification and characterization of novel genetic alterations in cancers, particularly pancreatic cancer, and the development of new therapeutic agents that target these alterations.</p></figure></div><div class="bio"><figure id="" data-index="" class="article__inlineFigure"><h2 class="fig-label"></h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=BIO-d2704e1019-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Hong-yu Li</b> is currently an Associate Professor of Medicinal Chemistry at the University of Arizona. He received his Ph.D. degree from the University of Tokyo, Japan, and did his postdoctoral trainings at Columbia University, NY, and Harvard University, MA. He previously worked at Eli Lilly where he focused on oncology drug discovery. His current research interests are in chemical biology and drug discovery, especially for oncology related targets and phenotypes. In his lab at the University of Arizona, a robust oncology pipeline including a clinical candidate and three advanced leads were discovered and currently under development. The clinical candidate is a highly potent (picomolar activity in oncogene-driven cancer cell lines), selective, and orally bioavailable small molecule inhibitor and currently ready for preclinical development and further IND filing.</p></figure></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i15" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i15"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i16" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i16"> Abbreviations Used</h2><tr><td class="NLM_term">Nek2</td><td class="NLM_def"><p class="first last">never in mitosis/<i>Aspergillus</i> related kinase 2</p></td></tr><tr><td class="NLM_term">Akt</td><td class="NLM_def"><p class="first last">protein kinase B</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">ABC</td><td class="NLM_def"><p class="first last">ATP binding cassette</p></td></tr><tr><td class="NLM_term">MDR</td><td class="NLM_def"><p class="first last">multidrug resistance</p></td></tr><tr><td class="NLM_term">NIMA</td><td class="NLM_def"><p class="first last">never in mitosis/<i>Aspergillus</i></p></td></tr><tr><td class="NLM_term">NIP</td><td class="NLM_def"><p class="first last">ninein-like protein</p></td></tr><tr><td class="NLM_term">C-Nap1</td><td class="NLM_def"><p class="first last">centrosomal Nek2-associated protein 1</p></td></tr><tr><td class="NLM_term">PP1</td><td class="NLM_def"><p class="first last">protein phosphatase 1</p></td></tr><tr><td class="NLM_term">DLBCL</td><td class="NLM_def"><p class="first last">diffuse large B-cell lymphoma</p></td></tr><tr><td class="NLM_term">FL</td><td class="NLM_def"><p class="first last">follicular lymphoma</p></td></tr><tr><td class="NLM_term">Plk1</td><td class="NLM_def"><p class="first last">polo-like kinase 1</p></td></tr><tr><td class="NLM_term">HFF</td><td class="NLM_def"><p class="first last">human foreskin fibroblast</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">ABCC1</td><td class="NLM_def"><p class="first last">a multidrug resistance-associated protein 1</p></td></tr><tr><td class="NLM_term">ABCG2</td><td class="NLM_def"><p class="first last">a breast cancer resistance protein</p></td></tr><tr><td class="NLM_term">PI3K</td><td class="NLM_def"><p class="first last">phosphoinositide 3-kinase</p></td></tr><tr><td class="NLM_term">RCC</td><td class="NLM_def"><p class="first last">renal cell carcinoma</p></td></tr><tr><td class="NLM_term">GIST</td><td class="NLM_def"><p class="first last">gastrointestinal stromal tumor</p></td></tr><tr><td class="NLM_term">Cdk1</td><td class="NLM_def"><p class="first last">cyclin dependent kinase 1</p></td></tr><tr><td class="NLM_term">VTE</td><td class="NLM_def"><p class="first last">venous thromboembolism</p></td></tr><tr><td class="NLM_term">HTS</td><td class="NLM_def"><p class="first last">high throughput screening</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">Jnk</td><td class="NLM_def"><p class="first last">c-Jun N-terminal kinase</p></td></tr><tr><td class="NLM_term">CIN</td><td class="NLM_def"><p class="first last">chromosomal instability</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27078" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27078" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 59 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Ferlay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkin, D. M.</span><span> </span><span class="NLM_article-title">Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">2893</span><span class="NLM_x">–</span> <span class="NLM_lpage">2917</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1002%2Fijc.25516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=21351269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWhs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2010&pages=2893-2917&author=J.+Ferlayauthor=H.+R.+Shinauthor=F.+Brayauthor=D.+Formanauthor=C.+Mathersauthor=D.+M.+Parkin&title=Estimates+of+worldwide+burden+of+cancer+in+2008%3A+GLOBOCAN+2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</span></div><div class="casAuthors">Ferlay, Jacques; Shin, Hai-Rim; Bray, Freddie; Forman, David; Mathers, Colin; Parkin, Donald Maxwell</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2893-2917</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Ests. of the worldwide incidence and mortality from 27 cancers in 2008 have been prepd. for 182 countries as part of the GLOBOCAN series published by the International Agency for Research on Cancer.  In this article, we present the results for 20 world regions, summarizing the global patterns for the eight most common cancers.  Overall, an estd. 12.7 million new cancer cases and 7.6 million cancer deaths occur in 2008, with 56% of new cancer cases and 63% of the cancer deaths occurring in the less developed regions of the world.  The most commonly diagnosed cancers worldwide are lung (1.61 million, 12.7% of the total), breast (1.38 million, 10.9%) and colorectal cancers (1.23 million, 9.7%).  The most common causes of cancer death are lung cancer (1.38 million, 18.2% of the total), stomach cancer (738,000 deaths, 9.7%) and liver cancer (696,000 deaths, 9.2%).  Cancer is neither rare anywhere in the world, nor mainly confined to high-resource countries.  Striking differences in the patterns of cancer from region to region are obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNEfa8G4I-C7Vg90H21EOLACvtfcHk0lguBf3JqNvbPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWhs7fO&md5=986c00d4fc94238145c1d56b8dfc4840</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fijc.25516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25516%26sid%3Dliteratum%253Aachs%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DShin%26aufirst%3DH.%2BR.%26aulast%3DBray%26aufirst%3DF.%26aulast%3DForman%26aufirst%3DD.%26aulast%3DMathers%26aufirst%3DC.%26aulast%3DParkin%26aufirst%3DD.%2BM.%26atitle%3DEstimates%2520of%2520worldwide%2520burden%2520of%2520cancer%2520in%25202008%253A%2520GLOBOCAN%25202008%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2010%26volume%3D127%26spage%3D2893%26epage%3D2917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span> <span class="citation_source-book">Globocan 2008: Cancer Incidence and Mortality Worldwide</span>; <span class="NLM_contrib-group">Ferlay, J.; Shin, H. R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D. M.</span>, Eds.; IARC CancerBase No.10;  <span class="NLM_publisher-name">International Agency for Research on Cancer</span>: <span class="NLM_publisher-loc">Lyon, France</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Ferlay&author=H.+R.+Shin&author=F.+Bray&author=D.+Forman&author=C.+Mathers&author=D.+M.+Parkin&title=Globocan+2008%3A+Cancer+Incidence+and+Mortality+Worldwide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlobocan%25202008%253A%2520Cancer%2520Incidence%2520and%2520Mortality%2520Worldwide%26aulast%3DFerlay%26aufirst%3DJ.%26pub%3DInternational%2520Agency%2520for%2520Research%2520on%2520Cancer%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Kaye, S. B.</span><span> </span><span class="NLM_article-title">New antimetabolites in cancer chemotherapy and their clinical impact</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1038%2Fbjc.1998.747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=9717984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADyaK1cXlslWks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1998&pages=1-7&author=S.+B.+Kaye&title=New+antimetabolites+in+cancer+chemotherapy+and+their+clinical+impact"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">New antimetabolites in cancer chemotherapy and their clinical impact</span></div><div class="casAuthors">Kaye, S. B.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">Suppl. 3, New Antimetabolites in Cancer Chemotherapy and Their Clinical Impact</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">A review, with 68 refs.  It is almost 50 yr since antimetabolites were first found to have clin. antitumor activity, with Farber's discovery that aminopterin could cause remission in acute leukemia.  In the following 10 yr, methotrexate, 6-mercaptopurine and 5-fluorouracil (5-FU) found their way into clin. practice.  Subsequently, cytosine arabinoside was found to have activity in acute leukemia, but, until recently, other significant developments have involved optimizing the efficacy of existing antimetabolites, including the use of leucovorin with methotrexate or 5-FU.  Recently, new antimetabolites have become a fertile area for anti-cancer drug research.  Gemcitabine (GEMZAR) has emerged as an important new agent in several tumor types, including pancreatic, non-small-cell lung, bladder, breast and ovarian cancers.  Capecitabine is an intriguing new prodrug, offering tumor selectivity and prolonged tumor exposure to 5-FU.  More potent thymidylate synthase inhibitors have also emerged; raltitrexed is now com. available for the treatment of colorectal cancer.  Others under development include LY231514, which has other sites of action, hence the acronym MTA (multi-targeted antifolate).  A novel target is glycinamide ribonucleotide formyltransferase (GARFT) and LY309887 and AG2034 are undergoing clin. investigation as GARFT inhibitors.  A crit. element with LY309887 appears to be co-administration of folate.  It seems entirely possible that several novel antimetabolites will establish themselves in clin. practice in future for the treatment of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIb61ZThgIjbVg90H21EOLACvtfcHk0lgoN5w_PbJ5LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlslWks7g%253D&md5=95c33f58a319c4d921661dbf711616ea</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1998.747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1998.747%26sid%3Dliteratum%253Aachs%26aulast%3DKaye%26aufirst%3DS.%2BB.%26atitle%3DNew%2520antimetabolites%2520in%2520cancer%2520chemotherapy%2520and%2520their%2520clinical%2520impact%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1998%26volume%3D78%26spage%3D1%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Go, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1200%2FJCO.1999.17.1.409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=10458260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADyaK1MXltVyrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=409-422&author=R.+S.+Goauthor=A.+A.+Adjei&title=Review+of+the+comparative+pharmacology+and+clinical+activity+of+cisplatin+and+carboplatin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin</span></div><div class="casAuthors">Go, Ronald S.; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">409-422</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 113 refs.  To review the pharmacodynamics, pharmacokinetics, toxicities, and relative clin. activities of cisplatin and carboplatin.  Through a search of the MEDLINE database, we identified phase III clin. trials and pharmacol. studies comparing cisplatin and carboplatin published in the English language medical literature from Jan. 1966 to Dec. 1997.  Prospective randomized trials comparing cisplatin to carboplatin were identified for ovarian (n = 12), germ cell (n = 4), non-small-cell lung (n = 1), small-cell lung (n = 3), and head and neck (n = 4) cancers.  Carboplatin and cisplatin were equally effective in suboptimally debulked ovarian cancer and extensive-stage small-cell lung cancer.  One study each showed a trend toward better survival in favor of cisplatin for patients with optimally debulked ovarian and limited-stage small-cell lung cancers.  These results were, however, based on subset analyses.  In germ cell tumors, carboplatin was inferior because of lower relapse-free survival rates.  Cisplatin produced superior response rates and survival in head and neck cancers.  There are no published randomized phase III studies of bladder, cervical, endometrial, and esophageal cancers.  Carboplatin does not possess equiv. activity to cisplatin in all platinum-sensitive tumors.  Carboplatin can replace cisplatin in chemotherapy regimens for suboptimally debulked ovarian cancer.  Two ongoing studies will address the same question in optimally debulked disease.  Carboplatin can also be substituted for cisplatin in the treatment of non-small-cell and extensive-stage small-cell lung cancers.  Its role in limited-stage small-cell lung cancer needs to be investigated further.  Carboplatin is inferior to cisplatin in germ cell, head and neck, and esophageal cancers.  Randomized studies are needed to det. whether carboplatin has equiv. efficacy to cisplatin in bladder, cervical, and endometrial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6oRZSRTFXkLVg90H21EOLACvtfcHk0lgoN5w_PbJ5LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVyrug%253D%253D&md5=670468515a36db5297f6eb2997242aa4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1200%2FJCO.1999.17.1.409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.1999.17.1.409%26sid%3Dliteratum%253Aachs%26aulast%3DGo%26aufirst%3DR.%2BS.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DReview%2520of%2520the%2520comparative%2520pharmacology%2520and%2520clinical%2520activity%2520of%2520cisplatin%2520and%2520carboplatin%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1999%26volume%3D17%26spage%3D409%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Bollag, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQueney, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hensens, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koupal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liesch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazarides, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, C. M.</span><span> </span><span class="NLM_article-title">Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2325</span><span class="NLM_x">–</span> <span class="NLM_lpage">2333</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=7757983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADyaK2MXlvFeqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=2325-2333&author=D.+M.+Bollagauthor=P.+A.+McQueneyauthor=J.+Zhuauthor=O.+Hensensauthor=L.+Koupalauthor=J.+Lieschauthor=M.+Goetzauthor=E.+Lazaridesauthor=C.+M.+Woods&title=Epothilones%2C+a+new+class+of+microtubule-stabilizing+agents+with+a+Taxol-like+mechanism+of+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action</span></div><div class="casAuthors">Bollag, Daniel M.; McQueney, Patricia A.; Zhu, Jian; Hensens, Otto; Koupal, Lawrence; Liesch, Jerrold; Goetz, Michael; Lazarides, Elias; Woods, Catherine M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2325-33</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The antineoplastic agent taxol hyperstabilizes polymd. microtubules, leading to mitotic arrest and cytotoxicity in proliferating cells.  By using a sensitive filtration-calorimetric assay to detect microtubule nucleating activity, epothilones A and B were identified as compds. that possess all the biol. effects of taxol both in vitro and in cultured cells.  The 2 epothilones were equipotent and exhibited kinetics similar to those of taxol in inducing tubulin polymn. to microtubules in vitro and in producing enhanced microtubule stability and bundling in cultured cells.  Furthermore, these 16-membered macrolides were competitive inhibitors of [3H]taxol binding, exhibiting an IC50 almost identical to that of taxol in displacement competition assays.  Like taxol, the epothilones also caused cell cycle arrest at the G2-M transition, leading to cytotoxicity.  In contrast to taxol, the epothilones retained much greater toxicity against P-glycoprotein-expressing multiple-drug-resistant cells.  Epothilones, therefore, represent a novel structural class of compds. which not only mimic the biol. effects of taxol but also appear to bind to the same microtubule-binding site as taxol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaxKCSWNo8RLVg90H21EOLACvtfcHk0lgoN5w_PbJ5LA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXlvFeqsr0%253D&md5=f858620138df4b7d800d641db7da9962</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DD.%2BM.%26aulast%3DMcQueney%26aufirst%3DP.%2BA.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DHensens%26aufirst%3DO.%26aulast%3DKoupal%26aufirst%3DL.%26aulast%3DLiesch%26aufirst%3DJ.%26aulast%3DGoetz%26aufirst%3DM.%26aulast%3DLazarides%26aufirst%3DE.%26aulast%3DWoods%26aufirst%3DC.%2BM.%26atitle%3DEpothilones%252C%2520a%2520new%2520class%2520of%2520microtubule-stabilizing%2520agents%2520with%2520a%2520Taxol-like%2520mechanism%2520of%2520action%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D2325%26epage%3D2333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Jordan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toso, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thrower, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span> </span><span class="NLM_article-title">Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">9552</span><span class="NLM_x">–</span> <span class="NLM_lpage">9556</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=9552-9556&author=M.+A.+Jordanauthor=R.+J.+Tosoauthor=D.+Throwerauthor=L.+Wilson&title=Mechanism+of+mitotic+block+and+inhibition+of+cell+proliferation+by+taxol+at+low+concentrations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DToso%26aufirst%3DR.%2BJ.%26aulast%3DThrower%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMechanism%2520of%2520mitotic%2520block%2520and%2520inhibition%2520of%2520cell%2520proliferation%2520by%2520taxol%2520at%2520low%2520concentrations%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1993%26volume%3D90%26spage%3D9552%26epage%3D9556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Fisher, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pusztai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanton, C.</span><span> </span><span class="NLM_article-title">Cancer heterogeneity: implications for targeted therapeutics</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1038%2Fbjc.2012.581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=23299535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtV2rtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2013&pages=479-485&author=R.+Fisherauthor=L.+Pusztaiauthor=C.+Swanton&title=Cancer+heterogeneity%3A+implications+for+targeted+therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer heterogeneity: implications for targeted therapeutics</span></div><div class="casAuthors">Fisher, R.; Pusztai, L.; Swanton, C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">479-485</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Developments in genomic techniques have provided insight into the remarkable genetic complexity of malignant tumors.  There is increasing evidence that solid tumors may comprise of subpopulations of cells with distinct genomic alterations within the same tumor, a phenomenon termed intra-tumor heterogeneity.  Intra-tumor heterogeneity is likely to have implications for cancer therapeutics and biomarker discovery, particularly in the era of targeted treatment, and evidence for a relationship between intra-tumoral heterogeneity and clin. outcome is emerging.  Our understanding of the processes that exacerbate intra-tumoral heterogeneity, both iatrogenic and tumor specific, is likely to increase with the development and more widespread implementation of advanced sequencing technologies, and adaptation of clin. trial design to include comprehensive tissue collection protocols.  The current evidence for intra-tumor heterogeneity and its relevance to cancer therapeutics will be presented in this mini-review.  British Journal of Cancer (2013) 108, 479-485; doi:10.1038/bjc.2012.581 www.bjcancer.com Published online 8 Jan. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWp4WYese5nbVg90H21EOLACvtfcHk0lgES1RZpvlYnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtV2rtbo%253D&md5=a786527dd05a52a16c1c96b72fdc01c5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2012.581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2012.581%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DR.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DSwanton%26aufirst%3DC.%26atitle%3DCancer%2520heterogeneity%253A%2520implications%2520for%2520targeted%2520therapeutics%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2013%26volume%3D108%26spage%3D479%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">STI571 (Gleevec) as a paradigm for cancer therapy</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">S14</span><span class="NLM_x">–</span> <span class="NLM_lpage">S18</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=S14-S18&author=B.+J.+Druker&title=STI571+%28Gleevec%29+as+a+paradigm+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DSTI571%2520%2528Gleevec%2529%2520as%2520a%2520paradigm%2520for%2520cancer%2520therapy%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2002%26volume%3D8%26spage%3DS14%26epage%3DS18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Wells, S. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosnell, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfister, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosa, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skinner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasselli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M.</span><span> </span><span class="NLM_article-title">Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1200%2FJCO.2009.23.6604" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=67-72&author=S.+A.+Wellsauthor=J.+E.+Gosnellauthor=R.+F.+Gagelauthor=J.+Moleyauthor=D.+Pfisterauthor=J.+A.+Sosaauthor=M.+Skinnerauthor=A.+Krebsauthor=J.+Vasselliauthor=M.+Schlumberger&title=Vandetanib+for+the+treatment+of+patients+with+locally+advanced+or+metastatic+hereditary+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.23.6604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.23.6604%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DS.%2BA.%26aulast%3DGosnell%26aufirst%3DJ.%2BE.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26aulast%3DMoley%26aufirst%3DJ.%26aulast%3DPfister%26aufirst%3DD.%26aulast%3DSosa%26aufirst%3DJ.%2BA.%26aulast%3DSkinner%26aufirst%3DM.%26aulast%3DKrebs%26aufirst%3DA.%26aulast%3DVasselli%26aufirst%3DJ.%26aulast%3DSchlumberger%26aufirst%3DM.%26atitle%3DVandetanib%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520locally%2520advanced%2520or%2520metastatic%2520hereditary%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D67%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Escudier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadler, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczylik, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siebels, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negrier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevreau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolland, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demkow, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukowski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TARGET Study Group.</span><span> </span><span class="NLM_article-title">Sorafenib in advanced clear-cell renal-cell carcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1056%2FNEJMoa060655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=17215530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVKitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=125-134&author=B.+Escudierauthor=T.+Eisenauthor=W.+M.+Stadlerauthor=C.+Szczylikauthor=S.+Oudardauthor=M.+Siebelsauthor=S.+Negrierauthor=C.+Chevreauauthor=E.+Solskaauthor=A.+A.+Desaiauthor=F.+Rollandauthor=T.+Demkowauthor=T.+E.+Hutsonauthor=M.+Goreauthor=S.+Freemanauthor=B.+Schwartzauthor=M.+Shanauthor=R.+Simantovauthor=R.+M.+Bukowskiauthor=TARGET+Study+Group.&title=Sorafenib+in+advanced+clear-cell+renal-cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib in advanced clear-cell renal-cell carcinoma</span></div><div class="casAuthors">Escudier, Bernard; Eisen, Tim; Stadler, Walter M.; Szczylik, Cezary; Oudard, Stephane; Siebels, Michael; Negrier, Sylvie; Chevreau, Christine; Solska, Ewa; Desai, Apurva A.; Rolland, Frederic; Demkow, Tomasz; Hutson, Thomas E.; Gore, Martin; Freeman, Scott; Schwartz, Brian; Shan, Minghua; Simantov, Ronit; Bukowski, Ronald M.; Blajman, C.; Fein, L.; Martin, C.; Taber, R.; Boyer, M.; Davis, I.; Gurney, H.; Hovey, E.; Leong, D.; Steer, C.; DeGreve, J.; Gil, T.; Barrios, C.; David, W.; Skare, N. G.; Notari, A.; Schwartsmann, G.; Gunnar, N.; Ernst, S.; Hotte, S.; Miller, W.; Moore, M.; North, S.; Fodor, M.; Caty, A.; Chevreau, C.; Duclos, B.; Gravis, G.; Negrier, S.; Oudard, S.; Ravaud, A.; Rolland, F.; Sevin, E.; Grimm, M. O.; Gschwennd, J.; Heinzer, H.; Jager, E.; Krause, S.; Michel, M.-S.; Rohde, D.; Siebels, M.; Siegsmund, M.; Staehler, M.; Wirth, M.; Baki, M.; Bodrogi, I.; Cseh, J.; Ruzsa, A.; Toth, C.; Ben-Yosef, R.; Gez, E.; Bajetta, E.; Boni, C.; Bracarda, S.; Cognetti, F.; Conte, P.; Porta, C.; Spronsen, D. J.; Blasinka-Morawiec, M.; Dernkow, T.; Lorenz, J.; Mazurkiewicz, M.; Roslki, J.; Sikorski, A.; Solska, E.; Tomczak, P.; Bolotina, L.; Karlov, P.; Karyakin, O.; Khasanov, R.; Lichinitser, M.; Lubennikov, V.; Moiseenko, V.; Sherman, N.; Abratt, R.; Coetzee, L.; Cohen, G.; Heyns, C.; Jordaan, J.; Ruff, P.; Wentzel, S.; Bellmunt, J.; Climent, M. A.; Gonzalez, J. L.; Lopez, G.; Bashtan, V.; Dumamsky, Y.; Klimenko, I.; Pilipenko, N.; Shparik, Y.; Hawkins, R.; McMenemin, R.; Nathan, P.; Porfiri, E.; Savage, P.; White, J.; Anderson, C.; Bains, Y.; Bleickardt, E.; Bradof, J.; Brooks, D.; Cardi, G.; Cervera, A.; Davis, N.; Desai, A.; Drabkin, H.; Dudek, A.; Dutcher, J.; Formanek, G.; Gabrail, N.; Gorss, H.; Haung, Y.; Henderson, C.; Hutson, T.; Jonasch, E.; Lara, P.; McCracken, J.; McDermott, D.; Mena, R.; Middleton, R.; Petrylak, D.; Picus, D.; Quinn, D.; Rausch, P.; Rinaldi, D.; Ryan, C.; Tchekmedyian, N.; Vuky, J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-134</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma.  From Nov. 2003 to Mar. 2005, we randomly assigned 903 patients with renal-cell carcinoma that was resistant to std. therapy to receive either continuous treatment with oral sorafenib (at a dose of 400 mg twice daily) or placebo; 451 patients received sorafenib and 452 received placebo.  The primary end point was overall survival.  A single planned anal. of progression-free survival in Jan. 2005 showed a statistically significant benefit of sorafenib over placebo.  Consequently, crossover was permitted from placebo to sorafenib, beginning in May 2005.  At the Jan. 2005 cutoff, the median progression-free survival was 5.5 mo in the sorafenib group and 2.8 mo in the placebo group (hazard ratio for disease progression in the sorafenib group, 0.44; 95% confidence interval [CI], 0.35 to 0.55).  The 1st interim anal. of overall survival in May 2005 showed that sorafenib reduced the risk of death, as compared with placebo (hazard ratio, 0.72; 95% CI, 0.54 to 0.94), although this benefit was not statistically significant according to the O'Brien-Fleming threshold.  Partial responses were reported as the best response in 10% of patients receiving sorafenib and in 2% of those receiving placebo.  Diarrhea, rash, fatigue, and hand-foot skin reactions were the most common adverse events assocd. with sorafenib.  Hypertension and cardiac ischemia were rare serious adverse events that were more common in patients receiving sorafenib than in those receiving placebo.  As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is assocd. with increased toxic effects.  (ClinicalTrials.gov no., NCT00073307).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV_8zTNHmXrLVg90H21EOLACvtfcHk0lgES1RZpvlYnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVKitg%253D%253D&md5=8f6da990729f8ff17587d71744b834f4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa060655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa060655%26sid%3Dliteratum%253Aachs%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DSiebels%26aufirst%3DM.%26aulast%3DNegrier%26aufirst%3DS.%26aulast%3DChevreau%26aufirst%3DC.%26aulast%3DSolska%26aufirst%3DE.%26aulast%3DDesai%26aufirst%3DA.%2BA.%26aulast%3DRolland%26aufirst%3DF.%26aulast%3DDemkow%26aufirst%3DT.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DFreeman%26aufirst%3DS.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DShan%26aufirst%3DM.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26aulast%3D%26atitle%3DSorafenib%2520in%2520advanced%2520clear-cell%2520renal-cell%2520carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D125%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Branford, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudzki, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grigg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joske, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, T.</span><span> </span><span class="NLM_article-title">Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">276</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=276-283&author=S.+Branfordauthor=Z.+Rudzkiauthor=S.+Walshauthor=I.+Parkinsonauthor=A.+Griggauthor=J.+Szerauthor=K.+Taylorauthor=R.+Herrmannauthor=J.+F.+Seymourauthor=C.+Arthurauthor=D.+Joskeauthor=K.+Lynchauthor=T.+Hughes&title=Detection+of+BCR-ABL+mutations+in+patients+with+CML+treated+with+imatinib+is+virtually+always+accompanied+by+clinical+resistance%2C+and+mutations+in+the+ATP+phosphate-binding+loop+%28P-loop%29+are+associated+with+a+poor+prognosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBranford%26aufirst%3DS.%26aulast%3DRudzki%26aufirst%3DZ.%26aulast%3DWalsh%26aufirst%3DS.%26aulast%3DParkinson%26aufirst%3DI.%26aulast%3DGrigg%26aufirst%3DA.%26aulast%3DSzer%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DK.%26aulast%3DHerrmann%26aufirst%3DR.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DArthur%26aufirst%3DC.%26aulast%3DJoske%26aufirst%3DD.%26aulast%3DLynch%26aufirst%3DK.%26aulast%3DHughes%26aufirst%3DT.%26atitle%3DDetection%2520of%2520BCR-ABL%2520mutations%2520in%2520patients%2520with%2520CML%2520treated%2520with%2520imatinib%2520is%2520virtually%2520always%2520accompanied%2520by%2520clinical%2520resistance%252C%2520and%2520mutations%2520in%2520the%2520ATP%2520phosphate-binding%2520loop%2520%2528P-loop%2529%2520are%2520associated%2520with%2520a%2520poor%2520prognosis%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D276%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salerno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travers, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadt, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasarskis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span> </span><span class="NLM_article-title">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">485</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1038%2Fnature11016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=22504184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=260-326&author=C.+C.+Smithauthor=Q.+Wangauthor=C.+S.+Chinauthor=S.+Salernoauthor=L.+E.+Damonauthor=M.+J.+Levisauthor=A.+E.+Perlauthor=K.+J.+Traversauthor=S.+Wangauthor=J.+P.+Huntauthor=P.+P.+Zarrinkarauthor=E.+E.+Schadtauthor=A.+Kasarskisauthor=J.+Kuriyanauthor=N.+P.+Shah&title=Validation+of+ITD+mutations+in+FLT3+as+a+therapeutic+target+in+human+acute+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia</span></div><div class="casAuthors">Smith, Catherine C.; Wang, Qi; Chin, Chen-Shan; Salerno, Sara; Damon, Lauren E.; Levis, Mark J.; Perl, Alexander E.; Travers, Kevin J.; Wang, Susana; Hunt, Jeremy P.; Zarrinkar, Patrick P.; Schadt, Eric E.; Kasarskis, Andrew; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7397</span>),
    <span class="NLM_cas:pages">260-263</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Effective targeted cancer therapeutic development depends upon distinguishing disease-assocd. driver' mutations, which have causative roles in malignancy pathogenesis, from passenger' mutations, which are dispensable for cancer initiation and maintenance.  Translational studies of clin. active targeted therapeutics can definitively discriminate driver from passenger lesions and provide valuable insights into human cancer biol.  Activating internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD) are detected in approx. 20% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  Abundant scientific and clin. evidence, including the lack of convincing clin. activity of early FLT3 inhibitors, suggests that FLT3-ITD probably represents a passenger lesion.  Here we report point mutations at three residues within the kinase domain of FLT3-ITD that confer substantial in vitro resistance to AC220 (quizartinib), an active investigational inhibitor of FLT3, KIT, PDGFRA, PDGFRB and RET; evolution of AC220-resistant substitutions at two of these amino acid positions was obsd. in eight of eight FLT3-ITD-pos. AML patients with acquired resistance to AC220.  Our findings demonstrate that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML.  AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq0PeqhlWLObVg90H21EOLACvtfcHk0lg5TRTuDo_x5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D&md5=228dae85b08e65918f74ee8c5d20ddb0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnature11016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11016%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DChin%26aufirst%3DC.%2BS.%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DTravers%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DSchadt%26aufirst%3DE.%2BE.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DValidation%2520of%2520ITD%2520mutations%2520in%2520FLT3%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520acute%2520myeloid%2520leukaemia%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D260%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberhardt, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germonpré, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabbinavar, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biesma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langmuir, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span> </span><span class="NLM_article-title">Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">619</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1016%2FS1470-2045%2810%2970132-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=20570559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotVWqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=619-626&author=R.+S.+Herbstauthor=Y.+Sunauthor=W.+E.+Eberhardtauthor=P.+Germonpr%C3%A9author=N.+Saijoauthor=C.+Zhouauthor=J.+Wangauthor=L.+Liauthor=F.+Kabbinavarauthor=Y.+Ichinoseauthor=S.+Qinauthor=L.+Zhangauthor=B.+Biesmaauthor=J.+V.+Heymachauthor=P.+Langmuirauthor=S.+J.+Kennedyauthor=H.+Tadaauthor=B.+E.+Johnson&title=Vandetanib+plus+docetaxel+versus+docetaxel+as+second-line+treatment+for+patients+with+advanced+non-small-cell+lung+cancer+%28ZODIAC%29%3A+a+double-blind%2C+randomised%2C+phase+3+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial</span></div><div class="casAuthors">Herbst, Roy S.; Sun, Yan; Eberhardt, Wilfried E. E.; Germonpre, Paul; Saijo, Nagahiro; Zhou, Caicun; Wang, Jie; Li, Longyun; Kabbinavar, Fairooz; Ichinose, Yukito; Qin, Shukui; Zhang, Li; Biesma, Bonne; Heymach, John V.; Langmuir, Peter; Kennedy, Sarah J.; Tada, Hiroomi; Johnson, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">619-626</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) tyrosine kinases.  In a randomized phase 2 study in patients with previously treated non-small-cell lung cancer (NSCLC), adding vandetanib 100 mg to docetaxel significantly improved progression-free survival (PFS) compared with docetaxel alone, including a longer PFS in women.  These results supported investigation of the combination in this larger, definitive phase 3 trial (ZODIAC).  Between May, 2006, and Apr., 2008, patients with locally advanced or metastatic (stage IIIB-IV) NSCLC after progression following first-line chemotherapy were randomly assigned 1:1 through a third-party interactive voice system to receive vandetanib (100 mg/day) plus docetaxel (75 mg/m2 i.v. every 21 days; max. six cycles) or placebo plus docetaxel.  The primary objective was comparison of PFS between the two groups in the intention-to-treat population.  Women were a coprimary anal. population.  This study has been completed and is registered with ClinicalTrials.gov, no. NCT00312377.  1391 patients received vandetanib plus docetaxel (n=694 [197 women]) or placebo plus docetaxel (n=697 [224 women]).  Vandetanib plus docetaxel led to a significant improvement in PFS vs. placebo plus docetaxel (hazard ratio [HR] 0.79, 97.58% CI 0.70-0.90; p<0.0001); median PFS was 4.0 mo in the vandetanib group vs. 3.2 mo in placebo group.  A similar improvement in PFS with vandetanib plus docetaxel vs. placebo plus docetaxel was seen in women (HR 0.79, 0.62-1.00, p=0.024); median PFS was 4.6 mo in the vandetanib group vs. 4.2 mo in the placebo group.  Among grade 3 or higher adverse events, rash (63/689 [9%] vs 7/690 [1%]), neutropenia (199/689 [29%] vs 164/690 [24%]), leukopenia (99/689 [14%] vs 77/690 [11%]), and febrile neutropenia (61/689 [9%] vs 48/690 [7%]) were more common with vandetanib plus docetaxel than with placebo plus docetaxel.  The most common serious adverse event was febrile neutropenia (46/689 [7%] in the vandetanib group vs 38/690 [6%] in the placebo group).  The addn. of vandetanib to docetaxel provides a significant improvement in PFS in patients with advanced NSCLC after progression following first-line therapy.  Funding: AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryVcdfCkTN-LVg90H21EOLACvtfcHk0lg5TRTuDo_x5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotVWqu78%253D&md5=47402d2231220fb5b081a4a521bf1b9c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2810%2970132-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252810%252970132-7%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DEberhardt%26aufirst%3DW.%2BE.%26aulast%3DGermonpr%25C3%25A9%26aufirst%3DP.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DKabbinavar%26aufirst%3DF.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBiesma%26aufirst%3DB.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DLangmuir%26aufirst%3DP.%26aulast%3DKennedy%26aufirst%3DS.%2BJ.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26atitle%3DVandetanib%2520plus%2520docetaxel%2520versus%2520docetaxel%2520as%2520second-line%2520treatment%2520for%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528ZODIAC%2529%253A%2520a%2520double-blind%252C%2520randomised%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2010%26volume%3D11%26spage%3D619%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Braud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebastian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberhardt, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranade, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trigo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandler, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonomi, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasselli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span> </span><span class="NLM_article-title">Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5407</span><span class="NLM_x">–</span> <span class="NLM_lpage">5415</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1200%2FJCO.2008.17.3138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=18936474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslClsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=5407-5415&author=J.+V.+Heymachauthor=L.+Paz-Aresauthor=F.+De+Braudauthor=M.+Sebastianauthor=D.+J.+Stewartauthor=W.+E.+Eberhardtauthor=A.+A.+Ranadeauthor=G.+Cohenauthor=J.+M.+Trigoauthor=A.+B.+Sandlerauthor=P.+D.+Bonomiauthor=R.+S.+Herbstauthor=A.+D.+Krebsauthor=J.+Vasselliauthor=B.+E.+Johnson&title=Randomized+phase+II+study+of+vandetanib+alone+or+with+paclitaxel+and+carboplatin+as+first-line+treatment+for+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer</span></div><div class="casAuthors">Heymach, John V.; Paz-Ares, Luis; De Braud, Filippo; Sebastian, Martin; Stewart, David J.; Eberhardt, Wilfried E. E.; Ranade, Anantbhushan A.; Cohen, Graham; Trigo, Jose Manuel; Sandler, Alan B.; Bonomi, Philip D.; Herbst, Roy S.; Krebs, Annetta D.; Vasselli, James; Johnson, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5407-5415</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Vandetanib is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling.  The antitumor activity of vandetanib monotherapy or vandetanib with paclitaxel and carboplatin (VPC) was compared with paclitaxel and carboplatin (PC) in previously untreated patients with non-small-cell lung cancer (NSCLC).  All NSCLC histologies and previously treated CNS metastases were permitted in this partially blinded, placebo-controlled, randomized phase II study.  Patients were randomly assigned 2:1:1 to receive vandetanib, VPC, or PC.  Progression-free survival (PFS) was the primary end point, and the study was powered to detect a reduced risk of progression with VPC vs. PC (hazard ratio = 0.70; one-sided P < .2) and to demonstrate noninferiority for vandetanib vs. PC.  Overall survival was a secondary assessment.  The risk of progression was reduced for patients receiving VPC (n = 56) vs. PC (n = 52; hazard ratio = 0.76, one-sided P = .098); median PFS was 24 wk (VPC) and 23 wk (PC).  The vandetanib monotherapy arm (n = 73) was discontinued after a planned interim PFS anal. met the criterion for discontinuation (hazard ratio > 1.33 v PC).  Overall survival was not significantly different between patients receiving VPC or PC.  Rash, diarrhea, and hypertension were common adverse events; no pulmonary or CNS hemorrhage events required intervention.  VPC could be safely administered to patients with NSCLC, including those with squamous cell histol. and treated brain metastases.  Compared with the PC control arm, patients receiving VPC had longer PFS, meeting the prespecified study end point, whereas those receiving vandetanib monotherapy had shorter PFS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpBa6v0Wn07Vg90H21EOLACvtfcHk0liiml2GFG9YUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslClsg%253D%253D&md5=d6b3cc3f1e238ca09c2d929385d85c29</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.17.3138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.17.3138%26sid%3Dliteratum%253Aachs%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DDe%2BBraud%26aufirst%3DF.%26aulast%3DSebastian%26aufirst%3DM.%26aulast%3DStewart%26aufirst%3DD.%2BJ.%26aulast%3DEberhardt%26aufirst%3DW.%2BE.%26aulast%3DRanade%26aufirst%3DA.%2BA.%26aulast%3DCohen%26aufirst%3DG.%26aulast%3DTrigo%26aufirst%3DJ.%2BM.%26aulast%3DSandler%26aufirst%3DA.%2BB.%26aulast%3DBonomi%26aufirst%3DP.%2BD.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DKrebs%26aufirst%3DA.%2BD.%26aulast%3DVasselli%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520vandetanib%2520alone%2520or%2520with%2520paclitaxel%2520and%2520carboplatin%2520as%2520first-line%2520treatment%2520for%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D5407%26epage%3D5415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Peters, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Wilt, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Moorsel, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroep, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackland, S. P.</span><span> </span><span class="NLM_article-title">Basis for effective combination cancer chemotherapy with antimetabolites</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1016%2FS0163-7258%2800%2900086-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=11008002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmslOjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2000&pages=227-253&author=G.+J.+Petersauthor=C.+L.+van+der+Wiltauthor=C.+J.+van+Moorselauthor=J.+R.+Kroepauthor=A.+M.+Bergmanauthor=S.+P.+Ackland&title=Basis+for+effective+combination+cancer+chemotherapy+with+antimetabolites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Basis for effective combination cancer chemotherapy with antimetabolites</span></div><div class="casAuthors">Peters, G. J.; van der Wilt, C. L.; van Moorsel, C. J. A.; Kroep, J. R.; Bergman, A. M.; Ackland, S. P.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">227-253</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with many refs.  Most current chemotherapy regimens for cancer consist of empirically designed combinations, based on efficacy and lack of overlapping toxicity.  In the development of combinations, several aspects are often overlooked: (1) possible metabolic and biol. interactions between drugs, (2) scheduling, and (3) different pharmacokinetic profiles.  Antimetabolites are used widely in chemotherapy combinations for treatment of various leukemias and solid tumors.  Ideally, the combination of two or more agents should be more effective than each agent sep. (synergism), although additive and even antagonistic combinations may result in a higher therapeutic efficacy in the clinic.  The median-drug effect anal. method is one of the most widely used methods for in vitro evaluation of combinations.  Several examples of classical effective antimetabolite-(anti)metabolite combinations are discussed, such as that of methotrexate with 6-mercaptopurine or leucovorin in (childhood) leukemia and 5-fluorouracil (5FU) with leucovorin in colon cancer.  More recent combinations include treatment of acute-myeloid leukemia with fludarabine and arabinosylcytosine.  Other combinations, currently frequently used in the treatment of solid malignancies, include an antimetabolite with a DNA-damaging agent, such as gemcitabine with cisplatin and 5FU with the cisplatin analog oxaliplatin.  The combination of 5FU and the topoisomerase inhibitor irinotecan is based on decreased repair of irinotecan-induced DNA damage.  These combinations may increase induction of apoptosis.  The latter combinations have dramatically changed the treatment of incurable cancers, such as lung and colon cancer, and have demonstrated that rationally designed drug combinations offer new possibilities to treat solid malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVGv8e94tDbbVg90H21EOLACvtfcHk0liiml2GFG9YUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmslOjtbY%253D&md5=532d9a7faa9de51650b4db7136038b8d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2800%2900086-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252800%252900086-3%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3Dvan%2Bder%2BWilt%26aufirst%3DC.%2BL.%26aulast%3Dvan%2BMoorsel%26aufirst%3DC.%2BJ.%26aulast%3DKroep%26aufirst%3DJ.%2BR.%26aulast%3DBergman%26aufirst%3DA.%2BM.%26aulast%3DAckland%26aufirst%3DS.%2BP.%26atitle%3DBasis%2520for%2520effective%2520combination%2520cancer%2520chemotherapy%2520with%2520antimetabolites%26jtitle%3DPharmacol.%2520Ther.%26date%3D2000%26volume%3D87%26spage%3D227%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Bunn, P. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K.</span><span> </span><span class="NLM_article-title">New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1087</span><span class="NLM_x">–</span> <span class="NLM_lpage">1100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=9607565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADyaK1cXjt1yiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=1087-1100&author=P.+A.+Bunnauthor=K.+Kelly&title=New+chemotherapeutic+agents+prolong+survival+and+improve+quality+of+life+in+non-small+cell+lung+cancer%3A+a+review+of+the+literature+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">New chemotherapeutic agents prolong survival and improve quality of life in non-small-cell lung cancer: a review of the literature and future directions</span></div><div class="casAuthors">Bunn, Paul A., Jr.; Kelly, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1087-1100</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review with 139 refs. In past years, there has been considerable pessimism over the role of chemotherapy in non-small-cell lung cancers.  The pessimism was largely derived from the fact that alkylating agent-based therapies shortened survival and produced severe side effects.  This was esp. important because the vast majority of patients (∼85%) develop metastatic disease during their course.  Randomized trials from the 1980s showed that cisplatin-based chemotherapy improved patient survival, improved quality of life as assessed by the patients, and relieved symptoms in the majority of symptomatic patients.  When chemotherapy was administered on an outpatient basis, it actually lowered the total patient care costs for advanced-stage patients.  In the 1990s, 5 new agents: 2 taxanes (paclitaxel, docetaxel), gemcitabine, navelbine, and irinotecan, were shown to produce higher response rates and longer survival in Phase II trials than cisplatin or carboplatin.  In randomized trials, combinations of paclitaxel, gemcitabine, and vinorelbine with cisplatin improved the survival of advanced-stage patients compared to cisplatin alone or in combination with etoposide.  The toxicity profile of the new agents is also favorable compared to that of cisplatin-based therapy.  Preliminary results in earlier stages are also encouraging.  Thus, currently available chemotherapy given to non-small-cell lung cancer patients with good performance status can improve survival to a similar extent as in other solid tumors, such as small-cell lung cancer and breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonu6iFWGmXmrVg90H21EOLACvtfcHk0liiml2GFG9YUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjt1yiur8%253D&md5=e022672096f71a77157e5ba1a5f8d8a6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBunn%26aufirst%3DP.%2BA.%26aulast%3DKelly%26aufirst%3DK.%26atitle%3DNew%2520chemotherapeutic%2520agents%2520prolong%2520survival%2520and%2520improve%2520quality%2520of%2520life%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520a%2520review%2520of%2520the%2520literature%2520and%2520future%2520directions%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1998%26volume%3D4%26spage%3D1087%26epage%3D1100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span> </span><span class="NLM_article-title">Drug interactions in oncology</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">496</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1016%2FS1470-2045%2804%2901528-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=15288238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1Kjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=489-496&author=J.+H.+Beijnenauthor=J.+H.+Schellens&title=Drug+interactions+in+oncology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Drug interactions in oncology</span></div><div class="casAuthors">Beijnen, Jos H.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">489-496</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Lancet Publishing Group</span>)
        </div><div class="casAbstract">A review.  Drug interactions are an ongoing concern in treatment of cancer, esp. when cytotoxic drugs are being used.  However, the clin. relevance of these interactions is not always investigated.  Drug interactions can be pharmaceutical, pharmacokinetic, or pharmacodynamic.  They can also be wanted (eg, use of ciclosporin to enhance the oral bioavailability of paclitaxel); unwanted (eg, combination of the antiviral agent sorivudine and oral fluorouracil analogs can lead to fatal complications); between cytotoxic drugs, cytotoxic drugs and non-cytotoxic drugs; or with pharmaceutical vehicles.  Potential interactions between anticancer drugs and over-the-counter or alternative medicines and herbs should not be underestimated.  More attention should be given to the recognition of potential drug interactions in the preclin. and early clin. development phase of a new anticancer drug.  Here, we provide a comprehensive overview of drug interactions, with selected examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGtAyZKbv5y7Vg90H21EOLACvtfcHk0liXiY8_KRS_bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Kjsr8%253D&md5=b0f770ed7f6fa05acf619b23aea5aa1e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2804%2901528-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252804%252901528-1%26sid%3Dliteratum%253Aachs%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26atitle%3DDrug%2520interactions%2520in%2520oncology%26jtitle%3DLancet%2520Oncol.%26date%3D2004%26volume%3D5%26spage%3D489%26epage%3D496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Wai, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schramm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korsching, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Valen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boecker, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweigerer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dockhorn-Dworniczak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poremba, C.</span><span> </span><span class="NLM_article-title">Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=11836553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVChurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=441-451&author=D.+H.+Waiauthor=K.+L.+Schaeferauthor=A.+Schrammauthor=E.+Korschingauthor=F.+Van+Valenauthor=T.+Ozakiauthor=W.+Boeckerauthor=L.+Schweigererauthor=B.+Dockhorn-Dworniczakauthor=C.+Poremba&title=Expression+analysis+of+pediatric+solid+tumor+cell+lines+using+oligonucleotide+microarrays"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays</span></div><div class="casAuthors">Wai, Daniel H.; Schaeffer, Karl-Ludwig; Schramm, Alexander; Korsching, Eberhard; Van Valen, Frans; Ozaki, Toshifumi; Boecker, Werner; Schweigerer, Lothar; Dockhorn-Dworniczak, Barbara; Poremba, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-451</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">The authors identified patterns of differentially-expressed genes in cell lines derived from several pediatric solid tumors.  Affymetrix Human Cancer G110 Arrays, carrying 1,700 cancer-assocd. genes, were applied to a panel of 11 cell lines originating from Ewing tumors (ETs), neuroblastomas, and malignant melanoma of soft parts.  Hierarchical clustering clearly differentiated these 3 entities and revealed groups of 75, 102, and 36 gene probe-sets exhibiting tumor-type specific up-regulation in these cell lines, resp.  Whereas ET lines demonstrated increased expression of microtubule-assocd. protein tau (MAPT), protein phosphatase 1 regulatory subunit 1A (PPPlRlA), NIMA (never in mitosis gene a)-related kinase 2 (NEK2), and cyclin D1 (CCNDl), neuroblastoma samples exhibited high expression of wingless-type mouse mammary tumor virus integration site family member 11 (WNT11), Drosophila frizzled homolog 2 (FZD2), and adenomatous polyposis coli (APC) which are involved in regulating free β-catenin levels.  These genes likely maintain tumor-specific characteristics and participate in key down-stream regulatory mechanisms.  The authors also correlated the expression levels of up-regulated genes in ETs with their chromosomal localization and compared these data to the comparative genomic hybridization profiles of the cell lines.  The authors demonstrate that gains of genetic material contribute essentially to differential gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdxN3dNcX0I7Vg90H21EOLACvtfcHk0liXiY8_KRS_bg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVChurY%253D&md5=24e904a9a5dbdc1c7a7776e4585536e3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWai%26aufirst%3DD.%2BH.%26aulast%3DSchaefer%26aufirst%3DK.%2BL.%26aulast%3DSchramm%26aufirst%3DA.%26aulast%3DKorsching%26aufirst%3DE.%26aulast%3DVan%2BValen%26aufirst%3DF.%26aulast%3DOzaki%26aufirst%3DT.%26aulast%3DBoecker%26aufirst%3DW.%26aulast%3DSchweigerer%26aufirst%3DL.%26aulast%3DDockhorn-Dworniczak%26aufirst%3DB.%26aulast%3DPoremba%26aufirst%3DC.%26atitle%3DExpression%2520analysis%2520of%2520pediatric%2520solid%2520tumor%2520cell%2520lines%2520using%2520oligonucleotide%2520microarrays%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D441%26epage%3D451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">de Vos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grogan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krug, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrage, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wachsman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeffler, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Said, J. W.</span><span> </span><span class="NLM_article-title">Gene expression profile of serial samples of transformed B-cell lymphomas</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">285</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2003&pages=271-285&author=S.+de+Vosauthor=W.+K.+Hofmannauthor=T.+M.+Groganauthor=U.+Krugauthor=M.+Schrageauthor=T.+P.+Millerauthor=J.+G.+Braunauthor=W.+Wachsmanauthor=H.+P.+Koefflerauthor=J.+W.+Said&title=Gene+expression+profile+of+serial+samples+of+transformed+B-cell+lymphomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DHofmann%26aufirst%3DW.%2BK.%26aulast%3DGrogan%26aufirst%3DT.%2BM.%26aulast%3DKrug%26aufirst%3DU.%26aulast%3DSchrage%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DT.%2BP.%26aulast%3DBraun%26aufirst%3DJ.%2BG.%26aulast%3DWachsman%26aufirst%3DW.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26aulast%3DSaid%26aufirst%3DJ.%2BW.%26atitle%3DGene%2520expression%2520profile%2520of%2520serial%2520samples%2520of%2520transformed%2520B-cell%2520lymphomas%26jtitle%3DLab.%2520Invest.%26date%3D2003%26volume%3D83%26spage%3D271%26epage%3D285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Hayward, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faragher, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillai, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, A. M.</span><span> </span><span class="NLM_article-title">The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7370</span><span class="NLM_x">–</span> <span class="NLM_lpage">7376</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1158%2F0008-5472.CAN-04-0960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=15492258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosFyntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7370-7376&author=D.+G.+Haywardauthor=R.+B.+Clarkeauthor=A.+J.+Faragherauthor=M.+R.+Pillaiauthor=I.+M.+Haganauthor=A.+M.+Fry&title=The+centrosomal+kinase+Nek2+displays+elevated+levels+of+protein+expression+in+human+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The Centrosomal Kinase Nek2 Displays Elevated Levels of Protein Expression in Human Breast Cancer</span></div><div class="casAuthors">Hayward, Daniel G.; Clarke, Robert B.; Faragher, Alison J.; Pillai, Meenu R.; Hagan, Iain M.; Fry, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7370-7376</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aneuploidy and chromosome instability are common abnormalities in human cancer.  Loss of control over mitotic progression, multipolar spindle formation, and cytokinesis defects are all likely to contribute to these phenotypes.  Nek2 is a cell cycle-regulated protein kinase with maximal activity at the onset of mitosis that localizes to the centrosome.  Functional studies have implicated Nek2 in regulation of centrosome sepn. and spindle formation.  Here, the authors present the first study of the protein expression levels of the Nek2 kinase in human cancer cell lines and primary tumors.  Nek2 protein is elevated 2- to 5-fold in cell lines derived from a range of human tumors including those of cervical, ovarian, breast, prostate, and leukemic origin.  Most importantly, by immunohistochem., the authors find that Nek2 protein is significantly up-regulated in preinvasive in situ ductal carcinomas of the breast as well as in invasive breast carcinomas.  Finally, by ectopic expression of Nek2A in immortalized HBL100 breast epithelial cells, the authors show that increased Nek2 protein leads to accumulation of multinucleated cells with supernumerary centrosomes.  These data highlight the Nek2 kinase as novel potential target for chemotherapeutic intervention in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4ko1rEDu8fbVg90H21EOLACvtfcHk0lgjRH22rjauRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosFyntLc%253D&md5=10b8d50fa1025dd8013fced43532e4c2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-0960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-0960%26sid%3Dliteratum%253Aachs%26aulast%3DHayward%26aufirst%3DD.%2BG.%26aulast%3DClarke%26aufirst%3DR.%2BB.%26aulast%3DFaragher%26aufirst%3DA.%2BJ.%26aulast%3DPillai%26aufirst%3DM.%2BR.%26aulast%3DHagan%26aufirst%3DI.%2BM.%26aulast%3DFry%26aufirst%3DA.%2BM.%26atitle%3DThe%2520centrosomal%2520kinase%2520Nek2%2520displays%2520elevated%2520levels%2520of%2520protein%2520expression%2520in%2520human%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7370%26epage%3D7376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Kokuryo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, M.</span><span> </span><span class="NLM_article-title">Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">9637</span><span class="NLM_x">–</span> <span class="NLM_lpage">9642</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9637-9642&author=T.+Kokuryoauthor=T.+Sengaauthor=Y.+Yokoyamaauthor=M.+Naginoauthor=Y.+Nimuraauthor=M.+Hamaguchi&title=Nek2+as+an+effective+target+for+inhibition+of+tumorigenic+growth+and+peritoneal+dissemination+of+cholangiocarcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKokuryo%26aufirst%3DT.%26aulast%3DSenga%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DY.%26aulast%3DNagino%26aufirst%3DM.%26aulast%3DNimura%26aufirst%3DY.%26aulast%3DHamaguchi%26aufirst%3DM.%26atitle%3DNek2%2520as%2520an%2520effective%2520target%2520for%2520inhibition%2520of%2520tumorigenic%2520growth%2520and%2520peritoneal%2520dissemination%2520of%2520cholangiocarcinoma%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D9637%26epage%3D9642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Tsunoda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kokuryo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, M.</span><span> </span><span class="NLM_article-title">Nek2 as a novel molecular target for the treatment of breast carcinoma</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1111%2Fj.1349-7006.2008.01007.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=19038001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2009&pages=111-116&author=N.+Tsunodaauthor=T.+Kokuryoauthor=K.+Odaauthor=T.+Sengaauthor=Y.+Yokoyamaauthor=M.+Naginoauthor=Y.+Nimuraauthor=M.+Hamaguchi&title=Nek2+as+a+novel+molecular+target+for+the+treatment+of+breast+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Nek2 as a novel molecular target for the treatment of breast carcinoma</span></div><div class="casAuthors">Tsunoda, Nobuyuki; Kokuryo, Toshio; Oda, Koji; Senga, Takeshi; Yokoyama, Yukihiro; Nagino, Masato; Nimura, Yuji; Hamaguchi, Michinari</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-116</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The role of Nek2, a member of the serine-threonine kinase family, was investigated in the tumorigenic growth of breast carcinoma.  Increased expression of Nek2 was obsd. in all breast carcinoma cell lines examd. (BT20, BT474, Hs578T, MCF7, MDA-MB-231, T47D, and ZR-75-1) by immunoblotting.  By treatment with Nek2 short interfering RNA (siRNA), expression of Nek2 was clearly decreased in both estrogen receptor (ER)-pos. (MCF7) and ER-neg. (MDA-MB-231) breast carcinoma cell lines.  Cell growth, colony formation in soft agar, and in vitro invasiveness of these cell lines were substantially suppressed by Nek2 siRNA treatment.  In a xenograft nude mouse model with s.c. implantation of MCF7 or MDA-MB-231, s.c. injection of Nek2 siRNA around the tumor nodules resulted in a redn. of tumor size compared with those of control siRNA injection.  Taken together, Nek2 appears to play a pivotal role in tumorigenic growth of breast carcinoma cells, and could be a useful therapeutic mol. target for the treatment of breast carcinoma both in ER-pos. and ER-neg. cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTBN0t3kO2frVg90H21EOLACvtfcHk0lgjRH22rjauRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGns7g%253D&md5=360ba1082e73540e4a42642e16f52cc8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.01007.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.01007.x%26sid%3Dliteratum%253Aachs%26aulast%3DTsunoda%26aufirst%3DN.%26aulast%3DKokuryo%26aufirst%3DT.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DSenga%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DY.%26aulast%3DNagino%26aufirst%3DM.%26aulast%3DNimura%26aufirst%3DY.%26aulast%3DHamaguchi%26aufirst%3DM.%26atitle%3DNek2%2520as%2520a%2520novel%2520molecular%2520target%2520for%2520the%2520treatment%2520of%2520breast%2520carcinoma%26jtitle%3DCancer%2520Sci.%26date%3D2009%26volume%3D100%26spage%3D111%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Das, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paroly, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perumal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jhun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendse, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagan, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talele, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span> </span><span class="NLM_article-title">Centrosomal kinase Nek2 cooperates with oncogenic pathways to promote metastasis</span> <span class="citation_source-journal">Oncogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=1-14&author=T.+K.+Dasauthor=D.+Danaauthor=S.+S.+Parolyauthor=S.+K.+Perumalauthor=S.+Singhauthor=H.+Jhunauthor=J.+Pendseauthor=R.+L.+Caganauthor=T.+T.+Taleleauthor=S.+Kumar&title=Centrosomal+kinase+Nek2+cooperates+with+oncogenic+pathways+to+promote+metastasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DT.%2BK.%26aulast%3DDana%26aufirst%3DD.%26aulast%3DParoly%26aufirst%3DS.%2BS.%26aulast%3DPerumal%26aufirst%3DS.%2BK.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DJhun%26aufirst%3DH.%26aulast%3DPendse%26aufirst%3DJ.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26aulast%3DTalele%26aufirst%3DT.%2BT.%26aulast%3DKumar%26aufirst%3DS.%26atitle%3DCentrosomal%2520kinase%2520Nek2%2520cooperates%2520with%2520oncogenic%2520pathways%2520to%2520promote%2520metastasis%26jtitle%3DOncogenesis%26date%3D2013%26volume%3D2%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salama, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shetty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zangari, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tricot, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, F.</span><span> </span><span class="NLM_article-title">NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=48-62&author=W.+Zhouauthor=Y.+Yangauthor=J.+Xiaauthor=H.+Wangauthor=M.+E.+Salamaauthor=W.+Xiongauthor=H.+Xuauthor=S.+Shettyauthor=T.+Chenauthor=Z.+Zengauthor=L.+Shiauthor=M.+Zangariauthor=R.+Milesauthor=D.+Bearssauthor=G.+Tricotauthor=F.+Zhan&title=NEK2+induces+drug+resistance+mainly+through+activation+of+efflux+drug+pumps+and+is+associated+with+poor+prognosis+in+myeloma+and+other+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSalama%26aufirst%3DM.%2BE.%26aulast%3DXiong%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DShetty%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DZangari%26aufirst%3DM.%26aulast%3DMiles%26aufirst%3DR.%26aulast%3DBearss%26aufirst%3DD.%26aulast%3DTricot%26aufirst%3DG.%26aulast%3DZhan%26aufirst%3DF.%26atitle%3DNEK2%2520induces%2520drug%2520resistance%2520mainly%2520through%2520activation%2520of%2520efflux%2520drug%2520pumps%2520and%2520is%2520associated%2520with%2520poor%2520prognosis%2520in%2520myeloma%2520and%2520other%2520cancers%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26spage%3D48%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Vivanco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">The phosphatidylinositol 3-kinase AKT pathway in human cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1038%2Fnrc839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=12094235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=489-501&author=I.+Vivancoauthor=C.+L.+Sawyers&title=The+phosphatidylinositol+3-kinase+AKT+pathway+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol 3-Kinase-AKT pathway in human cancer</span></div><div class="casAuthors">Vivanco, Igor; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One signal that is overactivated in a wide range of tumor types is the prodn. of a phospholipid, phosphatidylinositol (3,4,5) trisphosphate, by phosphatidylinositol 3-kinase (PI3K).  This lipid and the protein kinase that is activated by it, AKT, trigger a cascade of responses, from cell growth and proliferation to survival and motility, that drive tumor progression.  Small-mol. therapeutics that block PI3K signaling might deal a severe blow to cancer cells by blocking many aspects of the tumor-cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAQ-0qeD7pLVg90H21EOLACvtfcHk0liVN6mXtixUbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D&md5=c6762d32f9f1281632f4ccdbcd29268c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrc839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc839%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DThe%2520phosphatidylinositol%25203-kinase%2520AKT%2520pathway%2520in%2520human%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D489%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Gottesman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fojo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, S. E.</span><span> </span><span class="NLM_article-title">Multidrug resistance in cancer: role of ATP-dependent transporters</span> <span class="citation_source-journal">Nat. Rev. Cancer.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1038%2Fnrc706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=11902585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=48-58&author=M.+M.+Gottesmanauthor=T.+Fojoauthor=S.+E.+Bates&title=Multidrug+resistance+in+cancer%3A+role+of+ATP-dependent+transporters"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance in cancer: role of ATP-dependent transporters</span></div><div class="casAuthors">Gottesman, Michael M.; Fojo, Tito; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemotherapeutics are the most effective treatment for metastatic tumors.  However, the ability of cancer cells to become simultaneously resistant to different drugs, a trait known as multidrug resistance, remains a significant impediment to successful chemotherapy.  Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents.  Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJtnCZv-ZtrVg90H21EOLACvtfcHk0liVN6mXtixUbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D&md5=ec5284e1fe4a878c5ffc30ee83bccc9d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrc706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc706%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DMultidrug%2520resistance%2520in%2520cancer%253A%2520role%2520of%2520ATP-dependent%2520transporters%26jtitle%3DNat.%2520Rev.%2520Cancer.%26date%3D2002%26volume%3D2%26spage%3D48%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Westwood, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheary, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayliss, R.</span><span> </span><span class="NLM_article-title">Insights into the conformational variability and regulation of human Nek2 kinase</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">386</span><span class="NLM_x">, </span> <span class="NLM_fpage">476</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2009&pages=476-485&author=I.+Westwoodauthor=D.+M.+Chearyauthor=J.+E.+Baxterauthor=M.+W.+Richardsauthor=R.+L.+van+Montfortauthor=A.+M.+Fryauthor=R.+Bayliss&title=Insights+into+the+conformational+variability+and+regulation+of+human+Nek2+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWestwood%26aufirst%3DI.%26aulast%3DCheary%26aufirst%3DD.%2BM.%26aulast%3DBaxter%26aufirst%3DJ.%2BE.%26aulast%3DRichards%26aufirst%3DM.%2BW.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DBayliss%26aufirst%3DR.%26atitle%3DInsights%2520into%2520the%2520conformational%2520variability%2520and%2520regulation%2520of%2520human%2520Nek2%2520kinase%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D386%26spage%3D476%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Fry, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Regan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabir, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayliss, R.</span><span> </span><span class="NLM_article-title">Cell cycle regulation by the NEK family of protein kinases</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">4423</span><span class="NLM_x">–</span> <span class="NLM_lpage">4433</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1242%2Fjcs.111195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=23132929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsl2gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=4423-4433&author=A.+M.+Fryauthor=L.+O%E2%80%99Reganauthor=S.+R.+Sabirauthor=R.+Bayliss&title=Cell+cycle+regulation+by+the+NEK+family+of+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle regulation by the NEK family of protein kinases</span></div><div class="casAuthors">Fry, Andrew M.; O'Regan, Laura; Sabir, Sarah R.; Bayliss, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4423-4433</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Genetic screens for cell division cycle mutants in the filamentous fungus Aspergillus nidulans led to the discovery of never-in-mitosis A (NIMA) kinase, a serine/threonine kinase that is required for mitotic entry.  Since that discovery, NIMA-related kinases, or NEKs, have been identified in most eukaryotes, including humans where 11 genetically distinct proteins named NEK1 to NEK11 are expressed.  Although there is no evidence that human NEKs are essential for mitotic entry, it is clear that several NEK family members play important roles in cell cycle control.  In particular, NEK2, NEK6, NEK7, and NEK9 contribute to the establishment of the microtubule-based mitotic spindle, whereas NEK1, NEK10, and NEK11 have been implicated in the DNA damage response.  Roles for NEKs in other aspects of mitotic progression, such as chromatin condensation, nuclear envelope breakdown, spindle assembly checkpoint signaling, and cytokinesis have also been proposed.  Interestingly, NEK1 and NEK8 also function within cilia, the microtubule-based structures that are nucleated from basal bodies.  This has led to the current hypothesis that NEKs have evolved to coordinate microtubule-dependent processes in both dividing and non-dividing cells.  Here, the authors review the functions of human NEKs, with particular emphasis on those family members that are involved in cell cycle control, and consider their potential as therapeutic targets in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKCk9miADRfLVg90H21EOLACvtfcHk0liVN6mXtixUbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsl2gtA%253D%253D&md5=6965616ca443eeeb40fb320bea94bd36</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1242%2Fjcs.111195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.111195%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DO%25E2%2580%2599Regan%26aufirst%3DL.%26aulast%3DSabir%26aufirst%3DS.%2BR.%26aulast%3DBayliss%26aufirst%3DR.%26atitle%3DCell%2520cycle%2520regulation%2520by%2520the%2520NEK%2520family%2520of%2520protein%2520kinases%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2012%26volume%3D125%26spage%3D4423%26epage%3D4433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Fry, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nigg, E. A.</span><span> </span><span class="NLM_article-title">Substrate specificity and cell cycle regulation of the Nek2 protein kinase, a potential human homolog of the mitotic regulator NIMA of <i>Aspergillus nidulans</i></span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">12899</span><span class="NLM_x">–</span> <span class="NLM_lpage">12905</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=12899-12905&author=A.+M.+Fryauthor=S.+J.+Schultzauthor=J.+Bartekauthor=E.+A.+Nigg&title=Substrate+specificity+and+cell+cycle+regulation+of+the+Nek2+protein+kinase%2C+a+potential+human+homolog+of+the+mitotic+regulator+NIMA+of+Aspergillus+nidulans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DSchultz%26aufirst%3DS.%2BJ.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DNigg%26aufirst%3DE.%2BA.%26atitle%3DSubstrate%2520specificity%2520and%2520cell%2520cycle%2520regulation%2520of%2520the%2520Nek2%2520protein%2520kinase%252C%2520a%2520potential%2520human%2520homolog%2520of%2520the%2520mitotic%2520regulator%2520NIMA%2520of%2520Aspergillus%2520nidulans%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D12899%26epage%3D12905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Reininger, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tewari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldring, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranford-Cartwright, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billker, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerig, C.</span><span> </span><span class="NLM_article-title">An essential role for the <i>Plasmodium</i> Nek-2 Nima-related protein kinase in the sexual development of malaria parasites</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">20858</span><span class="NLM_x">–</span> <span class="NLM_lpage">20868</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=20858-20868&author=L.+Reiningerauthor=R.+Tewariauthor=C.+Fennellauthor=Z.+Hollandauthor=D.+Goldringauthor=L.+Ranford-Cartwrightauthor=O.+Billkerauthor=C.+Doerig&title=An+essential+role+for+the+Plasmodium+Nek-2+Nima-related+protein+kinase+in+the+sexual+development+of+malaria+parasites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReininger%26aufirst%3DL.%26aulast%3DTewari%26aufirst%3DR.%26aulast%3DFennell%26aufirst%3DC.%26aulast%3DHolland%26aufirst%3DZ.%26aulast%3DGoldring%26aufirst%3DD.%26aulast%3DRanford-Cartwright%26aufirst%3DL.%26aulast%3DBillker%26aufirst%3DO.%26aulast%3DDoerig%26aufirst%3DC.%26atitle%3DAn%2520essential%2520role%2520for%2520the%2520Plasmodium%2520Nek-2%2520Nima-related%2520protein%2520kinase%2520in%2520the%2520sexual%2520development%2520of%2520malaria%2520parasites%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D20858%26epage%3D20868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Bahmanyar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deluca, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giddings, T. H.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Toole, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmon, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, A. I.</span><span> </span><span class="NLM_article-title">β-Catenin is a Nek2 substrate involved in centrosome separation</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=91-105&author=S.+Bahmanyarauthor=D.+D.+Kaplanauthor=J.+G.+Delucaauthor=T.+H.+Giddingsauthor=E.+T.+O%E2%80%99Tooleauthor=M.+Wineyauthor=E.+D.+Salmonauthor=P.+J.+Caseyauthor=W.+J.+Nelsonauthor=A.+I.+Barth&title=%CE%B2-Catenin+is+a+Nek2+substrate+involved+in+centrosome+separation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBahmanyar%26aufirst%3DS.%26aulast%3DKaplan%26aufirst%3DD.%2BD.%26aulast%3DDeluca%26aufirst%3DJ.%2BG.%26aulast%3DGiddings%26aufirst%3DT.%2BH.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DE.%2BT.%26aulast%3DWiney%26aufirst%3DM.%26aulast%3DSalmon%26aufirst%3DE.%2BD.%26aulast%3DCasey%26aufirst%3DP.%2BJ.%26aulast%3DNelson%26aufirst%3DW.%2BJ.%26aulast%3DBarth%26aufirst%3DA.%2BI.%26atitle%3D%25CE%25B2-Catenin%2520is%2520a%2520Nek2%2520substrate%2520involved%2520in%2520centrosome%2520separation%26jtitle%3DGenes%2520Dev.%26date%3D2008%26volume%3D22%26spage%3D91%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Sonn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhee, K.</span><span> </span><span class="NLM_article-title">Nip2/centrobin may be a substrate of Nek2 that is required for proper spindle assembly during mitosis in early mouse embryos</span> <span class="citation_source-journal">Mol. Reprod. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2009&pages=587-592&author=S.+Sonnauthor=Y.+Jeongauthor=K.+Rhee&title=Nip2%2Fcentrobin+may+be+a+substrate+of+Nek2+that+is+required+for+proper+spindle+assembly+during+mitosis+in+early+mouse+embryos"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSonn%26aufirst%3DS.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DRhee%26aufirst%3DK.%26atitle%3DNip2%252Fcentrobin%2520may%2520be%2520a%2520substrate%2520of%2520Nek2%2520that%2520is%2520required%2520for%2520proper%2520spindle%2520assembly%2520during%2520mitosis%2520in%2520early%2520mouse%2520embryos%26jtitle%3DMol.%2520Reprod.%2520Dev.%26date%3D2009%26volume%3D76%26spage%3D587%26epage%3D592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Fry, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nigg, E. A.</span><span> </span><span class="NLM_article-title">Characterization of mammalian NIMA-related kinases</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=270-282&author=A.+M.+Fryauthor=E.+A.+Nigg&title=Characterization+of+mammalian+NIMA-related+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DNigg%26aufirst%3DE.%2BA.%26atitle%3DCharacterization%2520of%2520mammalian%2520NIMA-related%2520kinases%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D283%26spage%3D270%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Helps, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P. T.</span><span> </span><span class="NLM_article-title">NIMA-related kinase 2 (Nek2), a cell-cycle-regulated protein kinase localized to centrosomes, is complexed to protein phosphatase 1</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">509</span><span class="NLM_x">–</span> <span class="NLM_lpage">518</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2000&pages=509-518&author=N.+R.+Helpsauthor=X.+Luoauthor=H.+M.+Barkerauthor=P.+T.+Cohen&title=NIMA-related+kinase+2+%28Nek2%29%2C+a+cell-cycle-regulated+protein+kinase+localized+to+centrosomes%2C+is+complexed+to+protein+phosphatase+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHelps%26aufirst%3DN.%2BR.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DBarker%26aufirst%3DH.%2BM.%26aulast%3DCohen%26aufirst%3DP.%2BT.%26atitle%3DNIMA-related%2520kinase%25202%2520%2528Nek2%2529%252C%2520a%2520cell-cycle-regulated%2520protein%2520kinase%2520localized%2520to%2520centrosomes%252C%2520is%2520complexed%2520to%2520protein%2520phosphatase%25201%26jtitle%3DBiochem.%2520J.%26date%3D2000%26volume%3D349%26spage%3D509%26epage%3D518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Meraldi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nigg, E. A.</span><span> </span><span class="NLM_article-title">Centrosome cohesion is regulated by a balance of kinase and phosphatase activities</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">3749</span><span class="NLM_x">–</span> <span class="NLM_lpage">3757</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=11707526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD3MXot12nsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2001&pages=3749-3757&author=P.+Meraldiauthor=E.+A.+Nigg&title=Centrosome+cohesion+is+regulated+by+a+balance+of+kinase+and+phosphatase+activities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Centrosome cohesion is regulated by a balance of kinase and phosphatase activities</span></div><div class="casAuthors">Meraldi, Patrick; Nigg, Erich A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3749-3757</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Centrosome cohesion and sepn. are regulated throughout the cell cycle, but the underlying mechanisms are not well understood.  Since overexpression of a protein kinase, Nek2, is able to trigger centrosome splitting (the sepn. of parental centrioles), we have surveyed a panel of centrosome-assocd. kinases for their ability to induce a similar phenotype.  Cdk2, in assocn. with either cyclin A or E, was as effective as Nek2, but several other kinases tested did not significantly interfere with centrosome cohesion.  Centrosome splitting could also be triggered by inhibition of phosphatases, and protein phosphatase 1α (PP1α) was identified as a likely physiol. antagonist of Nek2.  Furthermore, we have revisited the role of the microtubule network in the control of centrosome cohesion.  We could confirm that microtubule depolymn. by nocodazole causes centrosome splitting.  Surprisingly, however, this drug-induced splitting also required kinase activity and could specifically be suppressed by a dominant-neg. mutant of Nek2.  These studies highlight the importance of protein phosphorylation in the control of centrosome cohesion, and they point to Nek2 and PP1α as crit. regulators of centrosome structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2MF69ghfWwrVg90H21EOLACvtfcHk0lht0jMQKB04rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXot12nsr0%253D&md5=7f44d5cbecf80b4669fa1a9f7f517f49</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeraldi%26aufirst%3DP.%26aulast%3DNigg%26aufirst%3DE.%2BA.%26atitle%3DCentrosome%2520cohesion%2520is%2520regulated%2520by%2520a%2520balance%2520of%2520kinase%2520and%2520phosphatase%2520activities%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2001%26volume%3D114%26spage%3D3749%26epage%3D3757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Wai, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schramm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korsching, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Valen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boecker, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweigerer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dockhorn-Dworniczak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poremba, C.</span><span> </span><span class="NLM_article-title">Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=11836553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVChurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=441-451&author=D.+H.+Waiauthor=K.+L.+Schaeferauthor=A.+Schrammauthor=E.+Korschingauthor=F.+Van+Valenauthor=T.+Ozakiauthor=W.+Boeckerauthor=L.+Schweigererauthor=B.+Dockhorn-Dworniczakauthor=C.+Poremba&title=Expression+analysis+of+pediatric+solid+tumor+cell+lines+using+oligonucleotide+microarrays"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays</span></div><div class="casAuthors">Wai, Daniel H.; Schaeffer, Karl-Ludwig; Schramm, Alexander; Korsching, Eberhard; Van Valen, Frans; Ozaki, Toshifumi; Boecker, Werner; Schweigerer, Lothar; Dockhorn-Dworniczak, Barbara; Poremba, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-451</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">The authors identified patterns of differentially-expressed genes in cell lines derived from several pediatric solid tumors.  Affymetrix Human Cancer G110 Arrays, carrying 1,700 cancer-assocd. genes, were applied to a panel of 11 cell lines originating from Ewing tumors (ETs), neuroblastomas, and malignant melanoma of soft parts.  Hierarchical clustering clearly differentiated these 3 entities and revealed groups of 75, 102, and 36 gene probe-sets exhibiting tumor-type specific up-regulation in these cell lines, resp.  Whereas ET lines demonstrated increased expression of microtubule-assocd. protein tau (MAPT), protein phosphatase 1 regulatory subunit 1A (PPPlRlA), NIMA (never in mitosis gene a)-related kinase 2 (NEK2), and cyclin D1 (CCNDl), neuroblastoma samples exhibited high expression of wingless-type mouse mammary tumor virus integration site family member 11 (WNT11), Drosophila frizzled homolog 2 (FZD2), and adenomatous polyposis coli (APC) which are involved in regulating free β-catenin levels.  These genes likely maintain tumor-specific characteristics and participate in key down-stream regulatory mechanisms.  The authors also correlated the expression levels of up-regulated genes in ETs with their chromosomal localization and compared these data to the comparative genomic hybridization profiles of the cell lines.  The authors demonstrate that gains of genetic material contribute essentially to differential gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdxN3dNcX0I7Vg90H21EOLACvtfcHk0lht0jMQKB04rw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVChurY%253D&md5=24e904a9a5dbdc1c7a7776e4585536e3</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWai%26aufirst%3DD.%2BH.%26aulast%3DSchaefer%26aufirst%3DK.%2BL.%26aulast%3DSchramm%26aufirst%3DA.%26aulast%3DKorsching%26aufirst%3DE.%26aulast%3DVan%2BValen%26aufirst%3DF.%26aulast%3DOzaki%26aufirst%3DT.%26aulast%3DBoecker%26aufirst%3DW.%26aulast%3DSchweigerer%26aufirst%3DL.%26aulast%3DDockhorn-Dworniczak%26aufirst%3DB.%26aulast%3DPoremba%26aufirst%3DC.%26atitle%3DExpression%2520analysis%2520of%2520pediatric%2520solid%2520tumor%2520cell%2520lines%2520using%2520oligonucleotide%2520microarrays%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D441%26epage%3D451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Fukuhara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Variakojis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golomb, H. M.</span><span> </span><span class="NLM_article-title">Chromosome abnormalities in poorly differentiated lymphocytic lymphoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">3119</span><span class="NLM_x">–</span> <span class="NLM_lpage">3128</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1979&pages=3119-3128&author=S.+Fukuharaauthor=J.+D.+Rowleyauthor=D.+Variakojisauthor=H.+M.+Golomb&title=Chromosome+abnormalities+in+poorly+differentiated+lymphocytic+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFukuhara%26aufirst%3DS.%26aulast%3DRowley%26aufirst%3DJ.%2BD.%26aulast%3DVariakojis%26aufirst%3DD.%26aulast%3DGolomb%26aufirst%3DH.%2BM.%26atitle%3DChromosome%2520abnormalities%2520in%2520poorly%2520differentiated%2520lymphocytic%2520lymphoma%26jtitle%3DCancer%2520Res.%26date%3D1979%26volume%3D39%26spage%3D3119%26epage%3D3128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Kokuryo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, M.</span><span> </span><span class="NLM_article-title">Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">9637</span><span class="NLM_x">–</span> <span class="NLM_lpage">9642</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9637-9642&author=T.+Kokuryoauthor=T.+Sengaauthor=Y.+Yokoyamaauthor=M.+Naginoauthor=Y.+Nimuraauthor=M.+Hamaguchi&title=Nek2+as+an+effective+target+for+inhibition+of+tumorigenic+growth+and+peritoneal+dissemination+of+cholangiocarcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKokuryo%26aufirst%3DT.%26aulast%3DSenga%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DY.%26aulast%3DNagino%26aufirst%3DM.%26aulast%3DNimura%26aufirst%3DY.%26aulast%3DHamaguchi%26aufirst%3DM.%26atitle%3DNek2%2520as%2520an%2520effective%2520target%2520for%2520inhibition%2520of%2520tumorigenic%2520growth%2520and%2520peritoneal%2520dissemination%2520of%2520cholangiocarcinoma%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D9637%26epage%3D9642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Tsunoda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kokuryo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, M.</span><span> </span><span class="NLM_article-title">Nek2 as a novel molecular target for the treatment of breast carcinoma</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1111%2Fj.1349-7006.2008.01007.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=19038001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2009&pages=111-116&author=N.+Tsunodaauthor=T.+Kokuryoauthor=K.+Odaauthor=T.+Sengaauthor=Y.+Yokoyamaauthor=M.+Naginoauthor=Y.+Nimuraauthor=M.+Hamaguchi&title=Nek2+as+a+novel+molecular+target+for+the+treatment+of+breast+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Nek2 as a novel molecular target for the treatment of breast carcinoma</span></div><div class="casAuthors">Tsunoda, Nobuyuki; Kokuryo, Toshio; Oda, Koji; Senga, Takeshi; Yokoyama, Yukihiro; Nagino, Masato; Nimura, Yuji; Hamaguchi, Michinari</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-116</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The role of Nek2, a member of the serine-threonine kinase family, was investigated in the tumorigenic growth of breast carcinoma.  Increased expression of Nek2 was obsd. in all breast carcinoma cell lines examd. (BT20, BT474, Hs578T, MCF7, MDA-MB-231, T47D, and ZR-75-1) by immunoblotting.  By treatment with Nek2 short interfering RNA (siRNA), expression of Nek2 was clearly decreased in both estrogen receptor (ER)-pos. (MCF7) and ER-neg. (MDA-MB-231) breast carcinoma cell lines.  Cell growth, colony formation in soft agar, and in vitro invasiveness of these cell lines were substantially suppressed by Nek2 siRNA treatment.  In a xenograft nude mouse model with s.c. implantation of MCF7 or MDA-MB-231, s.c. injection of Nek2 siRNA around the tumor nodules resulted in a redn. of tumor size compared with those of control siRNA injection.  Taken together, Nek2 appears to play a pivotal role in tumorigenic growth of breast carcinoma cells, and could be a useful therapeutic mol. target for the treatment of breast carcinoma both in ER-pos. and ER-neg. cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTBN0t3kO2frVg90H21EOLACvtfcHk0ljl5GFRofigCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGns7g%253D&md5=360ba1082e73540e4a42642e16f52cc8</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.01007.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.01007.x%26sid%3Dliteratum%253Aachs%26aulast%3DTsunoda%26aufirst%3DN.%26aulast%3DKokuryo%26aufirst%3DT.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DSenga%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DY.%26aulast%3DNagino%26aufirst%3DM.%26aulast%3DNimura%26aufirst%3DY.%26aulast%3DHamaguchi%26aufirst%3DM.%26atitle%3DNek2%2520as%2520a%2520novel%2520molecular%2520target%2520for%2520the%2520treatment%2520of%2520breast%2520carcinoma%26jtitle%3DCancer%2520Sci.%26date%3D2009%26volume%3D100%26spage%3D111%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Cappello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaser, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorrini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elia, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakeham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haider, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutros, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Done, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span> </span><span class="NLM_article-title">Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=1-10&author=P.+Cappelloauthor=H.+Blaserauthor=C.+Gorriniauthor=D.+C.+Linauthor=A.+J.+Eliaauthor=A.+Wakehamauthor=S.+Haiderauthor=P.+C.+Boutrosauthor=J.+M.+Masonauthor=N.+A.+Millerauthor=B.+Youngsonauthor=S.+J.+Doneauthor=T.+W.+Mak&title=Role+of+Nek2+on+centrosome+duplication+and+aneuploidy+in+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCappello%26aufirst%3DP.%26aulast%3DBlaser%26aufirst%3DH.%26aulast%3DGorrini%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DD.%2BC.%26aulast%3DElia%26aufirst%3DA.%2BJ.%26aulast%3DWakeham%26aufirst%3DA.%26aulast%3DHaider%26aufirst%3DS.%26aulast%3DBoutros%26aufirst%3DP.%2BC.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DN.%2BA.%26aulast%3DYoungson%26aufirst%3DB.%26aulast%3DDone%26aufirst%3DS.%2BJ.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DRole%2520of%2520Nek2%2520on%2520centrosome%2520duplication%2520and%2520aneuploidy%2520in%2520breast%2520cancer%2520cells%26jtitle%3DOncogene%26date%3D2013%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gollahon, L.</span><span> </span><span class="NLM_article-title">Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple-negative breast cancer cells</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">847</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=23340795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkt1Kiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2013&pages=839-847&author=J.+Leeauthor=L.+Gollahon&title=Nek2-targeted+ASO+or+siRNA+pretreatment+enhances+anticancer+drug+sensitivity+in+triple-negative+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple-negative breast cancer cells</span></div><div class="casAuthors">Lee, Jaehyung; Gollahon, Lauren</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-847</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Although the anticancer drugs paclitaxel and doxorubicin are commonly used to treat many solid tumors, their effectiveness is highly variable due to tumor cell resistance.  Therefore, it is important to find mechanisms that can be targeted to increase the sensitivity of cancer cells to current chemotherapeutic agents.  NIMA-related kinase 2 (Nek2), a serine/threonine kinase is emerging as an important oncogene because of its regulatory role in mitosis.  Thus, regulation of the Nek2 expression levels may prove important as a target for cancer treatment.  The purpose of our study was to det. whether drug sensitivity was increased in the triple neg. breast cancer cell lines MDA-MB-231 and MDA-MB-468 by using small interfering RNA (siRNA) and antisense oligonucleotides (ASOs) against Nek2.  To this end, MDA-MB-231 and MDA-MB-468 breast cancer cells transfected with Nek2 siRNA or ASO were exposed to various concns. of paclitaxel and doxorubicin.  Cell viability, cell cycle distribution and apoptosis were evaluated.  We obsd. that drug susceptibility in these transfected cells was dramatically increased compared with either agent alone.  FACS results showed that apoptosis was induced in siRNA- and ASO-transfected cells as expected due to the regulatory function of Nek2 in centrosome duplication.  Interestingly, the cell cycle was not arrested in transfected cells.  We found that siRNA and ASO against Nek2 worked synergistically with paclitaxel and doxorubicin by promoting cell apoptosis.  Our results suggest that these drugs in combination with Nek2 siRNA or ASO treatment may improve the sensitivity of cancer cells during chemotherapy treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozgctIypcsZrVg90H21EOLACvtfcHk0ljl5GFRofigCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkt1Kiur0%253D&md5=a796bd4185e8cda988701a414aa53182</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DGollahon%26aufirst%3DL.%26atitle%3DNek2-targeted%2520ASO%2520or%2520siRNA%2520pretreatment%2520enhances%2520anticancer%2520drug%2520sensitivity%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2013%26volume%3D42%26spage%3D839%26epage%3D847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Lage, H.</span><span> </span><span class="NLM_article-title">ABC-transporters: implications on drug resistance from microorganisms to human cancers</span> <span class="citation_source-journal">Int. J. Antimicrob. Agents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1016%2FS0924-8579%2803%2900203-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=13678820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1yqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=188-199&author=H.+Lage&title=ABC-transporters%3A+implications+on+drug+resistance+from+microorganisms+to+human+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">ABC-transporters: implications on drug resistance from microorganisms to human cancers</span></div><div class="casAuthors">Lage, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">188-199</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Resistance to chemotherapy is a common clin. problem in patients with infectious diseases as well as in patients with cancer.  During treatment of infections or malignant tumors, the drug targets of prokaryotic or eukaryotic microorganisms and neoplastic cells are often found to be refractory to a variety of drugs that have different structures and functions.  This phenomenon was termed multidrug resistance (MDR).  The mechanisms leading to MDR are frequently caused by trans-membrane xenobiotic transport mols. belonging to the superfamily of ATP-binding cassette (ABC) transporters.  There is an urgent need to understand the structure-function relationships of these efflux pumps that underlie their transport mechanism and drug selectivity.  This knowledge may allow the rational design of new drugs that can inhibit or circumvent the activity of these MDR transport mols.  Furthermore, the development of such chemosensitizing agents would help us learn more about the physiol. functions and substrates of these pump proteins.  This review will discuss the current state of knowledge of the functional and structural similarities among ABC-transporters in prokaryotic and eukaryotic cells and their impact on MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNtyU0p9Si4bVg90H21EOLACvtfcHk0lhyEGePyn8aQA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1yqur4%253D&md5=907a548d672092a967504876967f1c5d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0924-8579%2803%2900203-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0924-8579%252803%252900203-6%26sid%3Dliteratum%253Aachs%26aulast%3DLage%26aufirst%3DH.%26atitle%3DABC-transporters%253A%2520implications%2520on%2520drug%2520resistance%2520from%2520microorganisms%2520to%2520human%2520cancers%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2003%26volume%3D22%26spage%3D188%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Bell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kartner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buick, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, V.</span><span> </span><span class="NLM_article-title">Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=2857774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A280%3ADyaL2M7jtlOluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1985&pages=311-315&author=D.+R.+Bellauthor=J.+H.+Gerlachauthor=N.+Kartnerauthor=R.+N.+Buickauthor=V.+Ling&title=Detection+of+P-glycoprotein+in+ovarian+cancer%3A+a+molecular+marker+associated+with+multidrug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance</span></div><div class="casAuthors">Bell D R; Gerlach J H; Kartner N; Buick R N; Ling V</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">311-5</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">A multidrug resistance phenotype is frequently observed in animal and human cell lines selected for in vitro resistance to a single chemotherapeutic agent.  Overexpression of a highly conserved cell-surface glycoprotein (P-glycoprotein) is consistently associated with this phenotype in these mutant lines.  A monoclonal antibody against P-glycoprotein was used to examine tumor samples from five patients with advanced ovarian cancer for evidence of P-glycoprotein overexpression.  High levels of P-glycoprotein were detected in samples from two patients suggesting that a multidrug resistance mutation may also occur in ovarian cancer.  This finding has broad implications for the understanding of nonresponse to chemotherapy in a variety of human neoplasms, and may provide a rational explanation for failure of chemotherapy in treatment of advanced ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQQORUaC65AO3MPKNEWB5RfW6udTcc2ebwXKkkIiGGErntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2M7jtlOluw%253D%253D&md5=b14e36ba83450af03787beb760a5c420</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DD.%2BR.%26aulast%3DGerlach%26aufirst%3DJ.%2BH.%26aulast%3DKartner%26aufirst%3DN.%26aulast%3DBuick%26aufirst%3DR.%2BN.%26aulast%3DLing%26aufirst%3DV.%26atitle%3DDetection%2520of%2520P-glycoprotein%2520in%2520ovarian%2520cancer%253A%2520a%2520molecular%2520marker%2520associated%2520with%2520multidrug%2520resistance%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1985%26volume%3D3%26spage%3D311%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foekens, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer-van Gelder, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klijn, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiemer, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nooter, K.</span><span> </span><span class="NLM_article-title">RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">827</span><span class="NLM_x">–</span> <span class="NLM_lpage">836</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=12576456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVKksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=827-836&author=H.+Burgerauthor=J.+A.+Foekensauthor=M.+P.+Lookauthor=M.+E.+Meijer-van+Gelderauthor=J.+G.+Klijnauthor=E.+A.+Wiemerauthor=G.+Stoterauthor=K.+Nooter&title=RNA+expression+of+breast+cancer+resistance+protein%2C+lung+resistance-related+protein%2C+multidrug+resistance-associated+proteins+1+and+2%2C+and+multidrug+resistance+gene+1+in+breast+cancer%3A+correlation+with+chemotherapeutic+response"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response</span></div><div class="casAuthors">Burger, Herman; Foekens, John A.; Look, Maxime P.; Meijer-van Gelder, Marion E.; Klijn, Jan G. M.; Wiemer, Erik A. C.; Stoter, Gerrit; Nooter, Kees</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">827-836</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The aim of this study was to investigate whether expression of particular drug resistance genes in primary operable breast cancer correlates with response to first-line chemotherapy in advanced disease.  We detd. mRNA levels of BCRP, LRP, MRP1, MRP2, and MDR1 in 59 primary breast tumor specimens of patients who received chemotherapy as first-line systemic treatment after diagnosis of advanced disease.  The relative expression levels were measured by quant. real-time reverse transcription-PCR and subsequently analyzed in relation to the type of response to chemotherapy, the length of progression-free survival (PFS), and post-relapse overall survival.  For each of these drug resistance genes, a large variation in expression level was obsd. among the tumors of the different patients.  When analyzing mRNA expression in relation to overall response, it was found that the median expression level of these five drug resistance genes in the responding tumors, as compared with nonresponding tumors, was markedly lower.  Classification of tumors as high vs. low with respect to the expression level of these genes showed that the overall response in the MDR1-high subset (17%), as compared with the MDR1-low subset (68%), was significantly lower (P = 0.005).  Although similar differences in response rate were found for subsets of tumors stratified by the expression level of the other drug resistance genes, none of the obsd. differences were statistically significant.  However, in the subgroup of patients treated with anthracycline-based chemotherapy (5-fluorouracil, Adriamycin/epirubicin, and cyclophosphamide), a correlation between response and the expression of BCRP and MRP1 (only PFS) was found, whereas such an assocn. was not present in the cyclophosphamide, methotrexate, and 5-fluorouracil-treated group of patients.  Furthermore, high expression of LRP as well as MDR1 was found to be significantly assocd. with a poor PFS (P = 0.04 and P < 0.001, resp.).  For lung resistance-related protein, this assocn. was limited to 5-fluorouracil, Adriamycin/epirubicin, and cyclophosphamide.  Expression levels of BCRP, MRP1, or MRP2 were not related with the length of PFS.  Furthermore, no correlation between the expression level of these drug resistance genes and post-relapse overall survival was found.  In this pilot study, MDR1 expression in primary breast tumors was inversely related with the efficacy of first-line chemotherapy, and high expression level was a significant predictor of poor prognosis for patients with advanced disease.  Apart from MDR1, the expression levels of BCRP, LRP, and MRP1 might have some addnl. predictive value for clin. outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKQvPviASlqbVg90H21EOLACvtfcHk0ljgxMVK_yhJNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVKksbc%253D&md5=66a680552d3bed21d24fc42b12c36452</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26aulast%3DLook%26aufirst%3DM.%2BP.%26aulast%3DMeijer-van%2BGelder%26aufirst%3DM.%2BE.%26aulast%3DKlijn%26aufirst%3DJ.%2BG.%26aulast%3DWiemer%26aufirst%3DE.%2BA.%26aulast%3DStoter%26aufirst%3DG.%26aulast%3DNooter%26aufirst%3DK.%26atitle%3DRNA%2520expression%2520of%2520breast%2520cancer%2520resistance%2520protein%252C%2520lung%2520resistance-related%2520protein%252C%2520multidrug%2520resistance-associated%2520proteins%25201%2520and%25202%252C%2520and%2520multidrug%2520resistance%2520gene%25201%2520in%2520breast%2520cancer%253A%2520correlation%2520with%2520chemotherapeutic%2520response%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D827%26epage%3D836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Ro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ro, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsche, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blick, M.</span><span> </span><span class="NLM_article-title">Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer</span> <span class="citation_source-journal">Hum. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">787</span><span class="NLM_x">–</span> <span class="NLM_lpage">791</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1016%2F0046-8177%2890%2990046-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=1974874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A280%3ADyaK3czltl2htA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1990&pages=787-791&author=J.+Roauthor=A.+Sahinauthor=J.+Y.+Roauthor=H.+Fritscheauthor=G.+Hortobagyiauthor=M.+Blick&title=Immunohistochemical+analysis+of+P-glycoprotein+expression+correlated+with+chemotherapy+resistance+in+locally+advanced+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer</span></div><div class="casAuthors">Ro J; Sahin A; Ro J Y; Fritsche H; Hortobagyi G; Blick M</div><div class="citationInfo"><span class="NLM_cas:title">Human pathology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">787-91</span>
        ISSN:<span class="NLM_cas:issn">0046-8177</span>.
    </div><div class="casAbstract">We analyzed the expression of P-glycoprotein in samples from 48 patients with locally advanced breast cancer.  Tumor samples from 40 patients were obtained at mastectomy, which was performed after three cycles of induction chemotherapy consisting of doxorubicin, cyclophosphamide, vincristine, and prednisone.  P-glycoprotein expression distributed focally was observed in 20 tumors by the immunoperoxidase method using the anti-p170-monoclonal antibody C219.  The percentage of the tumor cell population expressing P-glycoprotein varied from less than 5% to greater than 30%; expression was observed significantly more often in tumors that showed less than partial response to the preoperative chemotherapy.  Furthermore, P-glycoprotein was not expressed in eight tumor specimens obtained at the time of diagnosis, prior to chemotherapy, from patients who subsequently had pathologic complete responses.  A comparative study of P-glycoprotein expression before and after chemotherapy and upon recurrence of tumor was done on a limited number of samples.  No significant differences in P-glycoprotein expression were found.  Therefore, it is possible that an intrinsic, rather than acquired, drug resistance may play a role in the failure of induction chemotherapy for locally advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTZvWaWpZH_5WtyewyzkyLfW6udTcc2eYwEJQs9GKMnLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3czltl2htA%253D%253D&md5=61c4a7686a67a7aee9ae3e132a0f8504</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2F0046-8177%2890%2990046-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0046-8177%252890%252990046-8%26sid%3Dliteratum%253Aachs%26aulast%3DRo%26aufirst%3DJ.%26aulast%3DSahin%26aufirst%3DA.%26aulast%3DRo%26aufirst%3DJ.%2BY.%26aulast%3DFritsche%26aufirst%3DH.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DBlick%26aufirst%3DM.%26atitle%3DImmunohistochemical%2520analysis%2520of%2520P-glycoprotein%2520expression%2520correlated%2520with%2520chemotherapy%2520resistance%2520in%2520locally%2520advanced%2520breast%2520cancer%26jtitle%3DHum.%2520Pathol.%26date%3D1990%26volume%3D21%26spage%3D787%26epage%3D791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Mi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brautigan, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larner, J. M.</span><span> </span><span class="NLM_article-title">Protein phosphatase-1alpha regulates centrosome splitting through Nek2</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1082</span><span class="NLM_x">–</span> <span class="NLM_lpage">1089</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=1082-1089&author=J.+Miauthor=C.+Guoauthor=D.+L.+Brautiganauthor=J.+M.+Larner&title=Protein+phosphatase-1alpha+regulates+centrosome+splitting+through+Nek2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMi%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DBrautigan%26aufirst%3DD.%2BL.%26aulast%3DLarner%26aufirst%3DJ.%2BM.%26atitle%3DProtein%2520phosphatase-1alpha%2520regulates%2520centrosome%2520splitting%2520through%2520Nek2%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D1082%26epage%3D1089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Xiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D. W.</span><span> </span><span class="NLM_article-title">Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation</span> <span class="citation_source-journal">Cell Death Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1448</span><span class="NLM_x">–</span> <span class="NLM_lpage">1462</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1038%2Fcdd.2010.16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=20186153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVantr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=1448-1462&author=L.+Xiaoauthor=L.+L.+Gongauthor=D.+Yuanauthor=M.+Dengauthor=X.+M.+Zengauthor=L.+L.+Chenauthor=L.+Zhangauthor=Q.+Yanauthor=J.+P.+Liuauthor=X.+H.+Huauthor=S.+M.+Sunauthor=J.+Liuauthor=H.+L.+Maauthor=C.+B.+Zhengauthor=H.+Fuauthor=P.+C.+Chenauthor=J.+Q.+Zhaoauthor=S.+S.+Xieauthor=L.+J.+Zouauthor=Y.+M.+Xiaoauthor=W.+B.+Liuauthor=J.+Zhangauthor=Y.+Liuauthor=D.+W.+Li&title=Protein+phosphatase-1+regulates+Akt1+signal+transduction+pathway+to+control+gene+expression%2C+cell+survival+and+differentiation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation</span></div><div class="casAuthors">Xiao, L.; Gong, L.-L.; Yuan, D.; Deng, M.; Zeng, X.-M.; Chen, L.-L.; Zhang, L.; Yan, Qin; Liu, J.-P.; Hu, X.-H.; Sun, S.-M.; Liu, J.; Ma, H.-L.; Zheng, C.-B.; Fu, H.; Chen, P.-C.; Zhao, J.-Q.; Xie, S.-S.; Zou, L.-J.; Xiao, Y.-M.; Liu, W.-B.; Zhang, J.; Liu, Y.; Li, D. W.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1448-1462</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">AKT pathway has a crit. role in mediating signaling transductions for cell proliferation, differentiation and survival.  Previous studies have shown that AKT activation is achieved through a series of phosphorylation steps: first, AKT is phosphorylated at Thr-450 by JNK kinases to prime its activation; then, phosphoinositide-dependent kinase 1 phosphorylates AKT at Thr-308 to expose the Ser-473 residue; and finally, AKT is phosphorylated at Ser-473 by several kinases (PKD2 and others) to achieve its full activation.  For its inactivation, the PH-domain contg. phosphatases dephosphorylate AKT at Ser-473, and protein serine/threonine phosphatase-2A (PP-2A) dephosphorylates it at Thr-308.  However, it remains unknown regarding which phosphatase dephosphorylates AKT at Thr-450 during its inactivation.  In this study, we present both in vitro and in vivo evidence to show that protein serine/threonine phosphatase-1 (PP-1) is a major phosphatase that directly dephosphorylates AKT to modulate its activation.  First, purified PP-1 directly dephosphorylates AKT in vitro.  Second, immunopptn. and immunocolocalization showed that PP-1 interacts with AKT.  Third, stable knock down of PP-1α or PP-1β but not PP-1γ, PP-2Aα or PP-2Aβ by shRNA leads to enhanced phosphorylation of AKT at Thr-450.  Finally, overexpression of PP-1α or PP-1β but not PP-1γ, PP-2Aα or PP-2Aβ results in attenuated phosphorylation of AKT at Thr-450.  Moreover, our results also show that dephosphorylation of AKT by PP-1 significantly modulates its functions in regulating the expression of downstream genes, promoting cell survival and modulating differentiation.  These results show that PP-1 acts as a major phosphatase to dephosphorylate AKT at Thr-450 and thus modulate its functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBKgabJTpywrVg90H21EOLACvtfcHk0ljgxMVK_yhJNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVantr7E&md5=d6f6b03e2bbad10a250809f52cf9e721</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2010.16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2010.16%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DGong%26aufirst%3DL.%2BL.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DM.%26aulast%3DZeng%26aufirst%3DX.%2BM.%26aulast%3DChen%26aufirst%3DL.%2BL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%2BP.%26aulast%3DHu%26aufirst%3DX.%2BH.%26aulast%3DSun%26aufirst%3DS.%2BM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DH.%2BL.%26aulast%3DZheng%26aufirst%3DC.%2BB.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DP.%2BC.%26aulast%3DZhao%26aufirst%3DJ.%2BQ.%26aulast%3DXie%26aufirst%3DS.%2BS.%26aulast%3DZou%26aufirst%3DL.%2BJ.%26aulast%3DXiao%26aufirst%3DY.%2BM.%26aulast%3DLiu%26aufirst%3DW.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.%2BW.%26atitle%3DProtein%2520phosphatase-1%2520regulates%2520Akt1%2520signal%2520transduction%2520pathway%2520to%2520control%2520gene%2520expression%252C%2520cell%2520survival%2520and%2520differentiation%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2010%26volume%3D17%26spage%3D1448%26epage%3D1462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fearen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olmos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baird, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delgado, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupinacci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riisnaes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pope, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaton, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span> </span><span class="NLM_article-title">First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">4688</span><span class="NLM_x">–</span> <span class="NLM_lpage">4695</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1200%2FJCO.2011.35.5263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=22025163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlOnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=4688-4695&author=T.+A.+Yapauthor=L.+Yanauthor=A.+Patnaikauthor=I.+Fearenauthor=D.+Olmosauthor=K.+Papadopoulosauthor=R.+D.+Bairdauthor=L.+Delgadoauthor=A.+Taylorauthor=L.+Lupinacciauthor=R.+Riisnaesauthor=L.+L.+Popeauthor=S.+P.+Heatonauthor=G.+Thomasauthor=M.+D.+Garrettauthor=D.+M.+Sullivanauthor=J.+S.+de+Bonoauthor=A.+W.+Tolcher&title=First-in-man+clinical+trial+of+the+oral+pan-AKT+inhibitor+MK-2206+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors</span></div><div class="casAuthors">Yap, Timothy A.; Yan, Li; Patnaik, Amita; Fearen, Ivy; Olmos, David; Papadopoulos, Kyriakos; Baird, Richard D.; Delgado, Liliana; Taylor, Adekemi; Lupinacci, Lisa; Riisnaes, Ruth; Pope, Lorna L.; Heaton, Simon P.; Thomas, George; Garrett, Michelle D.; Sullivan, Daniel M.; de Bono, Johann S.; Tolcher, Anthony W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">4688-4695</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose AKT signaling is frequently deregulated in human cancers.  MK-2206 is a potent, oral allosteric inhibitor of all AKT isoforms with antitumor activity in preclin. models.  A phase I study of MK-2206 was conducted to investigate its safety, max.-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics (PDs), and preliminary antitumor efficacy.  Patients and Methods Patients with advanced solid tumors received MK-2206 on alternate days.  Paired tumor biopsies were mandated at the MTD for biomarker studies.  PD studies incorporated tumor and hair follicle analyses, and putative predictive biomarker studies included tumor somatic mutation analyses and immunohistochem. for phosphatase and tensin homolog (PTEN) loss.  Results Thirty-three patients received MK-2206 at 30, 60, 75, or 90 mg on alternate days.  Dose-limiting toxicities included skin rash and stomatitis, establishing the MTD at 60 mg.  Drug-related toxicities included skin rash (51.5%), nausea (36.4%), pruritus (24.2%), hyperglycemia (21.2%), and diarrhea (21.2%).  PKs (area under the concn.-time curve from 0 to 48 h and max. measured plasma concn.) were dose proportional.  Phosphorylated serine 473 AKT declined in all tumor biopsies assessed (P = .015), and phosphorylated threonine 246 proline-rich AKT substrate 40 was suppressed in hair follicles at 6 h (P = .008), on days 7 (P = .028) and 15 (P = .025) with MK-2206; reversible hyperglycemia and increases in insulin c-peptide were also obsd., confirming target modulation.  A patient with pancreatic adenocarcinoma (PTEN loss; KRAS G12D mutation) treated at 60 mg on alternate days experienced a decrease of approx. 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.  Two patients with pancreatic neuroendocrine tumors had minor tumor responses.  Conclusion MK-2206 was well tolerated, with evidence of AKT signaling blockade.  Rational combination trials are ongoing to maximize clin. benefit with this therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdHD9mhSwVT7Vg90H21EOLACvtfcHk0lhl45eFWJ6uSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlOnsLw%253D&md5=2ee8b8985e337a161807b9c862b573d2</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.5263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.5263%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DFearen%26aufirst%3DI.%26aulast%3DOlmos%26aufirst%3DD.%26aulast%3DPapadopoulos%26aufirst%3DK.%26aulast%3DBaird%26aufirst%3DR.%2BD.%26aulast%3DDelgado%26aufirst%3DL.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DLupinacci%26aufirst%3DL.%26aulast%3DRiisnaes%26aufirst%3DR.%26aulast%3DPope%26aufirst%3DL.%2BL.%26aulast%3DHeaton%26aufirst%3DS.%2BP.%26aulast%3DThomas%26aufirst%3DG.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DFirst-in-man%2520clinical%2520trial%2520of%2520the%2520oral%2520pan-AKT%2520inhibitor%2520MK-2206%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D4688%26epage%3D4695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Rellos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivins, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nott, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Q. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smerdon, S. J.</span><span> </span><span class="NLM_article-title">Structure and regulation of the human Nek2 centrosomal kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">6833</span><span class="NLM_x">–</span> <span class="NLM_lpage">6842</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=6833-6842&author=P.+Rellosauthor=F.+J.+Ivinsauthor=J.+E.+Baxterauthor=A.+Pikeauthor=T.+J.+Nottauthor=D.+M.+Parkinsonauthor=S.+Dasauthor=S.+Howellauthor=O.+Fedorovauthor=Q.+Y.+Shenauthor=A.+M.+Fryauthor=S.+Knappauthor=S.+J.+Smerdon&title=Structure+and+regulation+of+the+human+Nek2+centrosomal+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRellos%26aufirst%3DP.%26aulast%3DIvins%26aufirst%3DF.%2BJ.%26aulast%3DBaxter%26aufirst%3DJ.%2BE.%26aulast%3DPike%26aufirst%3DA.%26aulast%3DNott%26aufirst%3DT.%2BJ.%26aulast%3DParkinson%26aufirst%3DD.%2BM.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DHowell%26aufirst%3DS.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DShen%26aufirst%3DQ.%2BY.%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DSmerdon%26aufirst%3DS.%2BJ.%26atitle%3DStructure%2520and%2520regulation%2520of%2520the%2520human%2520Nek2%2520centrosomal%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D6833%26epage%3D6842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Henise, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Irreversible Nek2 kinase inhibitors with cellular activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4133</span><span class="NLM_x">–</span> <span class="NLM_lpage">4146</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200222m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4133-4146&author=J.+C.+Heniseauthor=J.+Taunton&title=Irreversible+Nek2+kinase+inhibitors+with+cellular+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Nek2 Kinase Inhibitors with Cellular Activity</span></div><div class="casAuthors">Henise, Jeffrey C.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4133-4146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based approach was used to design irreversible, cysteine-targeted inhibitors of the human centrosomal kinase, Nek2.  Potent inhibition of Nek2 kinase activity in biochem. and cell-based assays required a noncatalytic cysteine residue (Cys22), located near the glycine-rich loop in a subset of human kinases.  Elaboration of an oxindole scaffold led to our most selective compd., oxindole propynamide 16 (JH295).  Propynamide 16 irreversibly inhibited cellular Nek2 without affecting the mitotic kinases, Cdk1, Aurora B, or Plk1.  Moreover, 16 did not perturb bipolar spindle assembly or the spindle assembly checkpoint.  To our knowledge, 16 is the first small mol. shown to inactivate Nek2 kinase activity in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq8mOvaT5BPbVg90H21EOLACvtfcHk0lhl45eFWJ6uSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D&md5=35277e74fc346501e4847bba6586f9d0</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm200222m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200222m%26sid%3Dliteratum%253Aachs%26aulast%3DHenise%26aufirst%3DJ.%2BC.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DIrreversible%2520Nek2%2520kinase%2520inhibitors%2520with%2520cellular%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4133%26epage%3D4146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Emmitte, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjabeng, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberti, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bambal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamberlain, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis-Ward, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassler, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornberger, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansing, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nailor, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pobanz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, M.</span><span> </span><span class="NLM_article-title">Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1694</span><span class="NLM_x">–</span> <span class="NLM_lpage">1697</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1016%2Fj.bmcl.2009.01.094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=19237286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1694-1697&author=K.+A.+Emmitteauthor=G.+M.+Adjabengauthor=C.+W.+Andrewsauthor=J.+G.+Albertiauthor=R.+Bambalauthor=S.+D.+Chamberlainauthor=R.+G.+Davis-Wardauthor=H.+D.+Dicksonauthor=D.+F.+Hasslerauthor=K.+R.+Hornbergerauthor=J.+R.+Jacksonauthor=K.+W.+Kuntzauthor=T.+J.+Lansingauthor=R.+A.+Mookauthor=K.+E.+Nailorauthor=M.+A.+Pobanzauthor=S.+C.+Smithauthor=C.+M.+Sungauthor=M.+Cheung&title=Design+of+potent+thiophene+inhibitors+of+polo-like+kinase+1+with+improved+solubility+and+reduced+protein+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding</span></div><div class="casAuthors">Emmitte, Kyle A.; Adjebang, George M.; Andrews, C. Webb; Badiang-Alberti, Jennifer G.; Bambal, Ramesh; Chamberlain, Stanley D.; Davis-Ward, Ronda G.; Dickson, Hamilton D.; Hassler, Daniel F.; Hornberger, Keith R.; Jackson, Jeffrey R.; Kuntz, Kevin W.; Lansing, Timothy J.; Mook, Robert A.; Nailor, Kristen E.; Pobanz, Mark A.; Smith, Stephon C.; Sung, Chiu-Mei; Cheung, Mui</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1694-1697</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of thiophene PLK1 inhibitors was optimized for increased soly. and reduced protein binding through the appendage of basic amine functionality.  Interesting selectivity between PLK1 and PLK3 was also obtained through these modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLrXXbB1J4-rVg90H21EOLACvtfcHk0liApL4Rp2mAXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSltrY%253D&md5=30831c589bae973ca9267dfea68971e1</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.094%26sid%3Dliteratum%253Aachs%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DAdjabeng%26aufirst%3DG.%2BM.%26aulast%3DAndrews%26aufirst%3DC.%2BW.%26aulast%3DAlberti%26aufirst%3DJ.%2BG.%26aulast%3DBambal%26aufirst%3DR.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DDickson%26aufirst%3DH.%2BD.%26aulast%3DHassler%26aufirst%3DD.%2BF.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DJackson%26aufirst%3DJ.%2BR.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DLansing%26aufirst%3DT.%2BJ.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNailor%26aufirst%3DK.%2BE.%26aulast%3DPobanz%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DSung%26aufirst%3DC.%2BM.%26aulast%3DCheung%26aufirst%3DM.%26atitle%3DDesign%2520of%2520potent%2520thiophene%2520inhibitors%2520of%2520polo-like%2520kinase%25201%2520with%2520improved%2520solubility%2520and%2520reduced%2520protein%2520binding%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1694%26epage%3D1697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Olmos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetto, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taegtmeyer, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barriuso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degenhardt, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allred, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lampkin, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dar, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagden, S. P.</span><span> </span><span class="NLM_article-title">Phase I study of GSK461364, a specific and competitive polo-like kinase 1 inhibitor, in patients with advanced solid malignancies</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3420</span><span class="NLM_x">–</span> <span class="NLM_lpage">3430</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1158%2F1078-0432.CCR-10-2946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=21459796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVGit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=3420-3430&author=D.+Olmosauthor=D.+Barkerauthor=R.+Sharmaauthor=A.+T.+Brunettoauthor=T.+A.+Yapauthor=A.+B.+Taegtmeyerauthor=J.+Barriusoauthor=H.+Medaniauthor=Y.+Y.+Degenhardtauthor=A.+J.+Allredauthor=D.+A.+Smithauthor=S.+C.+Murrayauthor=T.+A.+Lampkinauthor=M.+M.+Darauthor=R.+Wilsonauthor=J.+S.+de+Bonoauthor=S.+P.+Blagden&title=Phase+I+study+of+GSK461364%2C+a+specific+and+competitive+polo-like+kinase+1+inhibitor%2C+in+patients+with+advanced+solid+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies</span></div><div class="casAuthors">Olmos, David; Barker, Douglas; Sharma, Rohini; Brunetto, Andre T.; Yap, Timothy A.; Taegtmeyer, Anne B.; Barriuso, Jorge; Medani, Hanine; Degenhardt, Yan Y.; Allred, Alicia J.; Smith, Deborah A.; Murray, Sharon C.; Lampkin, Thomas A.; Dar, Mohammed M.; Wilson, Richard; de Bono, Johann S.; Blagden, Sarah P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3420-3430</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: GSK461364 is an ATP-competitive inhibitor of polo-like kinase 1 (Plk1).  A phase I study of two schedules of i.v. GSK461364 was conducted.  Exptl. Design: GSK461364 was administered in escalating doses to patients with solid malignancies by two schedules, either on days 1, 8, and 15 of 28-day cycles (schedule A) or on days 1, 2, 8, 9, 15, and 16 of 28-day cycles (schedule B).  Assessments included pharmacokinetic and pharmacodynamic profiles, as well as marker expression studies in pretreatment tumor biopsies.  RESULTS: Forty patients received GSK461364: 23 patients in schedule A and 17 in schedule B. Dose-limiting toxicities (DLT) in schedule A at 300 mg (2 of 7 patients) and 225 mg (1 of 8 patients) cohorts included grade 4 neutropenia and/or grade 3-4 thrombocytopenia.  In schedule B, DLTs of grade 4 pulmonary emboli and grade 4 neutropenia occurred at 7 or more days at 100 mg dose level.  Venous thrombotic emboli (VTE) and myelosuppression were the most common grade 3-4, drug-related events.  Pharmacokinetic data indicated that AUC (area under the curve) and Cmax (max. concn.) were proportional across doses, with a half-life of 9 to 13 h.  Pharmacodynamic studies in circulating tumor cells revealed an increase in phosphorylated histone H3 (pHH3) following drug administration.  A best response of prolonged stable disease of more than 16 wk occurred in 6 (15%) patients, including 4 esophageal cancer patients.  Those with prolonged stable disease had greater expression of Ki-67, pHH3, and Plk1 in archived tumor biopsies.  CONCLUSIONS: The final recommended phase II dose for GSK461364 was 225 mg administered i.v. in schedule A. Because of the high incidence (20%) of VTE, for further clin. evaluation, GSK461364 should involve coadministration of prophylactic anticoagulation.  Clin Cancer Res; 17(10); 3420-30.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOJ4inVI09-rVg90H21EOLACvtfcHk0liApL4Rp2mAXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVGit7c%253D&md5=3cf3213934f3a34aaeee469dc9cb6529</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2946%26sid%3Dliteratum%253Aachs%26aulast%3DOlmos%26aufirst%3DD.%26aulast%3DBarker%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DBrunetto%26aufirst%3DA.%2BT.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DTaegtmeyer%26aufirst%3DA.%2BB.%26aulast%3DBarriuso%26aufirst%3DJ.%26aulast%3DMedani%26aufirst%3DH.%26aulast%3DDegenhardt%26aufirst%3DY.%2BY.%26aulast%3DAllred%26aufirst%3DA.%2BJ.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DMurray%26aufirst%3DS.%2BC.%26aulast%3DLampkin%26aufirst%3DT.%2BA.%26aulast%3DDar%26aufirst%3DM.%2BM.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DBlagden%26aufirst%3DS.%2BP.%26atitle%3DPhase%2520I%2520study%2520of%2520GSK461364%252C%2520a%2520specific%2520and%2520competitive%2520polo-like%2520kinase%25201%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520malignancies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D3420%26epage%3D3430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Whelligan, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mas-Droux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barillari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grummitt, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayliss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span> </span><span class="NLM_article-title">Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7682</span><span class="NLM_x">–</span> <span class="NLM_lpage">7698</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1008727" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Krs7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7682-7698&author=D.+K.+Whelliganauthor=S.+Solankiauthor=D.+Taylorauthor=D.+W.+Thomsonauthor=K.+M.+Cheungauthor=K.+Boxallauthor=C.+Mas-Drouxauthor=C.+Barillariauthor=S.+Burnsauthor=C.+G.+Grummittauthor=I.+Collinsauthor=R.+L.+van+Montfortauthor=G.+W.+Aherneauthor=R.+Baylissauthor=S.+Hoelder&title=Aminopyrazine+inhibitors+binding+to+an+unusual+inactive+conformation+of+the+mitotic+kinase+Nek2%3A+SAR+and+structural+characterization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Aminopyrazine Inhibitors Binding to an Unusual Inactive Conformation of the Mitotic Kinase Nek2: SAR and Structural Characterization</span></div><div class="casAuthors">Whelligan, Daniel K.; Solanki, Savade; Taylor, Dawn; Thomson, Douglas W.; Cheung, Kwai-Ming J.; Boxall, Kathy; Mas-Droux, Corine; Barillari, Caterina; Burns, Samantha; Grummitt, Charles G.; Collins, Ian; van Montfort, Rob L. M.; Aherne, G. Wynne; Bayliss, Richard; Hoelder, Swen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7682-7698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report herein the first systematic exploration of inhibitors of the mitotic kinase Nek2.  Starting from HTS hit aminopyrazine I, compds. with improved activity were identified using structure-based design.  Our structural biol. investigations reveal two notable observations.  First, I and related compds. bind to an unusual, inactive conformation of the kinase which to the best of our knowledge has not been reported for other types of kinase inhibitors.  Second, a phenylalanine residue at the center of the ATP pocket strongly affects the ability of the inhibitor to bind to the protein.  The implications of these observations are discussed, and the work described here defines key features for potent and selective Nek2 inhibition, which will aid the identification of more advanced inhibitors of Nek2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhzgVaRXbQkrVg90H21EOLACvtfcHk0ljg4Lc90UP0yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Krs7nI&md5=d1a4af6869319bed0a340e8ff7db4397</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm1008727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1008727%26sid%3Dliteratum%253Aachs%26aulast%3DWhelligan%26aufirst%3DD.%2BK.%26aulast%3DSolanki%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DThomson%26aufirst%3DD.%2BW.%26aulast%3DCheung%26aufirst%3DK.%2BM.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DMas-Droux%26aufirst%3DC.%26aulast%3DBarillari%26aufirst%3DC.%26aulast%3DBurns%26aufirst%3DS.%26aulast%3DGrummitt%26aufirst%3DC.%2BG.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DBayliss%26aufirst%3DR.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DAminopyrazine%2520inhibitors%2520binding%2520to%2520an%2520unusual%2520inactive%2520conformation%2520of%2520the%2520mitotic%2520kinase%2520Nek2%253A%2520SAR%2520and%2520structural%2520characterization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7682%26epage%3D7698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Solanki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innocenti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mas-Droux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barillari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayliss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span> </span><span class="NLM_article-title">Benzimidazole inhibitors induce a DFG-out conformation of never in mitosis gene A-related kinase 2 (Nek2) without binding to the back pocket and reveal a nonlinear structure–activity relationship</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1626</span><span class="NLM_x">–</span> <span class="NLM_lpage">1639</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1011726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1626-1639&author=S.+Solankiauthor=P.+Innocentiauthor=C.+Mas-Drouxauthor=K.+Boxallauthor=C.+Barillariauthor=R.+L.+van+Montfortauthor=G.+W.+Aherneauthor=R.+Baylissauthor=S.+Hoelder&title=Benzimidazole+inhibitors+induce+a+DFG-out+conformation+of+never+in+mitosis+gene+A-related+kinase+2+%28Nek2%29+without+binding+to+the+back+pocket+and+reveal+a+nonlinear+structure%E2%80%93activity+relationship"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm1011726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1011726%26sid%3Dliteratum%253Aachs%26aulast%3DSolanki%26aufirst%3DS.%26aulast%3DInnocenti%26aufirst%3DP.%26aulast%3DMas-Droux%26aufirst%3DC.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DBarillari%26aufirst%3DC.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DBayliss%26aufirst%3DR.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DBenzimidazole%2520inhibitors%2520induce%2520a%2520DFG-out%2520conformation%2520of%2520never%2520in%2520mitosis%2520gene%2520A-related%2520kinase%25202%2520%2528Nek2%2529%2520without%2520binding%2520to%2520the%2520back%2520pocket%2520and%2520reveal%2520a%2520nonlinear%2520structure%25E2%2580%2593activity%2520relationship%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1626%26epage%3D1639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group">Innocenti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mas-Droux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeoh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlake, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayliss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span> </span><span class="NLM_article-title">Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure–activity relationship, structural biology, and cellular activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3228</span><span class="NLM_x">–</span> <span class="NLM_lpage">3241</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201683b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3228-3241&author=P.+Innocentiauthor=K.+M.+Cheungauthor=S.+Solankiauthor=C.+Mas-Drouxauthor=F.+Rowanauthor=S.+Yeohauthor=K.+Boxallauthor=M.+Westlakeauthor=L.+Pickardauthor=T.+Hardyauthor=J.+E.+Baxterauthor=G.+W.+Aherneauthor=R.+Baylissauthor=A.+M.+Fryauthor=S.+Hoelder&title=Design+of+potent+and+selective+hybrid+inhibitors+of+the+mitotic+kinase+Nek2%3A+structure%E2%80%93activity+relationship%2C+structural+biology%2C+and+cellular+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm201683b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201683b%26sid%3Dliteratum%253Aachs%26aulast%3DInnocenti%26aufirst%3DP.%26aulast%3DCheung%26aufirst%3DK.%2BM.%26aulast%3DSolanki%26aufirst%3DS.%26aulast%3DMas-Droux%26aufirst%3DC.%26aulast%3DRowan%26aufirst%3DF.%26aulast%3DYeoh%26aufirst%3DS.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DWestlake%26aufirst%3DM.%26aulast%3DPickard%26aufirst%3DL.%26aulast%3DHardy%26aufirst%3DT.%26aulast%3DBaxter%26aufirst%3DJ.%2BE.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DBayliss%26aufirst%3DR.%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DDesign%2520of%2520potent%2520and%2520selective%2520hybrid%2520inhibitors%2520of%2520the%2520mitotic%2520kinase%2520Nek2%253A%2520structure%25E2%2580%2593activity%2520relationship%252C%2520structural%2520biology%252C%2520and%2520cellular%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3228%26epage%3D3241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Torrance, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinzler, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogelstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span> </span><span class="NLM_article-title">Combinatorial chemoprevention of intestinal neoplasia</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1024</span><span class="NLM_x">–</span> <span class="NLM_lpage">1028</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1038%2F79534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=10973323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmslSju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=1024-1028&author=C.+J.+Torranceauthor=P.+E.+Jacksonauthor=E.+Montgomeryauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=A.+Wissnerauthor=M.+Nunesauthor=P.+Frostauthor=C.+M.+Discafani&title=Combinatorial+chemoprevention+of+intestinal+neoplasia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial chemoprevention of intestinal neoplasia</span></div><div class="casAuthors">Torrance, Christopher J.; Jackson, Peta E.; Montgomery, Elizabeth; Kinzler, Kenneth W.; Vogelstein, Bert; Wissner, Allan; Nunes, Maria; Frost, Philip; Discafani, Carolyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1024-1028</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">A combination of two drugs afforded remarkable protection from intestinal neoplasia in APCMin/+ mice, a murine model of human familial adenomatous polyposis (FAP).  One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventive activity.  The second drug was EKB569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase.  Although 100% of the untreated APCMin/+ mice developed -20 polyps, nearly half the mice treated with these two agents developed no polyps at all.  These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoysAYwWewtCrVg90H21EOLACvtfcHk0ljg4Lc90UP0yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmslSju7g%253D&md5=2b1da2bdcd72fec51856ff25643efd4c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2F79534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F79534%26sid%3Dliteratum%253Aachs%26aulast%3DTorrance%26aufirst%3DC.%2BJ.%26aulast%3DJackson%26aufirst%3DP.%2BE.%26aulast%3DMontgomery%26aufirst%3DE.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DNunes%26aufirst%3DM.%26aulast%3DFrost%26aufirst%3DP.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26atitle%3DCombinatorial%2520chemoprevention%2520of%2520intestinal%2520neoplasia%26jtitle%3DNat.%2520Med.%26date%3D2000%26volume%3D6%26spage%3D1024%26epage%3D1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">3958</span><span class="NLM_x">–</span> <span class="NLM_lpage">3965</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1158%2F0008-5472.CAN-03-2868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=15173008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=3958-3965&author=S.+K.+Rabindranauthor=C.+M.+Discafaniauthor=E.+C.+Rosfjordauthor=M.+Baxterauthor=M.+B.+Floydauthor=J.+Golasauthor=W.+A.+Hallettauthor=B.+D.+Johnsonauthor=R.+Nilakantanauthor=E.+Overbeekauthor=M.+F.+Reichauthor=R.+Shenauthor=X.+Shiauthor=H.+R.+Tsouauthor=Y.+F.+Wangauthor=A.+Wissner&title=Antitumor+activity+of+HKI-272%2C+an+orally+active%2C+irreversible+inhibitor+of+the+HER-2+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase</span></div><div class="casAuthors">Rabindran, Sridhar K.; Discafani, Carolyn M.; Rosfjord, Edward C.; Baxter, Michelle; Floyd, M. Brawner; Golas, Jonathan; Hallett, William A.; Johnson, Bernard D.; Nilakantan, Ramaswamy; Overbeek, Elsebe; Reich, Marvin F.; Shen, Ru; Shi, Xiaoqing; Tsou, Hwei-Ru; Wang, Yu-Fen; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3958-3965</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER-2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of cancers.  Overexpression of HER-2 is seen in 25-30% of breast cancer patients and predicts a poor outcome in patients with primary disease.  Trastuzumab (Herceptin), a monoclonal antibody to HER-2, is specifically approved for HER-2-pos. breast cancer but is active only in a subset of these tumors.  Blocking HER-2 function by a small mol. kinase inhibitor, therefore, represents an attractive alternate strategy to inhibit the growth of HER-2-pos. tumors.  HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro.  It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.  HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor.  In agreement with the predicted effects of HER-2 inactivation, HKI-272 treatment of cells results in inhibition of downstream signal transduction events and cell cycle regulatory pathways.  This leads to arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle, ultimately resulting in decreased cell proliferation.  In vivo, HKI-272 is active in HER-2- and EGFR-dependent tumor xenograft models when dosed orally on a once daily schedule.  On the basis of its favorable preclin. pharmacol. profile, HKI-272 has been selected as a candidate for addnl. development as an antitumor agent in breast and other HER-2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2xeLXlAwWvbVg90H21EOLACvtfcHk0lhTZJwEnjlpDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D&md5=60accd0599b7c489e4c3753d4f39cab4</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2868%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DBaxter%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DAntitumor%2520activity%2520of%2520HKI-272%252C%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520HER-2%2520tyrosine%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D3958%26epage%3D3965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Trott, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">461</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1002%2Fjcc.21334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=19499576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=455-461&author=O.+Trottauthor=A.+J.+Olson&title=AutoDock+Vina%3A+improving+the+speed+and+accuracy+of+docking+with+a+new+scoring+function%2C+efficient+optimization%2C+and+multithreading"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span></div><div class="casAuthors">Trott, Oleg; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">455-461</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AutoDock Vina, a new program for mol. docking and virtual screening, is presented.  AutoDock Vina achieves an approx. 2 orders of magnitude speed-up compared with the mol. docking software previously developed in the authors' lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by the authors' tests on the training set used in AutoDock 4 development.  Further speed-up is achieved from parallelism, by using multithreading on multicore machines.  AutoDock Vina automatically calcs. the grid maps and clusters the results in a way transparent to the user.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLecOIkUxIlrVg90H21EOLACvtfcHk0lhTZJwEnjlpDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O&md5=c6974af8a1235f7aa09918d3e6f70dc4</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21334%26sid%3Dliteratum%253Aachs%26aulast%3DTrott%26aufirst%3DO.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock%2520Vina%253A%2520improving%2520the%2520speed%2520and%2520accuracy%2520of%2520docking%2520with%2520a%2520new%2520scoring%2520function%252C%2520efficient%2520optimization%252C%2520and%2520multithreading%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D455%26epage%3D461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Nie, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feher, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiryanov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaldor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stafford, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hikami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchiyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hikichi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amano, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosfield, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichikawa, T.</span><span> </span><span class="NLM_article-title">Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3662</span><span class="NLM_x">–</span> <span class="NLM_lpage">3666</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1016%2Fj.bmcl.2013.02.083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=23664874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVyksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3662-3666&author=Z.+Nieauthor=V.+Feherauthor=S.+Natalaauthor=C.+McBrideauthor=A.+Kiryanovauthor=B.+Jonesauthor=B.+Lamauthor=Y.+Liuauthor=S.+Kaldorauthor=J.+Staffordauthor=K.+Hikamiauthor=N.+Uchiyamaauthor=T.+Kawamotoauthor=Y.+Hikichiauthor=S.+Matsumotoauthor=N.+Amanoauthor=L.+Zhangauthor=D.+Hosfieldauthor=R.+Skeneauthor=H.+Zouauthor=X.+Caoauthor=T.+Ichikawa&title=Discovery+of+TAK-960%3A+an+orally+available+small+molecule+inhibitor+of+polo-like+kinase+1+%28PLK1%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1)</span></div><div class="casAuthors">Nie, Zhe; Feher, Victoria; Natala, Srinivasa; McBride, Christopher; Kiryanov, Andre; Jones, Benjamin; Lam, Betty; Liu, Yan; Kaldor, Stephen; Stafford, Jeffrey; Hikami, Kouki; Uchiyama, Noriko; Kawamoto, Tomohiro; Hikichi, Yuichi; Matsumoto, Shin-ichi; Amano, Nobuyuki; Zhang, Lilly; Hosfield, David; Skene, Robert; Zou, Hua; Cao, Xiaodong; Ichikawa, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3662-3666</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using structure-based drug design, the authors identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in the selection of the development candidate TAK-960 (I).  TAK-960 is currently undergoing Phase I evaluation in adult patients with advanced solid malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo06c_HY-gD-LVg90H21EOLACvtfcHk0lhTZJwEnjlpDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVyksr0%253D&md5=25dca079405c47098fd261a77ceccf53</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.083%26sid%3Dliteratum%253Aachs%26aulast%3DNie%26aufirst%3DZ.%26aulast%3DFeher%26aufirst%3DV.%26aulast%3DNatala%26aufirst%3DS.%26aulast%3DMcBride%26aufirst%3DC.%26aulast%3DKiryanov%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKaldor%26aufirst%3DS.%26aulast%3DStafford%26aufirst%3DJ.%26aulast%3DHikami%26aufirst%3DK.%26aulast%3DUchiyama%26aufirst%3DN.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DHikichi%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DS.%26aulast%3DAmano%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHosfield%26aufirst%3DD.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DIchikawa%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520TAK-960%253A%2520an%2520orally%2520available%2520small%2520molecule%2520inhibitor%2520of%2520polo-like%2520kinase%25201%2520%2528PLK1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3662%26epage%3D3666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 12 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yusuke  Ebe</span> and <span class="hlFld-ContribAuthor ">Takahiro  Nishimura</span>  . </span><span class="cited-content_cbyCitation_article-title">Iridium-Catalyzed Branch-Selective Hydroarylation of Vinyl Ethers via C–H Bond Activation. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2015,</strong> <em>137 </em>
                                    (18)
                                     , 5899-5902. <a href="https://doi.org/10.1021/jacs.5b03099" title="DOI URL">https://doi.org/10.1021/jacs.5b03099</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.5b03099&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.5b03099%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DIridium-Catalyzed%252BBranch-Selective%252BHydroarylation%252Bof%252BVinyl%252BEthers%252Bvia%252BC%2525E2%252580%252593H%252BBond%252BActivation%26aulast%3DEbe%26aufirst%3DYusuke%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D25032015%26date%3D05052015%26date%3D13052015%26date%3D30042015%26volume%3D137%26issue%3D18%26spage%3D5899%26epage%3D5902" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexandru  Nita</span>, <span class="hlFld-ContribAuthor ">Sara P.  Abraham</span>, <span class="hlFld-ContribAuthor ">Pavel  Krejci</span>, <span class="hlFld-ContribAuthor ">Michaela  Bosakova</span>. </span><span class="cited-content_cbyCitation_article-title">Oncogenic FGFR Fusions Produce Centrosome and Cilia Defects by Ectopic Signaling. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2021,</strong> <em>10 </em>
                                    (6)
                                     , 1445. <a href="https://doi.org/10.3390/cells10061445" title="DOI URL">https://doi.org/10.3390/cells10061445</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells10061445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells10061445%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DOncogenic%252BFGFR%252BFusions%252BProduce%252BCentrosome%252Band%252BCilia%252BDefects%252Bby%252BEctopic%252BSignaling%26aulast%3DNita%26aufirst%3DAlexandru%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D6%26spage%3D1445" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bo  Wang</span>, <span class="hlFld-ContribAuthor ">Zheyong  Liang</span>, <span class="hlFld-ContribAuthor ">Peijun  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Functional aspects of primary cilium in signaling, assembly and microenvironment in cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Physiology</span><span> <strong>2021,</strong> <em>236 </em>
                                    (5)
                                     , 3207-3219. <a href="https://doi.org/10.1002/jcp.30117" title="DOI URL">https://doi.org/10.1002/jcp.30117</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcp.30117&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcp.30117%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Physiology%26atitle%3DFunctional%252Baspects%252Bof%252Bprimary%252Bcilium%252Bin%252Bsignaling%25252C%252Bassembly%252Band%252Bmicroenvironment%252Bin%252Bcancer%26aulast%3DWang%26aufirst%3DBo%26date%3D2021%26date%3D2020%26volume%3D236%26issue%3D5%26spage%3D3207%26epage%3D3219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sirichat  Kaowinn</span>, <span class="hlFld-ContribAuthor ">Sangtaek  Oh</span>, <span class="hlFld-ContribAuthor ">Jeong  Moon</span>, <span class="hlFld-ContribAuthor ">Ah Young  Yoo</span>, <span class="hlFld-ContribAuthor ">Ho Young  Kang</span>, <span class="hlFld-ContribAuthor ">Mi Rim  Lee</span>, <span class="hlFld-ContribAuthor ">Ji Eun  Kim</span>, <span class="hlFld-ContribAuthor ">Dae Youn  Hwang</span>, <span class="hlFld-ContribAuthor ">So Eun  Youn</span>, <span class="hlFld-ContribAuthor ">Sang Seok  Koh</span>, <span class="hlFld-ContribAuthor ">Young‑Hwa  Chung</span>. </span><span class="cited-content_cbyCitation_article-title">CGK062, a small chemical molecule, inhibits cancer upregulated gene 2‑induced oncogenesis through NEK2 and β‑catenin. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Oncology</span><span> <strong>2019,</strong> <em> </em><a href="https://doi.org/10.3892/ijo.2019.4724" title="DOI URL">https://doi.org/10.3892/ijo.2019.4724</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/ijo.2019.4724&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fijo.2019.4724%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Oncology%26atitle%3DCGK062%25252C%252Ba%252Bsmall%252Bchemical%252Bmolecule%25252C%252Binhibits%252Bcancer%252Bupregulated%252Bgene%252B2%2525E2%252580%252591induced%252Boncogenesis%252Bthrough%252BNEK2%252Band%252B%2525CE%2525B2%2525E2%252580%252591catenin%26aulast%3DKaowinn%26aufirst%3DSirichat%26date%3D2019%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Palovcak</span>, <span class="hlFld-ContribAuthor ">Wenjun  Liu</span>, <span class="hlFld-ContribAuthor ">Fenghua  Yuan</span>, <span class="hlFld-ContribAuthor ">Yanbin  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Maintenance of genome stability by Fanconi anemia proteins. </span><span class="cited-content_cbyCitation_journal-name">Cell & Bioscience</span><span> <strong>2017,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s13578-016-0134-2" title="DOI URL">https://doi.org/10.1186/s13578-016-0134-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s13578-016-0134-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs13578-016-0134-2%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520%2526%2520Bioscience%26atitle%3DMaintenance%252Bof%252Bgenome%252Bstability%252Bby%252BFanconi%252Banemia%252Bproteins%26aulast%3DPalovcak%26aufirst%3DAnna%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alicja  Czubaty</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Piekiełko-Witkowska</span>. </span><span class="cited-content_cbyCitation_article-title">Protein kinases that phosphorylate splicing factors: Roles in cancer development, progression and possible therapeutic options. </span><span class="cited-content_cbyCitation_journal-name">The International Journal of Biochemistry & Cell Biology</span><span> <strong>2017,</strong> <em>91 </em>, 102-115. <a href="https://doi.org/10.1016/j.biocel.2017.05.024" title="DOI URL">https://doi.org/10.1016/j.biocel.2017.05.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biocel.2017.05.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biocel.2017.05.024%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520International%2520Journal%2520of%2520Biochemistry%2520%2526%2520Cell%2520Biology%26atitle%3DProtein%252Bkinases%252Bthat%252Bphosphorylate%252Bsplicing%252Bfactors%25253A%252BRoles%252Bin%252Bcancer%252Bdevelopment%25252C%252Bprogression%252Band%252Bpossible%252Btherapeutic%252Boptions%26aulast%3DCzubaty%26aufirst%3DAlicja%26date%3D2017%26volume%3D91%26spage%3D102%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert C.  Jackson</span>, <span class="hlFld-ContribAuthor ">Giovanni Y.  Di Veroli</span>, <span class="hlFld-ContribAuthor ">Siang-Boon  Koh</span>, <span class="hlFld-ContribAuthor ">Ian  Goldlust</span>, <span class="hlFld-ContribAuthor ">Frances M.  Richards</span>, <span class="hlFld-ContribAuthor ">Duncan I.  Jodrell</span>, . </span><span class="cited-content_cbyCitation_article-title">Modelling of the cancer cell cycle as a tool for rational drug development: A systems pharmacology approach to cyclotherapy. </span><span class="cited-content_cbyCitation_journal-name">PLOS Computational Biology</span><span> <strong>2017,</strong> <em>13 </em>
                                    (5)
                                     , e1005529. <a href="https://doi.org/10.1371/journal.pcbi.1005529" title="DOI URL">https://doi.org/10.1371/journal.pcbi.1005529</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pcbi.1005529&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pcbi.1005529%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520Computational%2520Biology%26atitle%3DModelling%252Bof%252Bthe%252Bcancer%252Bcell%252Bcycle%252Bas%252Ba%252Btool%252Bfor%252Brational%252Bdrug%252Bdevelopment%25253A%252BA%252Bsystems%252Bpharmacology%252Bapproach%252Bto%252Bcyclotherapy%26aulast%3DJackson%26aufirst%3DRobert%2BC.%26date%3D2017%26date%3D2017%26volume%3D13%26issue%3D5%26spage%3De1005529" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jian-Bei  Xi</span>, <span class="hlFld-ContribAuthor ">Yan-Fen  Fang</span>, <span class="hlFld-ContribAuthor ">Brendan  Frett</span>, <span class="hlFld-ContribAuthor ">Meng-Li  Zhu</span>, <span class="hlFld-ContribAuthor ">Tong  Zhu</span>, <span class="hlFld-ContribAuthor ">Yan-Nan  Kong</span>, <span class="hlFld-ContribAuthor ">Feng-Jie  Guan</span>, <span class="hlFld-ContribAuthor ">Yun  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiong-Wen  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong-yu  Li</span>, <span class="hlFld-ContribAuthor ">Ming-Liang  Ma</span>, <span class="hlFld-ContribAuthor ">Wenhao  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>126 </em>, 1083-1106. <a href="https://doi.org/10.1016/j.ejmech.2016.12.026" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.12.026</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.12.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.12.026%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdesign%252Band%252Bsynthesis%252Bof%252Bimidazo%25255B1%25252C2-a%25255Dpyridine%252Bderivatives%252Bas%252Bnovel%252Band%252Bpotent%252BNek2%252Binhibitors%252Bwith%252Bin%2525C2%2525A0vitro%252Band%252Bin%2525C2%2525A0vivo%252Bantitumor%252Bactivities%26aulast%3DXi%26aufirst%3DJian-Bei%26date%3D2017%26volume%3D126%26spage%3D1083%26epage%3D1106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Irma  Sánchez</span>, <span class="hlFld-ContribAuthor ">Brian David  Dynlacht</span>. </span><span class="cited-content_cbyCitation_article-title">Cilium assembly and disassembly. </span><span class="cited-content_cbyCitation_journal-name">Nature Cell Biology</span><span> <strong>2016,</strong> <em>18 </em>
                                    (7)
                                     , 711-717. <a href="https://doi.org/10.1038/ncb3370" title="DOI URL">https://doi.org/10.1038/ncb3370</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/ncb3370&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fncb3370%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Cell%2520Biology%26atitle%3DCilium%252Bassembly%252Band%252Bdisassembly%26aulast%3DS%25C3%25A1nchez%26aufirst%3DIrma%26date%3D2016%26date%3D2016%26volume%3D18%26issue%3D7%26spage%3D711%26epage%3D717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">B.R.  Lackey</span>, <span class="hlFld-ContribAuthor ">S.L.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Second messengers, steroids and signaling cascades: Crosstalk in sperm development and function. </span><span class="cited-content_cbyCitation_journal-name">General and Comparative Endocrinology</span><span> <strong>2015,</strong> <em>224 </em>, 294-302. <a href="https://doi.org/10.1016/j.ygcen.2015.07.005" title="DOI URL">https://doi.org/10.1016/j.ygcen.2015.07.005</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ygcen.2015.07.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ygcen.2015.07.005%26sid%3Dliteratum%253Aachs%26jtitle%3DGeneral%2520and%2520Comparative%2520Endocrinology%26atitle%3DSecond%252Bmessengers%25252C%252Bsteroids%252Band%252Bsignaling%252Bcascades%25253A%252BCrosstalk%252Bin%252Bsperm%252Bdevelopment%252Band%252Bfunction%26aulast%3DLackey%26aufirst%3DB.R.%26date%3D2015%26volume%3D224%26spage%3D294%26epage%3D302" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sehyun  Kim</span>, <span class="hlFld-ContribAuthor ">Kwanwoo  Lee</span>, <span class="hlFld-ContribAuthor ">Jung-Hwan  Choi</span>, <span class="hlFld-ContribAuthor ">Niels  Ringstad</span>, <span class="hlFld-ContribAuthor ">Brian David  Dynlacht</span>. </span><span class="cited-content_cbyCitation_article-title">Nek2 activation of Kif24 ensures cilium disassembly during the cell cycle. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2015,</strong> <em>6 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/ncomms9087" title="DOI URL">https://doi.org/10.1038/ncomms9087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/ncomms9087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fncomms9087%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DNek2%252Bactivation%252Bof%252BKif24%252Bensures%252Bcilium%252Bdisassembly%252Bduring%252Bthe%252Bcell%252Bcycle%26aulast%3DKim%26aufirst%3DSehyun%26date%3D2015%26date%3D2015%26volume%3D6%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christopher P.  Neal</span>, <span class="hlFld-ContribAuthor ">Andrew M.  Fry</span>, <span class="hlFld-ContribAuthor ">Catherine  Moreman</span>, <span class="hlFld-ContribAuthor ">Angus  McGregor</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Garcea</span>, <span class="hlFld-ContribAuthor ">David P.  Berry</span>, <span class="hlFld-ContribAuthor ">Margaret M.  Manson</span>. </span><span class="cited-content_cbyCitation_article-title">Overexpression of the Nek2 kinase in colorectal cancer correlates with beta-catenin relocalization and shortened cancer-specific survival. </span><span class="cited-content_cbyCitation_journal-name">Journal of Surgical Oncology</span><span> <strong>2014,</strong> <em>110 </em>
                                    (7)
                                     , 828-838. <a href="https://doi.org/10.1002/jso.23717" title="DOI URL">https://doi.org/10.1002/jso.23717</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jso.23717&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjso.23717%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Surgical%2520Oncology%26atitle%3DOverexpression%252Bof%252Bthe%252BNek2%252Bkinase%252Bin%252Bcolorectal%252Bcancer%252Bcorrelates%252Bwith%252Bbeta-catenin%252Brelocalization%252Band%252Bshortened%252Bcancer-specific%252Bsurvival%26aulast%3DNeal%26aufirst%3DChristopher%2BP.%26date%3D2014%26date%3D2014%26volume%3D110%26issue%3D7%26spage%3D828%26epage%3D838" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0009.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (A) Protein phosphatase 1 (PP1) signaling axis regulates both Nek2 and Akt in a normal cell. (B) In a tumor environment, increased Nek2 expression disrupts the PP1 signaling axis, leading to more active Akt, which drives ABC mediated drug resistance.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Aberrant Nek2 activity causes an increase in Akt activity, cell division, drug resistance, and metastasis. Inhibiting the Nek2 oncogene can block Akt, reduce tumor cell proliferation, increase chemotherapy sensitivity, and lower the rate of metastasis. Crystal structure data were obtained from Westood et al.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Evolution from compound <b>1</b> to compound <b>3</b>, a Nek2 selective irreversible inhibitor. (B) (1) Design strategy of a selective Nek2 covalent inhibitor and (2) compound <b>3</b> computationally modeled in the Nek2 kinase. The alkyne moiety is in proximity to Cys22 for covalent modification of Nek2. The imidazole moiety provides Nek2 selectivity. Computational binding experiments were completed using AutoDock Vina,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(58)</a> and the Nek2 crystal structure was obtained from Innocenti et al.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(55)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Development of compound <b>8</b> from compound <b>4</b> and HTS hit <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Induced Nek2 conformational change. Adapted from Whelligan et al.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(53)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Nek2 (orange) and Plk1 (blue) 3D structure alignment. Key residues within the ATP binding pocket have been highlighted. Arg136 on Plk1 provides an avenue for the development of Nek2 selective inhibitors. The structure alignment was completed with CLICK: Topology Independent Comparison of Biomolecular 3D Structures. The Nek2 crystal structure was obtained from Innocenti et al.,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(55)</a> and the Plk1 crystal structure was obtained from Nie et al.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(59)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Novel Nek2/EGFR dual inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/medium/jm-2013-01719n_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Proposed four-part Nek2 selective pharmacophore, composed of (1) solubilizing group, (2) hinge warhead, (3) aryl linker, and (4) glycine pocket moiety. (B) Crystal structure of compound <b>11</b> bound to the Nek2 kinase.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(55)</a> Key residues within the ATP active site are highlighted. (C) Computational binding of compound <b>4</b> with Nek2. (D) Computational binding of compound <b>6</b> with Nek2. (E) Molecular landscape of the Nek2 kinase. Crucial regions have been highlighted to aid in the design of future inhibitors. Computational binding experiments were completed using AutoDock Vina,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(58)</a> and the Nek2 crystal structure was obtained from Innocenti et al.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(55)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2014/jmcmar.2014.57.issue-14/jm401719n/production/images/large/jm-2013-01719n_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm401719n&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i17">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27746" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27746" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 59 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Ferlay, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shin, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bray, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Forman, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkin, D. M.</span><span> </span><span class="NLM_article-title">Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</span> <span class="citation_source-journal">Int. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">127</span><span class="NLM_x">, </span> <span class="NLM_fpage">2893</span><span class="NLM_x">–</span> <span class="NLM_lpage">2917</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1002%2Fijc.25516" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=21351269" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWhs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=127&publication_year=2010&pages=2893-2917&author=J.+Ferlayauthor=H.+R.+Shinauthor=F.+Brayauthor=D.+Formanauthor=C.+Mathersauthor=D.+M.+Parkin&title=Estimates+of+worldwide+burden+of+cancer+in+2008%3A+GLOBOCAN+2008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008</span></div><div class="casAuthors">Ferlay, Jacques; Shin, Hai-Rim; Bray, Freddie; Forman, David; Mathers, Colin; Parkin, Donald Maxwell</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">127</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2893-2917</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Ests. of the worldwide incidence and mortality from 27 cancers in 2008 have been prepd. for 182 countries as part of the GLOBOCAN series published by the International Agency for Research on Cancer.  In this article, we present the results for 20 world regions, summarizing the global patterns for the eight most common cancers.  Overall, an estd. 12.7 million new cancer cases and 7.6 million cancer deaths occur in 2008, with 56% of new cancer cases and 63% of the cancer deaths occurring in the less developed regions of the world.  The most commonly diagnosed cancers worldwide are lung (1.61 million, 12.7% of the total), breast (1.38 million, 10.9%) and colorectal cancers (1.23 million, 9.7%).  The most common causes of cancer death are lung cancer (1.38 million, 18.2% of the total), stomach cancer (738,000 deaths, 9.7%) and liver cancer (696,000 deaths, 9.2%).  Cancer is neither rare anywhere in the world, nor mainly confined to high-resource countries.  Striking differences in the patterns of cancer from region to region are obsd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNEfa8G4I-C7Vg90H21EOLACvtfcHk0lgrtY70d5Iw6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWhs7fO&md5=986c00d4fc94238145c1d56b8dfc4840</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fijc.25516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.25516%26sid%3Dliteratum%253Aachs%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DShin%26aufirst%3DH.%2BR.%26aulast%3DBray%26aufirst%3DF.%26aulast%3DForman%26aufirst%3DD.%26aulast%3DMathers%26aufirst%3DC.%26aulast%3DParkin%26aufirst%3DD.%2BM.%26atitle%3DEstimates%2520of%2520worldwide%2520burden%2520of%2520cancer%2520in%25202008%253A%2520GLOBOCAN%25202008%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2010%26volume%3D127%26spage%3D2893%26epage%3D2917" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span> <span class="citation_source-book">Globocan 2008: Cancer Incidence and Mortality Worldwide</span>; <span class="NLM_contrib-group">Ferlay, J.; Shin, H. R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D. M.</span>, Eds.; IARC CancerBase No.10;  <span class="NLM_publisher-name">International Agency for Research on Cancer</span>: <span class="NLM_publisher-loc">Lyon, France</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Ferlay&author=H.+R.+Shin&author=F.+Bray&author=D.+Forman&author=C.+Mathers&author=D.+M.+Parkin&title=Globocan+2008%3A+Cancer+Incidence+and+Mortality+Worldwide"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlobocan%25202008%253A%2520Cancer%2520Incidence%2520and%2520Mortality%2520Worldwide%26aulast%3DFerlay%26aufirst%3DJ.%26pub%3DInternational%2520Agency%2520for%2520Research%2520on%2520Cancer%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Kaye, S. B.</span><span> </span><span class="NLM_article-title">New antimetabolites in cancer chemotherapy and their clinical impact</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">78</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1038%2Fbjc.1998.747" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=9717984" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADyaK1cXlslWks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=1998&pages=1-7&author=S.+B.+Kaye&title=New+antimetabolites+in+cancer+chemotherapy+and+their+clinical+impact"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">New antimetabolites in cancer chemotherapy and their clinical impact</span></div><div class="casAuthors">Kaye, S. B.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">78</span>
        (<span class="NLM_cas:issue">Suppl. 3, New Antimetabolites in Cancer Chemotherapy and Their Clinical Impact</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Churchill Livingstone</span>)
        </div><div class="casAbstract">A review, with 68 refs.  It is almost 50 yr since antimetabolites were first found to have clin. antitumor activity, with Farber's discovery that aminopterin could cause remission in acute leukemia.  In the following 10 yr, methotrexate, 6-mercaptopurine and 5-fluorouracil (5-FU) found their way into clin. practice.  Subsequently, cytosine arabinoside was found to have activity in acute leukemia, but, until recently, other significant developments have involved optimizing the efficacy of existing antimetabolites, including the use of leucovorin with methotrexate or 5-FU.  Recently, new antimetabolites have become a fertile area for anti-cancer drug research.  Gemcitabine (GEMZAR) has emerged as an important new agent in several tumor types, including pancreatic, non-small-cell lung, bladder, breast and ovarian cancers.  Capecitabine is an intriguing new prodrug, offering tumor selectivity and prolonged tumor exposure to 5-FU.  More potent thymidylate synthase inhibitors have also emerged; raltitrexed is now com. available for the treatment of colorectal cancer.  Others under development include LY231514, which has other sites of action, hence the acronym MTA (multi-targeted antifolate).  A novel target is glycinamide ribonucleotide formyltransferase (GARFT) and LY309887 and AG2034 are undergoing clin. investigation as GARFT inhibitors.  A crit. element with LY309887 appears to be co-administration of folate.  It seems entirely possible that several novel antimetabolites will establish themselves in clin. practice in future for the treatment of solid tumors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpIb61ZThgIjbVg90H21EOLACvtfcHk0lgHLfUOiJl-VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXlslWks7g%253D&md5=95c33f58a319c4d921661dbf711616ea</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fbjc.1998.747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.1998.747%26sid%3Dliteratum%253Aachs%26aulast%3DKaye%26aufirst%3DS.%2BB.%26atitle%3DNew%2520antimetabolites%2520in%2520cancer%2520chemotherapy%2520and%2520their%2520clinical%2520impact%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D1998%26volume%3D78%26spage%3D1%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Go, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjei, A. A.</span><span> </span><span class="NLM_article-title">Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">409</span><span class="NLM_x">–</span> <span class="NLM_lpage">422</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1200%2FJCO.1999.17.1.409" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=10458260" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADyaK1MXltVyrug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=1999&pages=409-422&author=R.+S.+Goauthor=A.+A.+Adjei&title=Review+of+the+comparative+pharmacology+and+clinical+activity+of+cisplatin+and+carboplatin"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin</span></div><div class="casAuthors">Go, Ronald S.; Adjei, Alex A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">409-422</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">A review with 113 refs.  To review the pharmacodynamics, pharmacokinetics, toxicities, and relative clin. activities of cisplatin and carboplatin.  Through a search of the MEDLINE database, we identified phase III clin. trials and pharmacol. studies comparing cisplatin and carboplatin published in the English language medical literature from Jan. 1966 to Dec. 1997.  Prospective randomized trials comparing cisplatin to carboplatin were identified for ovarian (n = 12), germ cell (n = 4), non-small-cell lung (n = 1), small-cell lung (n = 3), and head and neck (n = 4) cancers.  Carboplatin and cisplatin were equally effective in suboptimally debulked ovarian cancer and extensive-stage small-cell lung cancer.  One study each showed a trend toward better survival in favor of cisplatin for patients with optimally debulked ovarian and limited-stage small-cell lung cancers.  These results were, however, based on subset analyses.  In germ cell tumors, carboplatin was inferior because of lower relapse-free survival rates.  Cisplatin produced superior response rates and survival in head and neck cancers.  There are no published randomized phase III studies of bladder, cervical, endometrial, and esophageal cancers.  Carboplatin does not possess equiv. activity to cisplatin in all platinum-sensitive tumors.  Carboplatin can replace cisplatin in chemotherapy regimens for suboptimally debulked ovarian cancer.  Two ongoing studies will address the same question in optimally debulked disease.  Carboplatin can also be substituted for cisplatin in the treatment of non-small-cell and extensive-stage small-cell lung cancers.  Its role in limited-stage small-cell lung cancer needs to be investigated further.  Carboplatin is inferior to cisplatin in germ cell, head and neck, and esophageal cancers.  Randomized studies are needed to det. whether carboplatin has equiv. efficacy to cisplatin in bladder, cervical, and endometrial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6oRZSRTFXkLVg90H21EOLACvtfcHk0lgHLfUOiJl-VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXltVyrug%253D%253D&md5=670468515a36db5297f6eb2997242aa4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1200%2FJCO.1999.17.1.409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.1999.17.1.409%26sid%3Dliteratum%253Aachs%26aulast%3DGo%26aufirst%3DR.%2BS.%26aulast%3DAdjei%26aufirst%3DA.%2BA.%26atitle%3DReview%2520of%2520the%2520comparative%2520pharmacology%2520and%2520clinical%2520activity%2520of%2520cisplatin%2520and%2520carboplatin%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1999%26volume%3D17%26spage%3D409%26epage%3D422" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Bollag, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McQueney, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hensens, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koupal, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liesch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lazarides, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woods, C. M.</span><span> </span><span class="NLM_article-title">Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2325</span><span class="NLM_x">–</span> <span class="NLM_lpage">2333</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=7757983" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADyaK2MXlvFeqsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1995&pages=2325-2333&author=D.+M.+Bollagauthor=P.+A.+McQueneyauthor=J.+Zhuauthor=O.+Hensensauthor=L.+Koupalauthor=J.+Lieschauthor=M.+Goetzauthor=E.+Lazaridesauthor=C.+M.+Woods&title=Epothilones%2C+a+new+class+of+microtubule-stabilizing+agents+with+a+Taxol-like+mechanism+of+action"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action</span></div><div class="casAuthors">Bollag, Daniel M.; McQueney, Patricia A.; Zhu, Jian; Hensens, Otto; Koupal, Lawrence; Liesch, Jerrold; Goetz, Michael; Lazarides, Elias; Woods, Catherine M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2325-33</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The antineoplastic agent taxol hyperstabilizes polymd. microtubules, leading to mitotic arrest and cytotoxicity in proliferating cells.  By using a sensitive filtration-calorimetric assay to detect microtubule nucleating activity, epothilones A and B were identified as compds. that possess all the biol. effects of taxol both in vitro and in cultured cells.  The 2 epothilones were equipotent and exhibited kinetics similar to those of taxol in inducing tubulin polymn. to microtubules in vitro and in producing enhanced microtubule stability and bundling in cultured cells.  Furthermore, these 16-membered macrolides were competitive inhibitors of [3H]taxol binding, exhibiting an IC50 almost identical to that of taxol in displacement competition assays.  Like taxol, the epothilones also caused cell cycle arrest at the G2-M transition, leading to cytotoxicity.  In contrast to taxol, the epothilones retained much greater toxicity against P-glycoprotein-expressing multiple-drug-resistant cells.  Epothilones, therefore, represent a novel structural class of compds. which not only mimic the biol. effects of taxol but also appear to bind to the same microtubule-binding site as taxol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoaxKCSWNo8RLVg90H21EOLACvtfcHk0lgMIRyb8XaNfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXlvFeqsr0%253D&md5=f858620138df4b7d800d641db7da9962</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DD.%2BM.%26aulast%3DMcQueney%26aufirst%3DP.%2BA.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DHensens%26aufirst%3DO.%26aulast%3DKoupal%26aufirst%3DL.%26aulast%3DLiesch%26aufirst%3DJ.%26aulast%3DGoetz%26aufirst%3DM.%26aulast%3DLazarides%26aufirst%3DE.%26aulast%3DWoods%26aufirst%3DC.%2BM.%26atitle%3DEpothilones%252C%2520a%2520new%2520class%2520of%2520microtubule-stabilizing%2520agents%2520with%2520a%2520Taxol-like%2520mechanism%2520of%2520action%26jtitle%3DCancer%2520Res.%26date%3D1995%26volume%3D55%26spage%3D2325%26epage%3D2333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Jordan, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toso, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thrower, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, L.</span><span> </span><span class="NLM_article-title">Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">90</span><span class="NLM_x">, </span> <span class="NLM_fpage">9552</span><span class="NLM_x">–</span> <span class="NLM_lpage">9556</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=9552-9556&author=M.+A.+Jordanauthor=R.+J.+Tosoauthor=D.+Throwerauthor=L.+Wilson&title=Mechanism+of+mitotic+block+and+inhibition+of+cell+proliferation+by+taxol+at+low+concentrations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DJordan%26aufirst%3DM.%2BA.%26aulast%3DToso%26aufirst%3DR.%2BJ.%26aulast%3DThrower%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DL.%26atitle%3DMechanism%2520of%2520mitotic%2520block%2520and%2520inhibition%2520of%2520cell%2520proliferation%2520by%2520taxol%2520at%2520low%2520concentrations%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1993%26volume%3D90%26spage%3D9552%26epage%3D9556" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Fisher, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pusztai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swanton, C.</span><span> </span><span class="NLM_article-title">Cancer heterogeneity: implications for targeted therapeutics</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">108</span><span class="NLM_x">, </span> <span class="NLM_fpage">479</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1038%2Fbjc.2012.581" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=23299535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtV2rtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2013&pages=479-485&author=R.+Fisherauthor=L.+Pusztaiauthor=C.+Swanton&title=Cancer+heterogeneity%3A+implications+for+targeted+therapeutics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer heterogeneity: implications for targeted therapeutics</span></div><div class="casAuthors">Fisher, R.; Pusztai, L.; Swanton, C.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">479-485</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Developments in genomic techniques have provided insight into the remarkable genetic complexity of malignant tumors.  There is increasing evidence that solid tumors may comprise of subpopulations of cells with distinct genomic alterations within the same tumor, a phenomenon termed intra-tumor heterogeneity.  Intra-tumor heterogeneity is likely to have implications for cancer therapeutics and biomarker discovery, particularly in the era of targeted treatment, and evidence for a relationship between intra-tumoral heterogeneity and clin. outcome is emerging.  Our understanding of the processes that exacerbate intra-tumoral heterogeneity, both iatrogenic and tumor specific, is likely to increase with the development and more widespread implementation of advanced sequencing technologies, and adaptation of clin. trial design to include comprehensive tissue collection protocols.  The current evidence for intra-tumor heterogeneity and its relevance to cancer therapeutics will be presented in this mini-review.  British Journal of Cancer (2013) 108, 479-485; doi:10.1038/bjc.2012.581 www.bjcancer.com Published online 8 Jan. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWp4WYese5nbVg90H21EOLACvtfcHk0lgMIRyb8XaNfQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtV2rtbo%253D&md5=a786527dd05a52a16c1c96b72fdc01c5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2012.581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2012.581%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DR.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DSwanton%26aufirst%3DC.%26atitle%3DCancer%2520heterogeneity%253A%2520implications%2520for%2520targeted%2520therapeutics%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2013%26volume%3D108%26spage%3D479%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Druker, B. J.</span><span> </span><span class="NLM_article-title">STI571 (Gleevec) as a paradigm for cancer therapy</span> <span class="citation_source-journal">Trends Mol. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">S14</span><span class="NLM_x">–</span> <span class="NLM_lpage">S18</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=S14-S18&author=B.+J.+Druker&title=STI571+%28Gleevec%29+as+a+paradigm+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDruker%26aufirst%3DB.%2BJ.%26atitle%3DSTI571%2520%2528Gleevec%2529%2520as%2520a%2520paradigm%2520for%2520cancer%2520therapy%26jtitle%3DTrends%2520Mol.%2520Med.%26date%3D2002%26volume%3D8%26spage%3DS14%26epage%3DS18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Wells, S. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gosnell, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagel, R. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfister, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosa, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skinner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasselli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M.</span><span> </span><span class="NLM_article-title">Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">67</span><span class="NLM_x">–</span> <span class="NLM_lpage">72</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1200%2FJCO.2009.23.6604" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2010&pages=67-72&author=S.+A.+Wellsauthor=J.+E.+Gosnellauthor=R.+F.+Gagelauthor=J.+Moleyauthor=D.+Pfisterauthor=J.+A.+Sosaauthor=M.+Skinnerauthor=A.+Krebsauthor=J.+Vasselliauthor=M.+Schlumberger&title=Vandetanib+for+the+treatment+of+patients+with+locally+advanced+or+metastatic+hereditary+medullary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.23.6604&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.23.6604%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DS.%2BA.%26aulast%3DGosnell%26aufirst%3DJ.%2BE.%26aulast%3DGagel%26aufirst%3DR.%2BF.%26aulast%3DMoley%26aufirst%3DJ.%26aulast%3DPfister%26aufirst%3DD.%26aulast%3DSosa%26aufirst%3DJ.%2BA.%26aulast%3DSkinner%26aufirst%3DM.%26aulast%3DKrebs%26aufirst%3DA.%26aulast%3DVasselli%26aufirst%3DJ.%26aulast%3DSchlumberger%26aufirst%3DM.%26atitle%3DVandetanib%2520for%2520the%2520treatment%2520of%2520patients%2520with%2520locally%2520advanced%2520or%2520metastatic%2520hereditary%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2010%26volume%3D28%26spage%3D67%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Escudier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eisen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stadler, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szczylik, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oudard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Siebels, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negrier, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevreau, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solska, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rolland, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Demkow, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freeman, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bukowski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">TARGET Study Group.</span><span> </span><span class="NLM_article-title">Sorafenib in advanced clear-cell renal-cell carcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1056%2FNEJMoa060655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=17215530" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD2sXksVKitg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=125-134&author=B.+Escudierauthor=T.+Eisenauthor=W.+M.+Stadlerauthor=C.+Szczylikauthor=S.+Oudardauthor=M.+Siebelsauthor=S.+Negrierauthor=C.+Chevreauauthor=E.+Solskaauthor=A.+A.+Desaiauthor=F.+Rollandauthor=T.+Demkowauthor=T.+E.+Hutsonauthor=M.+Goreauthor=S.+Freemanauthor=B.+Schwartzauthor=M.+Shanauthor=R.+Simantovauthor=R.+M.+Bukowskiauthor=TARGET+Study+Group.&title=Sorafenib+in+advanced+clear-cell+renal-cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib in advanced clear-cell renal-cell carcinoma</span></div><div class="casAuthors">Escudier, Bernard; Eisen, Tim; Stadler, Walter M.; Szczylik, Cezary; Oudard, Stephane; Siebels, Michael; Negrier, Sylvie; Chevreau, Christine; Solska, Ewa; Desai, Apurva A.; Rolland, Frederic; Demkow, Tomasz; Hutson, Thomas E.; Gore, Martin; Freeman, Scott; Schwartz, Brian; Shan, Minghua; Simantov, Ronit; Bukowski, Ronald M.; Blajman, C.; Fein, L.; Martin, C.; Taber, R.; Boyer, M.; Davis, I.; Gurney, H.; Hovey, E.; Leong, D.; Steer, C.; DeGreve, J.; Gil, T.; Barrios, C.; David, W.; Skare, N. G.; Notari, A.; Schwartsmann, G.; Gunnar, N.; Ernst, S.; Hotte, S.; Miller, W.; Moore, M.; North, S.; Fodor, M.; Caty, A.; Chevreau, C.; Duclos, B.; Gravis, G.; Negrier, S.; Oudard, S.; Ravaud, A.; Rolland, F.; Sevin, E.; Grimm, M. O.; Gschwennd, J.; Heinzer, H.; Jager, E.; Krause, S.; Michel, M.-S.; Rohde, D.; Siebels, M.; Siegsmund, M.; Staehler, M.; Wirth, M.; Baki, M.; Bodrogi, I.; Cseh, J.; Ruzsa, A.; Toth, C.; Ben-Yosef, R.; Gez, E.; Bajetta, E.; Boni, C.; Bracarda, S.; Cognetti, F.; Conte, P.; Porta, C.; Spronsen, D. J.; Blasinka-Morawiec, M.; Dernkow, T.; Lorenz, J.; Mazurkiewicz, M.; Roslki, J.; Sikorski, A.; Solska, E.; Tomczak, P.; Bolotina, L.; Karlov, P.; Karyakin, O.; Khasanov, R.; Lichinitser, M.; Lubennikov, V.; Moiseenko, V.; Sherman, N.; Abratt, R.; Coetzee, L.; Cohen, G.; Heyns, C.; Jordaan, J.; Ruff, P.; Wentzel, S.; Bellmunt, J.; Climent, M. A.; Gonzalez, J. L.; Lopez, G.; Bashtan, V.; Dumamsky, Y.; Klimenko, I.; Pilipenko, N.; Shparik, Y.; Hawkins, R.; McMenemin, R.; Nathan, P.; Porfiri, E.; Savage, P.; White, J.; Anderson, C.; Bains, Y.; Bleickardt, E.; Bradof, J.; Brooks, D.; Cardi, G.; Cervera, A.; Davis, N.; Desai, A.; Drabkin, H.; Dudek, A.; Dutcher, J.; Formanek, G.; Gabrail, N.; Gorss, H.; Haung, Y.; Henderson, C.; Hutson, T.; Jonasch, E.; Lara, P.; McCracken, J.; McDermott, D.; Mena, R.; Middleton, R.; Petrylak, D.; Picus, D.; Quinn, D.; Rausch, P.; Rinaldi, D.; Ryan, C.; Tchekmedyian, N.; Vuky, J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-134</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a phase 3, randomized, double-blind, placebo-controlled trial of sorafenib, a multikinase inhibitor of tumor-cell proliferation and angiogenesis, in patients with advanced clear-cell renal-cell carcinoma.  From Nov. 2003 to Mar. 2005, we randomly assigned 903 patients with renal-cell carcinoma that was resistant to std. therapy to receive either continuous treatment with oral sorafenib (at a dose of 400 mg twice daily) or placebo; 451 patients received sorafenib and 452 received placebo.  The primary end point was overall survival.  A single planned anal. of progression-free survival in Jan. 2005 showed a statistically significant benefit of sorafenib over placebo.  Consequently, crossover was permitted from placebo to sorafenib, beginning in May 2005.  At the Jan. 2005 cutoff, the median progression-free survival was 5.5 mo in the sorafenib group and 2.8 mo in the placebo group (hazard ratio for disease progression in the sorafenib group, 0.44; 95% confidence interval [CI], 0.35 to 0.55).  The 1st interim anal. of overall survival in May 2005 showed that sorafenib reduced the risk of death, as compared with placebo (hazard ratio, 0.72; 95% CI, 0.54 to 0.94), although this benefit was not statistically significant according to the O'Brien-Fleming threshold.  Partial responses were reported as the best response in 10% of patients receiving sorafenib and in 2% of those receiving placebo.  Diarrhea, rash, fatigue, and hand-foot skin reactions were the most common adverse events assocd. with sorafenib.  Hypertension and cardiac ischemia were rare serious adverse events that were more common in patients receiving sorafenib than in those receiving placebo.  As compared with placebo, treatment with sorafenib prolongs progression-free survival in patients with advanced clear-cell renal-cell carcinoma in whom previous therapy has failed; however, treatment is assocd. with increased toxic effects.  (ClinicalTrials.gov no., NCT00073307).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqV_8zTNHmXrLVg90H21EOLACvtfcHk0lhx4xhKc_MLuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXksVKitg%253D%253D&md5=8f6da990729f8ff17587d71744b834f4</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa060655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa060655%26sid%3Dliteratum%253Aachs%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DStadler%26aufirst%3DW.%2BM.%26aulast%3DSzczylik%26aufirst%3DC.%26aulast%3DOudard%26aufirst%3DS.%26aulast%3DSiebels%26aufirst%3DM.%26aulast%3DNegrier%26aufirst%3DS.%26aulast%3DChevreau%26aufirst%3DC.%26aulast%3DSolska%26aufirst%3DE.%26aulast%3DDesai%26aufirst%3DA.%2BA.%26aulast%3DRolland%26aufirst%3DF.%26aulast%3DDemkow%26aufirst%3DT.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DFreeman%26aufirst%3DS.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DShan%26aufirst%3DM.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26aulast%3D%26atitle%3DSorafenib%2520in%2520advanced%2520clear-cell%2520renal-cell%2520carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D125%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Branford, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudzki, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walsh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grigg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joske, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, T.</span><span> </span><span class="NLM_article-title">Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">102</span><span class="NLM_x">, </span> <span class="NLM_fpage">276</span><span class="NLM_x">–</span> <span class="NLM_lpage">283</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2003&pages=276-283&author=S.+Branfordauthor=Z.+Rudzkiauthor=S.+Walshauthor=I.+Parkinsonauthor=A.+Griggauthor=J.+Szerauthor=K.+Taylorauthor=R.+Herrmannauthor=J.+F.+Seymourauthor=C.+Arthurauthor=D.+Joskeauthor=K.+Lynchauthor=T.+Hughes&title=Detection+of+BCR-ABL+mutations+in+patients+with+CML+treated+with+imatinib+is+virtually+always+accompanied+by+clinical+resistance%2C+and+mutations+in+the+ATP+phosphate-binding+loop+%28P-loop%29+are+associated+with+a+poor+prognosis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBranford%26aufirst%3DS.%26aulast%3DRudzki%26aufirst%3DZ.%26aulast%3DWalsh%26aufirst%3DS.%26aulast%3DParkinson%26aufirst%3DI.%26aulast%3DGrigg%26aufirst%3DA.%26aulast%3DSzer%26aufirst%3DJ.%26aulast%3DTaylor%26aufirst%3DK.%26aulast%3DHerrmann%26aufirst%3DR.%26aulast%3DSeymour%26aufirst%3DJ.%2BF.%26aulast%3DArthur%26aufirst%3DC.%26aulast%3DJoske%26aufirst%3DD.%26aulast%3DLynch%26aufirst%3DK.%26aulast%3DHughes%26aufirst%3DT.%26atitle%3DDetection%2520of%2520BCR-ABL%2520mutations%2520in%2520patients%2520with%2520CML%2520treated%2520with%2520imatinib%2520is%2520virtually%2520always%2520accompanied%2520by%2520clinical%2520resistance%252C%2520and%2520mutations%2520in%2520the%2520ATP%2520phosphate-binding%2520loop%2520%2528P-loop%2529%2520are%2520associated%2520with%2520a%2520poor%2520prognosis%26jtitle%3DBlood%26date%3D2003%26volume%3D102%26spage%3D276%26epage%3D283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Smith, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chin, C. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salerno, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Damon, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levis, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perl, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Travers, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadt, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasarskis, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuriyan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, N. P.</span><span> </span><span class="NLM_article-title">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">485</span><span class="NLM_x">, </span> <span class="NLM_fpage">260</span><span class="NLM_x">–</span> <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1038%2Fnature11016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=22504184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=485&publication_year=2012&pages=260-326&author=C.+C.+Smithauthor=Q.+Wangauthor=C.+S.+Chinauthor=S.+Salernoauthor=L.+E.+Damonauthor=M.+J.+Levisauthor=A.+E.+Perlauthor=K.+J.+Traversauthor=S.+Wangauthor=J.+P.+Huntauthor=P.+P.+Zarrinkarauthor=E.+E.+Schadtauthor=A.+Kasarskisauthor=J.+Kuriyanauthor=N.+P.+Shah&title=Validation+of+ITD+mutations+in+FLT3+as+a+therapeutic+target+in+human+acute+myeloid+leukaemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukemia</span></div><div class="casAuthors">Smith, Catherine C.; Wang, Qi; Chin, Chen-Shan; Salerno, Sara; Damon, Lauren E.; Levis, Mark J.; Perl, Alexander E.; Travers, Kevin J.; Wang, Susana; Hunt, Jeremy P.; Zarrinkar, Patrick P.; Schadt, Eric E.; Kasarskis, Andrew; Kuriyan, John; Shah, Neil P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">485</span>
        (<span class="NLM_cas:issue">7397</span>),
    <span class="NLM_cas:pages">260-263</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Effective targeted cancer therapeutic development depends upon distinguishing disease-assocd. driver' mutations, which have causative roles in malignancy pathogenesis, from passenger' mutations, which are dispensable for cancer initiation and maintenance.  Translational studies of clin. active targeted therapeutics can definitively discriminate driver from passenger lesions and provide valuable insights into human cancer biol.  Activating internal tandem duplication (ITD) mutations in FLT3 (FLT3-ITD) are detected in approx. 20% of acute myeloid leukemia (AML) patients and are assocd. with a poor prognosis.  Abundant scientific and clin. evidence, including the lack of convincing clin. activity of early FLT3 inhibitors, suggests that FLT3-ITD probably represents a passenger lesion.  Here we report point mutations at three residues within the kinase domain of FLT3-ITD that confer substantial in vitro resistance to AC220 (quizartinib), an active investigational inhibitor of FLT3, KIT, PDGFRA, PDGFRB and RET; evolution of AC220-resistant substitutions at two of these amino acid positions was obsd. in eight of eight FLT3-ITD-pos. AML patients with acquired resistance to AC220.  Our findings demonstrate that FLT3-ITD can represent a driver lesion and valid therapeutic target in human AML.  AC220-resistant FLT3 kinase domain mutants represent high-value targets for future FLT3 inhibitor development efforts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqq0PeqhlWLObVg90H21EOLACvtfcHk0lgVqwqex8TwEg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtVeqtr8%253D&md5=228dae85b08e65918f74ee8c5d20ddb0</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnature11016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature11016%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BC.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DChin%26aufirst%3DC.%2BS.%26aulast%3DSalerno%26aufirst%3DS.%26aulast%3DDamon%26aufirst%3DL.%2BE.%26aulast%3DLevis%26aufirst%3DM.%2BJ.%26aulast%3DPerl%26aufirst%3DA.%2BE.%26aulast%3DTravers%26aufirst%3DK.%2BJ.%26aulast%3DWang%26aufirst%3DS.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26aulast%3DSchadt%26aufirst%3DE.%2BE.%26aulast%3DKasarskis%26aufirst%3DA.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShah%26aufirst%3DN.%2BP.%26atitle%3DValidation%2520of%2520ITD%2520mutations%2520in%2520FLT3%2520as%2520a%2520therapeutic%2520target%2520in%2520human%2520acute%2520myeloid%2520leukaemia%26jtitle%3DNature%26date%3D2012%26volume%3D485%26spage%3D260%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberhardt, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Germonpré, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kabbinavar, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichinose, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biesma, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langmuir, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kennedy, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tada, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span> </span><span class="NLM_article-title">Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">619</span><span class="NLM_x">–</span> <span class="NLM_lpage">626</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1016%2FS1470-2045%2810%2970132-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=20570559" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXotVWqu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2010&pages=619-626&author=R.+S.+Herbstauthor=Y.+Sunauthor=W.+E.+Eberhardtauthor=P.+Germonpr%C3%A9author=N.+Saijoauthor=C.+Zhouauthor=J.+Wangauthor=L.+Liauthor=F.+Kabbinavarauthor=Y.+Ichinoseauthor=S.+Qinauthor=L.+Zhangauthor=B.+Biesmaauthor=J.+V.+Heymachauthor=P.+Langmuirauthor=S.+J.+Kennedyauthor=H.+Tadaauthor=B.+E.+Johnson&title=Vandetanib+plus+docetaxel+versus+docetaxel+as+second-line+treatment+for+patients+with+advanced+non-small-cell+lung+cancer+%28ZODIAC%29%3A+a+double-blind%2C+randomised%2C+phase+3+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial</span></div><div class="casAuthors">Herbst, Roy S.; Sun, Yan; Eberhardt, Wilfried E. E.; Germonpre, Paul; Saijo, Nagahiro; Zhou, Caicun; Wang, Jie; Li, Longyun; Kabbinavar, Fairooz; Ichinose, Yukito; Qin, Shukui; Zhang, Li; Biesma, Bonne; Heymach, John V.; Langmuir, Peter; Kennedy, Sarah J.; Tada, Hiroomi; Johnson, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">619-626</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Vandetanib is a once-daily oral inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), and rearranged during transfection (RET) tyrosine kinases.  In a randomized phase 2 study in patients with previously treated non-small-cell lung cancer (NSCLC), adding vandetanib 100 mg to docetaxel significantly improved progression-free survival (PFS) compared with docetaxel alone, including a longer PFS in women.  These results supported investigation of the combination in this larger, definitive phase 3 trial (ZODIAC).  Between May, 2006, and Apr., 2008, patients with locally advanced or metastatic (stage IIIB-IV) NSCLC after progression following first-line chemotherapy were randomly assigned 1:1 through a third-party interactive voice system to receive vandetanib (100 mg/day) plus docetaxel (75 mg/m2 i.v. every 21 days; max. six cycles) or placebo plus docetaxel.  The primary objective was comparison of PFS between the two groups in the intention-to-treat population.  Women were a coprimary anal. population.  This study has been completed and is registered with ClinicalTrials.gov, no. NCT00312377.  1391 patients received vandetanib plus docetaxel (n=694 [197 women]) or placebo plus docetaxel (n=697 [224 women]).  Vandetanib plus docetaxel led to a significant improvement in PFS vs. placebo plus docetaxel (hazard ratio [HR] 0.79, 97.58% CI 0.70-0.90; p<0.0001); median PFS was 4.0 mo in the vandetanib group vs. 3.2 mo in placebo group.  A similar improvement in PFS with vandetanib plus docetaxel vs. placebo plus docetaxel was seen in women (HR 0.79, 0.62-1.00, p=0.024); median PFS was 4.6 mo in the vandetanib group vs. 4.2 mo in the placebo group.  Among grade 3 or higher adverse events, rash (63/689 [9%] vs 7/690 [1%]), neutropenia (199/689 [29%] vs 164/690 [24%]), leukopenia (99/689 [14%] vs 77/690 [11%]), and febrile neutropenia (61/689 [9%] vs 48/690 [7%]) were more common with vandetanib plus docetaxel than with placebo plus docetaxel.  The most common serious adverse event was febrile neutropenia (46/689 [7%] in the vandetanib group vs 38/690 [6%] in the placebo group).  The addn. of vandetanib to docetaxel provides a significant improvement in PFS in patients with advanced NSCLC after progression following first-line therapy.  Funding: AstraZeneca.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryVcdfCkTN-LVg90H21EOLACvtfcHk0ljTw_RPCkbyOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXotVWqu78%253D&md5=47402d2231220fb5b081a4a521bf1b9c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2810%2970132-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252810%252970132-7%26sid%3Dliteratum%253Aachs%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DEberhardt%26aufirst%3DW.%2BE.%26aulast%3DGermonpr%25C3%25A9%26aufirst%3DP.%26aulast%3DSaijo%26aufirst%3DN.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DKabbinavar%26aufirst%3DF.%26aulast%3DIchinose%26aufirst%3DY.%26aulast%3DQin%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DBiesma%26aufirst%3DB.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DLangmuir%26aufirst%3DP.%26aulast%3DKennedy%26aufirst%3DS.%2BJ.%26aulast%3DTada%26aufirst%3DH.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26atitle%3DVandetanib%2520plus%2520docetaxel%2520versus%2520docetaxel%2520as%2520second-line%2520treatment%2520for%2520patients%2520with%2520advanced%2520non-small-cell%2520lung%2520cancer%2520%2528ZODIAC%2529%253A%2520a%2520double-blind%252C%2520randomised%252C%2520phase%25203%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2010%26volume%3D11%26spage%3D619%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Heymach, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paz-Ares, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Braud, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sebastian, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eberhardt, W. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranade, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trigo, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandler, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonomi, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krebs, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vasselli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span> </span><span class="NLM_article-title">Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">5407</span><span class="NLM_x">–</span> <span class="NLM_lpage">5415</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1200%2FJCO.2008.17.3138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=18936474" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhslClsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=5407-5415&author=J.+V.+Heymachauthor=L.+Paz-Aresauthor=F.+De+Braudauthor=M.+Sebastianauthor=D.+J.+Stewartauthor=W.+E.+Eberhardtauthor=A.+A.+Ranadeauthor=G.+Cohenauthor=J.+M.+Trigoauthor=A.+B.+Sandlerauthor=P.+D.+Bonomiauthor=R.+S.+Herbstauthor=A.+D.+Krebsauthor=J.+Vasselliauthor=B.+E.+Johnson&title=Randomized+phase+II+study+of+vandetanib+alone+or+with+paclitaxel+and+carboplatin+as+first-line+treatment+for+advanced+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer</span></div><div class="casAuthors">Heymach, John V.; Paz-Ares, Luis; De Braud, Filippo; Sebastian, Martin; Stewart, David J.; Eberhardt, Wilfried E. E.; Ranade, Anantbhushan A.; Cohen, Graham; Trigo, Jose Manuel; Sandler, Alan B.; Bonomi, Philip D.; Herbst, Roy S.; Krebs, Annetta D.; Vasselli, James; Johnson, Bruce E.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5407-5415</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Vandetanib is a once-daily, oral inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling.  The antitumor activity of vandetanib monotherapy or vandetanib with paclitaxel and carboplatin (VPC) was compared with paclitaxel and carboplatin (PC) in previously untreated patients with non-small-cell lung cancer (NSCLC).  All NSCLC histologies and previously treated CNS metastases were permitted in this partially blinded, placebo-controlled, randomized phase II study.  Patients were randomly assigned 2:1:1 to receive vandetanib, VPC, or PC.  Progression-free survival (PFS) was the primary end point, and the study was powered to detect a reduced risk of progression with VPC vs. PC (hazard ratio = 0.70; one-sided P < .2) and to demonstrate noninferiority for vandetanib vs. PC.  Overall survival was a secondary assessment.  The risk of progression was reduced for patients receiving VPC (n = 56) vs. PC (n = 52; hazard ratio = 0.76, one-sided P = .098); median PFS was 24 wk (VPC) and 23 wk (PC).  The vandetanib monotherapy arm (n = 73) was discontinued after a planned interim PFS anal. met the criterion for discontinuation (hazard ratio > 1.33 v PC).  Overall survival was not significantly different between patients receiving VPC or PC.  Rash, diarrhea, and hypertension were common adverse events; no pulmonary or CNS hemorrhage events required intervention.  VPC could be safely administered to patients with NSCLC, including those with squamous cell histol. and treated brain metastases.  Compared with the PC control arm, patients receiving VPC had longer PFS, meeting the prespecified study end point, whereas those receiving vandetanib monotherapy had shorter PFS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpEpBa6v0Wn07Vg90H21EOLACvtfcHk0ljTw_RPCkbyOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhslClsg%253D%253D&md5=d6b3cc3f1e238ca09c2d929385d85c29</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1200%2FJCO.2008.17.3138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2008.17.3138%26sid%3Dliteratum%253Aachs%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26aulast%3DPaz-Ares%26aufirst%3DL.%26aulast%3DDe%2BBraud%26aufirst%3DF.%26aulast%3DSebastian%26aufirst%3DM.%26aulast%3DStewart%26aufirst%3DD.%2BJ.%26aulast%3DEberhardt%26aufirst%3DW.%2BE.%26aulast%3DRanade%26aufirst%3DA.%2BA.%26aulast%3DCohen%26aufirst%3DG.%26aulast%3DTrigo%26aufirst%3DJ.%2BM.%26aulast%3DSandler%26aufirst%3DA.%2BB.%26aulast%3DBonomi%26aufirst%3DP.%2BD.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DKrebs%26aufirst%3DA.%2BD.%26aulast%3DVasselli%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26atitle%3DRandomized%2520phase%2520II%2520study%2520of%2520vandetanib%2520alone%2520or%2520with%2520paclitaxel%2520and%2520carboplatin%2520as%2520first-line%2520treatment%2520for%2520advanced%2520non-small-cell%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2008%26volume%3D26%26spage%3D5407%26epage%3D5415" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Peters, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van der Wilt, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Moorsel, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroep, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergman, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ackland, S. P.</span><span> </span><span class="NLM_article-title">Basis for effective combination cancer chemotherapy with antimetabolites</span> <span class="citation_source-journal">Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">87</span><span class="NLM_x">, </span> <span class="NLM_fpage">227</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1016%2FS0163-7258%2800%2900086-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=11008002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmslOjtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=87&publication_year=2000&pages=227-253&author=G.+J.+Petersauthor=C.+L.+van+der+Wiltauthor=C.+J.+van+Moorselauthor=J.+R.+Kroepauthor=A.+M.+Bergmanauthor=S.+P.+Ackland&title=Basis+for+effective+combination+cancer+chemotherapy+with+antimetabolites"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Basis for effective combination cancer chemotherapy with antimetabolites</span></div><div class="casAuthors">Peters, G. J.; van der Wilt, C. L.; van Moorsel, C. J. A.; Kroep, J. R.; Bergman, A. M.; Ackland, S. P.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">87</span>
        (<span class="NLM_cas:issue">2-3</span>),
    <span class="NLM_cas:pages">227-253</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review with many refs.  Most current chemotherapy regimens for cancer consist of empirically designed combinations, based on efficacy and lack of overlapping toxicity.  In the development of combinations, several aspects are often overlooked: (1) possible metabolic and biol. interactions between drugs, (2) scheduling, and (3) different pharmacokinetic profiles.  Antimetabolites are used widely in chemotherapy combinations for treatment of various leukemias and solid tumors.  Ideally, the combination of two or more agents should be more effective than each agent sep. (synergism), although additive and even antagonistic combinations may result in a higher therapeutic efficacy in the clinic.  The median-drug effect anal. method is one of the most widely used methods for in vitro evaluation of combinations.  Several examples of classical effective antimetabolite-(anti)metabolite combinations are discussed, such as that of methotrexate with 6-mercaptopurine or leucovorin in (childhood) leukemia and 5-fluorouracil (5FU) with leucovorin in colon cancer.  More recent combinations include treatment of acute-myeloid leukemia with fludarabine and arabinosylcytosine.  Other combinations, currently frequently used in the treatment of solid malignancies, include an antimetabolite with a DNA-damaging agent, such as gemcitabine with cisplatin and 5FU with the cisplatin analog oxaliplatin.  The combination of 5FU and the topoisomerase inhibitor irinotecan is based on decreased repair of irinotecan-induced DNA damage.  These combinations may increase induction of apoptosis.  The latter combinations have dramatically changed the treatment of incurable cancers, such as lung and colon cancer, and have demonstrated that rationally designed drug combinations offer new possibilities to treat solid malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoVGv8e94tDbbVg90H21EOLACvtfcHk0ljTw_RPCkbyOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmslOjtbY%253D&md5=532d9a7faa9de51650b4db7136038b8d</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2FS0163-7258%2800%2900086-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0163-7258%252800%252900086-3%26sid%3Dliteratum%253Aachs%26aulast%3DPeters%26aufirst%3DG.%2BJ.%26aulast%3Dvan%2Bder%2BWilt%26aufirst%3DC.%2BL.%26aulast%3Dvan%2BMoorsel%26aufirst%3DC.%2BJ.%26aulast%3DKroep%26aufirst%3DJ.%2BR.%26aulast%3DBergman%26aufirst%3DA.%2BM.%26aulast%3DAckland%26aufirst%3DS.%2BP.%26atitle%3DBasis%2520for%2520effective%2520combination%2520cancer%2520chemotherapy%2520with%2520antimetabolites%26jtitle%3DPharmacol.%2520Ther.%26date%3D2000%26volume%3D87%26spage%3D227%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Bunn, P. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelly, K.</span><span> </span><span class="NLM_article-title">New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1087</span><span class="NLM_x">–</span> <span class="NLM_lpage">1100</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=9607565" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADyaK1cXjt1yiur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1998&pages=1087-1100&author=P.+A.+Bunnauthor=K.+Kelly&title=New+chemotherapeutic+agents+prolong+survival+and+improve+quality+of+life+in+non-small+cell+lung+cancer%3A+a+review+of+the+literature+and+future+directions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">New chemotherapeutic agents prolong survival and improve quality of life in non-small-cell lung cancer: a review of the literature and future directions</span></div><div class="casAuthors">Bunn, Paul A., Jr.; Kelly, Karen</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1087-1100</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review with 139 refs. In past years, there has been considerable pessimism over the role of chemotherapy in non-small-cell lung cancers.  The pessimism was largely derived from the fact that alkylating agent-based therapies shortened survival and produced severe side effects.  This was esp. important because the vast majority of patients (∼85%) develop metastatic disease during their course.  Randomized trials from the 1980s showed that cisplatin-based chemotherapy improved patient survival, improved quality of life as assessed by the patients, and relieved symptoms in the majority of symptomatic patients.  When chemotherapy was administered on an outpatient basis, it actually lowered the total patient care costs for advanced-stage patients.  In the 1990s, 5 new agents: 2 taxanes (paclitaxel, docetaxel), gemcitabine, navelbine, and irinotecan, were shown to produce higher response rates and longer survival in Phase II trials than cisplatin or carboplatin.  In randomized trials, combinations of paclitaxel, gemcitabine, and vinorelbine with cisplatin improved the survival of advanced-stage patients compared to cisplatin alone or in combination with etoposide.  The toxicity profile of the new agents is also favorable compared to that of cisplatin-based therapy.  Preliminary results in earlier stages are also encouraging.  Thus, currently available chemotherapy given to non-small-cell lung cancer patients with good performance status can improve survival to a similar extent as in other solid tumors, such as small-cell lung cancer and breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonu6iFWGmXmrVg90H21EOLACvtfcHk0lhQNyUXkVdPsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXjt1yiur8%253D&md5=e022672096f71a77157e5ba1a5f8d8a6</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBunn%26aufirst%3DP.%2BA.%26aulast%3DKelly%26aufirst%3DK.%26atitle%3DNew%2520chemotherapeutic%2520agents%2520prolong%2520survival%2520and%2520improve%2520quality%2520of%2520life%2520in%2520non-small%2520cell%2520lung%2520cancer%253A%2520a%2520review%2520of%2520the%2520literature%2520and%2520future%2520directions%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D1998%26volume%3D4%26spage%3D1087%26epage%3D1100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Beijnen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schellens, J. H.</span><span> </span><span class="NLM_article-title">Drug interactions in oncology</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">496</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1016%2FS1470-2045%2804%2901528-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=15288238" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmt1Kjsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2004&pages=489-496&author=J.+H.+Beijnenauthor=J.+H.+Schellens&title=Drug+interactions+in+oncology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Drug interactions in oncology</span></div><div class="casAuthors">Beijnen, Jos H.; Schellens, Jan H. M.</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">489-496</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Lancet Publishing Group</span>)
        </div><div class="casAbstract">A review.  Drug interactions are an ongoing concern in treatment of cancer, esp. when cytotoxic drugs are being used.  However, the clin. relevance of these interactions is not always investigated.  Drug interactions can be pharmaceutical, pharmacokinetic, or pharmacodynamic.  They can also be wanted (eg, use of ciclosporin to enhance the oral bioavailability of paclitaxel); unwanted (eg, combination of the antiviral agent sorivudine and oral fluorouracil analogs can lead to fatal complications); between cytotoxic drugs, cytotoxic drugs and non-cytotoxic drugs; or with pharmaceutical vehicles.  Potential interactions between anticancer drugs and over-the-counter or alternative medicines and herbs should not be underestimated.  More attention should be given to the recognition of potential drug interactions in the preclin. and early clin. development phase of a new anticancer drug.  Here, we provide a comprehensive overview of drug interactions, with selected examples.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGtAyZKbv5y7Vg90H21EOLACvtfcHk0lhQNyUXkVdPsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmt1Kjsr8%253D&md5=b0f770ed7f6fa05acf619b23aea5aa1e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2804%2901528-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252804%252901528-1%26sid%3Dliteratum%253Aachs%26aulast%3DBeijnen%26aufirst%3DJ.%2BH.%26aulast%3DSchellens%26aufirst%3DJ.%2BH.%26atitle%3DDrug%2520interactions%2520in%2520oncology%26jtitle%3DLancet%2520Oncol.%26date%3D2004%26volume%3D5%26spage%3D489%26epage%3D496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Wai, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schramm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korsching, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Valen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boecker, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweigerer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dockhorn-Dworniczak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poremba, C.</span><span> </span><span class="NLM_article-title">Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=11836553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVChurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=441-451&author=D.+H.+Waiauthor=K.+L.+Schaeferauthor=A.+Schrammauthor=E.+Korschingauthor=F.+Van+Valenauthor=T.+Ozakiauthor=W.+Boeckerauthor=L.+Schweigererauthor=B.+Dockhorn-Dworniczakauthor=C.+Poremba&title=Expression+analysis+of+pediatric+solid+tumor+cell+lines+using+oligonucleotide+microarrays"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays</span></div><div class="casAuthors">Wai, Daniel H.; Schaeffer, Karl-Ludwig; Schramm, Alexander; Korsching, Eberhard; Van Valen, Frans; Ozaki, Toshifumi; Boecker, Werner; Schweigerer, Lothar; Dockhorn-Dworniczak, Barbara; Poremba, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-451</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">The authors identified patterns of differentially-expressed genes in cell lines derived from several pediatric solid tumors.  Affymetrix Human Cancer G110 Arrays, carrying 1,700 cancer-assocd. genes, were applied to a panel of 11 cell lines originating from Ewing tumors (ETs), neuroblastomas, and malignant melanoma of soft parts.  Hierarchical clustering clearly differentiated these 3 entities and revealed groups of 75, 102, and 36 gene probe-sets exhibiting tumor-type specific up-regulation in these cell lines, resp.  Whereas ET lines demonstrated increased expression of microtubule-assocd. protein tau (MAPT), protein phosphatase 1 regulatory subunit 1A (PPPlRlA), NIMA (never in mitosis gene a)-related kinase 2 (NEK2), and cyclin D1 (CCNDl), neuroblastoma samples exhibited high expression of wingless-type mouse mammary tumor virus integration site family member 11 (WNT11), Drosophila frizzled homolog 2 (FZD2), and adenomatous polyposis coli (APC) which are involved in regulating free β-catenin levels.  These genes likely maintain tumor-specific characteristics and participate in key down-stream regulatory mechanisms.  The authors also correlated the expression levels of up-regulated genes in ETs with their chromosomal localization and compared these data to the comparative genomic hybridization profiles of the cell lines.  The authors demonstrate that gains of genetic material contribute essentially to differential gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdxN3dNcX0I7Vg90H21EOLACvtfcHk0lhQNyUXkVdPsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVChurY%253D&md5=24e904a9a5dbdc1c7a7776e4585536e3</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWai%26aufirst%3DD.%2BH.%26aulast%3DSchaefer%26aufirst%3DK.%2BL.%26aulast%3DSchramm%26aufirst%3DA.%26aulast%3DKorsching%26aufirst%3DE.%26aulast%3DVan%2BValen%26aufirst%3DF.%26aulast%3DOzaki%26aufirst%3DT.%26aulast%3DBoecker%26aufirst%3DW.%26aulast%3DSchweigerer%26aufirst%3DL.%26aulast%3DDockhorn-Dworniczak%26aufirst%3DB.%26aulast%3DPoremba%26aufirst%3DC.%26atitle%3DExpression%2520analysis%2520of%2520pediatric%2520solid%2520tumor%2520cell%2520lines%2520using%2520oligonucleotide%2520microarrays%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D441%26epage%3D451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">de Vos, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grogan, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krug, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schrage, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braun, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wachsman, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koeffler, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Said, J. W.</span><span> </span><span class="NLM_article-title">Gene expression profile of serial samples of transformed B-cell lymphomas</span> <span class="citation_source-journal">Lab. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">271</span><span class="NLM_x">–</span> <span class="NLM_lpage">285</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2003&pages=271-285&author=S.+de+Vosauthor=W.+K.+Hofmannauthor=T.+M.+Groganauthor=U.+Krugauthor=M.+Schrageauthor=T.+P.+Millerauthor=J.+G.+Braunauthor=W.+Wachsmanauthor=H.+P.+Koefflerauthor=J.+W.+Said&title=Gene+expression+profile+of+serial+samples+of+transformed+B-cell+lymphomas"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BVos%26aufirst%3DS.%26aulast%3DHofmann%26aufirst%3DW.%2BK.%26aulast%3DGrogan%26aufirst%3DT.%2BM.%26aulast%3DKrug%26aufirst%3DU.%26aulast%3DSchrage%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DT.%2BP.%26aulast%3DBraun%26aufirst%3DJ.%2BG.%26aulast%3DWachsman%26aufirst%3DW.%26aulast%3DKoeffler%26aufirst%3DH.%2BP.%26aulast%3DSaid%26aufirst%3DJ.%2BW.%26atitle%3DGene%2520expression%2520profile%2520of%2520serial%2520samples%2520of%2520transformed%2520B-cell%2520lymphomas%26jtitle%3DLab.%2520Invest.%26date%3D2003%26volume%3D83%26spage%3D271%26epage%3D285" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Hayward, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clarke, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faragher, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pillai, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagan, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, A. M.</span><span> </span><span class="NLM_article-title">The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7370</span><span class="NLM_x">–</span> <span class="NLM_lpage">7376</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1158%2F0008-5472.CAN-04-0960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=15492258" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD2cXosFyntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7370-7376&author=D.+G.+Haywardauthor=R.+B.+Clarkeauthor=A.+J.+Faragherauthor=M.+R.+Pillaiauthor=I.+M.+Haganauthor=A.+M.+Fry&title=The+centrosomal+kinase+Nek2+displays+elevated+levels+of+protein+expression+in+human+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The Centrosomal Kinase Nek2 Displays Elevated Levels of Protein Expression in Human Breast Cancer</span></div><div class="casAuthors">Hayward, Daniel G.; Clarke, Robert B.; Faragher, Alison J.; Pillai, Meenu R.; Hagan, Iain M.; Fry, Andrew M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">7370-7376</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aneuploidy and chromosome instability are common abnormalities in human cancer.  Loss of control over mitotic progression, multipolar spindle formation, and cytokinesis defects are all likely to contribute to these phenotypes.  Nek2 is a cell cycle-regulated protein kinase with maximal activity at the onset of mitosis that localizes to the centrosome.  Functional studies have implicated Nek2 in regulation of centrosome sepn. and spindle formation.  Here, the authors present the first study of the protein expression levels of the Nek2 kinase in human cancer cell lines and primary tumors.  Nek2 protein is elevated 2- to 5-fold in cell lines derived from a range of human tumors including those of cervical, ovarian, breast, prostate, and leukemic origin.  Most importantly, by immunohistochem., the authors find that Nek2 protein is significantly up-regulated in preinvasive in situ ductal carcinomas of the breast as well as in invasive breast carcinomas.  Finally, by ectopic expression of Nek2A in immortalized HBL100 breast epithelial cells, the authors show that increased Nek2 protein leads to accumulation of multinucleated cells with supernumerary centrosomes.  These data highlight the Nek2 kinase as novel potential target for chemotherapeutic intervention in breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4ko1rEDu8fbVg90H21EOLACvtfcHk0lgGWU7HDNg9NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXosFyntLc%253D&md5=10b8d50fa1025dd8013fced43532e4c2</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-0960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-0960%26sid%3Dliteratum%253Aachs%26aulast%3DHayward%26aufirst%3DD.%2BG.%26aulast%3DClarke%26aufirst%3DR.%2BB.%26aulast%3DFaragher%26aufirst%3DA.%2BJ.%26aulast%3DPillai%26aufirst%3DM.%2BR.%26aulast%3DHagan%26aufirst%3DI.%2BM.%26aulast%3DFry%26aufirst%3DA.%2BM.%26atitle%3DThe%2520centrosomal%2520kinase%2520Nek2%2520displays%2520elevated%2520levels%2520of%2520protein%2520expression%2520in%2520human%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7370%26epage%3D7376" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Kokuryo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, M.</span><span> </span><span class="NLM_article-title">Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">9637</span><span class="NLM_x">–</span> <span class="NLM_lpage">9642</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9637-9642&author=T.+Kokuryoauthor=T.+Sengaauthor=Y.+Yokoyamaauthor=M.+Naginoauthor=Y.+Nimuraauthor=M.+Hamaguchi&title=Nek2+as+an+effective+target+for+inhibition+of+tumorigenic+growth+and+peritoneal+dissemination+of+cholangiocarcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKokuryo%26aufirst%3DT.%26aulast%3DSenga%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DY.%26aulast%3DNagino%26aufirst%3DM.%26aulast%3DNimura%26aufirst%3DY.%26aulast%3DHamaguchi%26aufirst%3DM.%26atitle%3DNek2%2520as%2520an%2520effective%2520target%2520for%2520inhibition%2520of%2520tumorigenic%2520growth%2520and%2520peritoneal%2520dissemination%2520of%2520cholangiocarcinoma%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D9637%26epage%3D9642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Tsunoda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kokuryo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, M.</span><span> </span><span class="NLM_article-title">Nek2 as a novel molecular target for the treatment of breast carcinoma</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1111%2Fj.1349-7006.2008.01007.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=19038001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2009&pages=111-116&author=N.+Tsunodaauthor=T.+Kokuryoauthor=K.+Odaauthor=T.+Sengaauthor=Y.+Yokoyamaauthor=M.+Naginoauthor=Y.+Nimuraauthor=M.+Hamaguchi&title=Nek2+as+a+novel+molecular+target+for+the+treatment+of+breast+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Nek2 as a novel molecular target for the treatment of breast carcinoma</span></div><div class="casAuthors">Tsunoda, Nobuyuki; Kokuryo, Toshio; Oda, Koji; Senga, Takeshi; Yokoyama, Yukihiro; Nagino, Masato; Nimura, Yuji; Hamaguchi, Michinari</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-116</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The role of Nek2, a member of the serine-threonine kinase family, was investigated in the tumorigenic growth of breast carcinoma.  Increased expression of Nek2 was obsd. in all breast carcinoma cell lines examd. (BT20, BT474, Hs578T, MCF7, MDA-MB-231, T47D, and ZR-75-1) by immunoblotting.  By treatment with Nek2 short interfering RNA (siRNA), expression of Nek2 was clearly decreased in both estrogen receptor (ER)-pos. (MCF7) and ER-neg. (MDA-MB-231) breast carcinoma cell lines.  Cell growth, colony formation in soft agar, and in vitro invasiveness of these cell lines were substantially suppressed by Nek2 siRNA treatment.  In a xenograft nude mouse model with s.c. implantation of MCF7 or MDA-MB-231, s.c. injection of Nek2 siRNA around the tumor nodules resulted in a redn. of tumor size compared with those of control siRNA injection.  Taken together, Nek2 appears to play a pivotal role in tumorigenic growth of breast carcinoma cells, and could be a useful therapeutic mol. target for the treatment of breast carcinoma both in ER-pos. and ER-neg. cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTBN0t3kO2frVg90H21EOLACvtfcHk0lgGWU7HDNg9NA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGns7g%253D&md5=360ba1082e73540e4a42642e16f52cc8</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.01007.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.01007.x%26sid%3Dliteratum%253Aachs%26aulast%3DTsunoda%26aufirst%3DN.%26aulast%3DKokuryo%26aufirst%3DT.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DSenga%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DY.%26aulast%3DNagino%26aufirst%3DM.%26aulast%3DNimura%26aufirst%3DY.%26aulast%3DHamaguchi%26aufirst%3DM.%26atitle%3DNek2%2520as%2520a%2520novel%2520molecular%2520target%2520for%2520the%2520treatment%2520of%2520breast%2520carcinoma%26jtitle%3DCancer%2520Sci.%26date%3D2009%26volume%3D100%26spage%3D111%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Das, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dana, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paroly, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perumal, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jhun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pendse, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cagan, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Talele, T. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span> </span><span class="NLM_article-title">Centrosomal kinase Nek2 cooperates with oncogenic pathways to promote metastasis</span> <span class="citation_source-journal">Oncogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">14</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=1-14&author=T.+K.+Dasauthor=D.+Danaauthor=S.+S.+Parolyauthor=S.+K.+Perumalauthor=S.+Singhauthor=H.+Jhunauthor=J.+Pendseauthor=R.+L.+Caganauthor=T.+T.+Taleleauthor=S.+Kumar&title=Centrosomal+kinase+Nek2+cooperates+with+oncogenic+pathways+to+promote+metastasis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DDas%26aufirst%3DT.%2BK.%26aulast%3DDana%26aufirst%3DD.%26aulast%3DParoly%26aufirst%3DS.%2BS.%26aulast%3DPerumal%26aufirst%3DS.%2BK.%26aulast%3DSingh%26aufirst%3DS.%26aulast%3DJhun%26aufirst%3DH.%26aulast%3DPendse%26aufirst%3DJ.%26aulast%3DCagan%26aufirst%3DR.%2BL.%26aulast%3DTalele%26aufirst%3DT.%2BT.%26aulast%3DKumar%26aufirst%3DS.%26atitle%3DCentrosomal%2520kinase%2520Nek2%2520cooperates%2520with%2520oncogenic%2520pathways%2520to%2520promote%2520metastasis%26jtitle%3DOncogenesis%26date%3D2013%26volume%3D2%26spage%3D1%26epage%3D14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salama, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shetty, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zangari, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tricot, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhan, F.</span><span> </span><span class="NLM_article-title">NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=48-62&author=W.+Zhouauthor=Y.+Yangauthor=J.+Xiaauthor=H.+Wangauthor=M.+E.+Salamaauthor=W.+Xiongauthor=H.+Xuauthor=S.+Shettyauthor=T.+Chenauthor=Z.+Zengauthor=L.+Shiauthor=M.+Zangariauthor=R.+Milesauthor=D.+Bearssauthor=G.+Tricotauthor=F.+Zhan&title=NEK2+induces+drug+resistance+mainly+through+activation+of+efflux+drug+pumps+and+is+associated+with+poor+prognosis+in+myeloma+and+other+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DXia%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DSalama%26aufirst%3DM.%2BE.%26aulast%3DXiong%26aufirst%3DW.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DShetty%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZeng%26aufirst%3DZ.%26aulast%3DShi%26aufirst%3DL.%26aulast%3DZangari%26aufirst%3DM.%26aulast%3DMiles%26aufirst%3DR.%26aulast%3DBearss%26aufirst%3DD.%26aulast%3DTricot%26aufirst%3DG.%26aulast%3DZhan%26aufirst%3DF.%26atitle%3DNEK2%2520induces%2520drug%2520resistance%2520mainly%2520through%2520activation%2520of%2520efflux%2520drug%2520pumps%2520and%2520is%2520associated%2520with%2520poor%2520prognosis%2520in%2520myeloma%2520and%2520other%2520cancers%26jtitle%3DCancer%2520Cell%26date%3D2013%26volume%3D23%26spage%3D48%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Vivanco, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C. L.</span><span> </span><span class="NLM_article-title">The phosphatidylinositol 3-kinase AKT pathway in human cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">489</span><span class="NLM_x">–</span> <span class="NLM_lpage">501</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1038%2Fnrc839" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=12094235" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=489-501&author=I.+Vivancoauthor=C.+L.+Sawyers&title=The+phosphatidylinositol+3-kinase+AKT+pathway+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">The phosphatidylinositol 3-Kinase-AKT pathway in human cancer</span></div><div class="casAuthors">Vivanco, Igor; Sawyers, Charles L.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">489-501</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  One signal that is overactivated in a wide range of tumor types is the prodn. of a phospholipid, phosphatidylinositol (3,4,5) trisphosphate, by phosphatidylinositol 3-kinase (PI3K).  This lipid and the protein kinase that is activated by it, AKT, trigger a cascade of responses, from cell growth and proliferation to survival and motility, that drive tumor progression.  Small-mol. therapeutics that block PI3K signaling might deal a severe blow to cancer cells by blocking many aspects of the tumor-cell phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrzAQ-0qeD7pLVg90H21EOLACvtfcHk0lidsTLFf6UJtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvFKltLs%253D&md5=c6762d32f9f1281632f4ccdbcd29268c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnrc839&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc839%26sid%3Dliteratum%253Aachs%26aulast%3DVivanco%26aufirst%3DI.%26aulast%3DSawyers%26aufirst%3DC.%2BL.%26atitle%3DThe%2520phosphatidylinositol%25203-kinase%2520AKT%2520pathway%2520in%2520human%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2002%26volume%3D2%26spage%3D489%26epage%3D501" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Gottesman, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fojo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bates, S. E.</span><span> </span><span class="NLM_article-title">Multidrug resistance in cancer: role of ATP-dependent transporters</span> <span class="citation_source-journal">Nat. Rev. Cancer.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">48</span><span class="NLM_x">–</span> <span class="NLM_lpage">58</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1038%2Fnrc706" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=11902585" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2002&pages=48-58&author=M.+M.+Gottesmanauthor=T.+Fojoauthor=S.+E.+Bates&title=Multidrug+resistance+in+cancer%3A+role+of+ATP-dependent+transporters"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Multidrug resistance in cancer: role of ATP-dependent transporters</span></div><div class="casAuthors">Gottesman, Michael M.; Fojo, Tito; Bates, Susan E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">48-58</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Chemotherapeutics are the most effective treatment for metastatic tumors.  However, the ability of cancer cells to become simultaneously resistant to different drugs, a trait known as multidrug resistance, remains a significant impediment to successful chemotherapy.  Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents.  Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRJtnCZv-ZtrVg90H21EOLACvtfcHk0lidsTLFf6UJtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XhvF2jtL8%253D&md5=ec5284e1fe4a878c5ffc30ee83bccc9d</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Fnrc706&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc706%26sid%3Dliteratum%253Aachs%26aulast%3DGottesman%26aufirst%3DM.%2BM.%26aulast%3DFojo%26aufirst%3DT.%26aulast%3DBates%26aufirst%3DS.%2BE.%26atitle%3DMultidrug%2520resistance%2520in%2520cancer%253A%2520role%2520of%2520ATP-dependent%2520transporters%26jtitle%3DNat.%2520Rev.%2520Cancer.%26date%3D2002%26volume%3D2%26spage%3D48%26epage%3D58" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Westwood, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheary, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richards, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayliss, R.</span><span> </span><span class="NLM_article-title">Insights into the conformational variability and regulation of human Nek2 kinase</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">386</span><span class="NLM_x">, </span> <span class="NLM_fpage">476</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=386&publication_year=2009&pages=476-485&author=I.+Westwoodauthor=D.+M.+Chearyauthor=J.+E.+Baxterauthor=M.+W.+Richardsauthor=R.+L.+van+Montfortauthor=A.+M.+Fryauthor=R.+Bayliss&title=Insights+into+the+conformational+variability+and+regulation+of+human+Nek2+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWestwood%26aufirst%3DI.%26aulast%3DCheary%26aufirst%3DD.%2BM.%26aulast%3DBaxter%26aufirst%3DJ.%2BE.%26aulast%3DRichards%26aufirst%3DM.%2BW.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DBayliss%26aufirst%3DR.%26atitle%3DInsights%2520into%2520the%2520conformational%2520variability%2520and%2520regulation%2520of%2520human%2520Nek2%2520kinase%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D2009%26volume%3D386%26spage%3D476%26epage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Fry, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Regan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabir, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayliss, R.</span><span> </span><span class="NLM_article-title">Cell cycle regulation by the NEK family of protein kinases</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">125</span><span class="NLM_x">, </span> <span class="NLM_fpage">4423</span><span class="NLM_x">–</span> <span class="NLM_lpage">4433</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1242%2Fjcs.111195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=23132929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjsl2gtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2012&pages=4423-4433&author=A.+M.+Fryauthor=L.+O%E2%80%99Reganauthor=S.+R.+Sabirauthor=R.+Bayliss&title=Cell+cycle+regulation+by+the+NEK+family+of+protein+kinases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cell cycle regulation by the NEK family of protein kinases</span></div><div class="casAuthors">Fry, Andrew M.; O'Regan, Laura; Sabir, Sarah R.; Bayliss, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">4423-4433</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  Genetic screens for cell division cycle mutants in the filamentous fungus Aspergillus nidulans led to the discovery of never-in-mitosis A (NIMA) kinase, a serine/threonine kinase that is required for mitotic entry.  Since that discovery, NIMA-related kinases, or NEKs, have been identified in most eukaryotes, including humans where 11 genetically distinct proteins named NEK1 to NEK11 are expressed.  Although there is no evidence that human NEKs are essential for mitotic entry, it is clear that several NEK family members play important roles in cell cycle control.  In particular, NEK2, NEK6, NEK7, and NEK9 contribute to the establishment of the microtubule-based mitotic spindle, whereas NEK1, NEK10, and NEK11 have been implicated in the DNA damage response.  Roles for NEKs in other aspects of mitotic progression, such as chromatin condensation, nuclear envelope breakdown, spindle assembly checkpoint signaling, and cytokinesis have also been proposed.  Interestingly, NEK1 and NEK8 also function within cilia, the microtubule-based structures that are nucleated from basal bodies.  This has led to the current hypothesis that NEKs have evolved to coordinate microtubule-dependent processes in both dividing and non-dividing cells.  Here, the authors review the functions of human NEKs, with particular emphasis on those family members that are involved in cell cycle control, and consider their potential as therapeutic targets in cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKCk9miADRfLVg90H21EOLACvtfcHk0lidsTLFf6UJtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjsl2gtA%253D%253D&md5=6965616ca443eeeb40fb320bea94bd36</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1242%2Fjcs.111195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.111195%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DO%25E2%2580%2599Regan%26aufirst%3DL.%26aulast%3DSabir%26aufirst%3DS.%2BR.%26aulast%3DBayliss%26aufirst%3DR.%26atitle%3DCell%2520cycle%2520regulation%2520by%2520the%2520NEK%2520family%2520of%2520protein%2520kinases%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2012%26volume%3D125%26spage%3D4423%26epage%3D4433" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Fry, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartek, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nigg, E. A.</span><span> </span><span class="NLM_article-title">Substrate specificity and cell cycle regulation of the Nek2 protein kinase, a potential human homolog of the mitotic regulator NIMA of <i>Aspergillus nidulans</i></span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">270</span><span class="NLM_x">, </span> <span class="NLM_fpage">12899</span><span class="NLM_x">–</span> <span class="NLM_lpage">12905</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=12899-12905&author=A.+M.+Fryauthor=S.+J.+Schultzauthor=J.+Bartekauthor=E.+A.+Nigg&title=Substrate+specificity+and+cell+cycle+regulation+of+the+Nek2+protein+kinase%2C+a+potential+human+homolog+of+the+mitotic+regulator+NIMA+of+Aspergillus+nidulans"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DSchultz%26aufirst%3DS.%2BJ.%26aulast%3DBartek%26aufirst%3DJ.%26aulast%3DNigg%26aufirst%3DE.%2BA.%26atitle%3DSubstrate%2520specificity%2520and%2520cell%2520cycle%2520regulation%2520of%2520the%2520Nek2%2520protein%2520kinase%252C%2520a%2520potential%2520human%2520homolog%2520of%2520the%2520mitotic%2520regulator%2520NIMA%2520of%2520Aspergillus%2520nidulans%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D12899%26epage%3D12905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Reininger, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tewari, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fennell, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holland, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldring, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ranford-Cartwright, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Billker, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Doerig, C.</span><span> </span><span class="NLM_article-title">An essential role for the <i>Plasmodium</i> Nek-2 Nima-related protein kinase in the sexual development of malaria parasites</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">20858</span><span class="NLM_x">–</span> <span class="NLM_lpage">20868</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=20858-20868&author=L.+Reiningerauthor=R.+Tewariauthor=C.+Fennellauthor=Z.+Hollandauthor=D.+Goldringauthor=L.+Ranford-Cartwrightauthor=O.+Billkerauthor=C.+Doerig&title=An+essential+role+for+the+Plasmodium+Nek-2+Nima-related+protein+kinase+in+the+sexual+development+of+malaria+parasites"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DReininger%26aufirst%3DL.%26aulast%3DTewari%26aufirst%3DR.%26aulast%3DFennell%26aufirst%3DC.%26aulast%3DHolland%26aufirst%3DZ.%26aulast%3DGoldring%26aufirst%3DD.%26aulast%3DRanford-Cartwright%26aufirst%3DL.%26aulast%3DBillker%26aufirst%3DO.%26aulast%3DDoerig%26aufirst%3DC.%26atitle%3DAn%2520essential%2520role%2520for%2520the%2520Plasmodium%2520Nek-2%2520Nima-related%2520protein%2520kinase%2520in%2520the%2520sexual%2520development%2520of%2520malaria%2520parasites%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D20858%26epage%3D20868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Bahmanyar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaplan, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deluca, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giddings, T. H.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Toole, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winey, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salmon, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Casey, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barth, A. I.</span><span> </span><span class="NLM_article-title">β-Catenin is a Nek2 substrate involved in centrosome separation</span> <span class="citation_source-journal">Genes Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2008&pages=91-105&author=S.+Bahmanyarauthor=D.+D.+Kaplanauthor=J.+G.+Delucaauthor=T.+H.+Giddingsauthor=E.+T.+O%E2%80%99Tooleauthor=M.+Wineyauthor=E.+D.+Salmonauthor=P.+J.+Caseyauthor=W.+J.+Nelsonauthor=A.+I.+Barth&title=%CE%B2-Catenin+is+a+Nek2+substrate+involved+in+centrosome+separation"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBahmanyar%26aufirst%3DS.%26aulast%3DKaplan%26aufirst%3DD.%2BD.%26aulast%3DDeluca%26aufirst%3DJ.%2BG.%26aulast%3DGiddings%26aufirst%3DT.%2BH.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DE.%2BT.%26aulast%3DWiney%26aufirst%3DM.%26aulast%3DSalmon%26aufirst%3DE.%2BD.%26aulast%3DCasey%26aufirst%3DP.%2BJ.%26aulast%3DNelson%26aufirst%3DW.%2BJ.%26aulast%3DBarth%26aufirst%3DA.%2BI.%26atitle%3D%25CE%25B2-Catenin%2520is%2520a%2520Nek2%2520substrate%2520involved%2520in%2520centrosome%2520separation%26jtitle%3DGenes%2520Dev.%26date%3D2008%26volume%3D22%26spage%3D91%26epage%3D105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Sonn, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rhee, K.</span><span> </span><span class="NLM_article-title">Nip2/centrobin may be a substrate of Nek2 that is required for proper spindle assembly during mitosis in early mouse embryos</span> <span class="citation_source-journal">Mol. Reprod. Dev.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">587</span><span class="NLM_x">–</span> <span class="NLM_lpage">592</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2009&pages=587-592&author=S.+Sonnauthor=Y.+Jeongauthor=K.+Rhee&title=Nip2%2Fcentrobin+may+be+a+substrate+of+Nek2+that+is+required+for+proper+spindle+assembly+during+mitosis+in+early+mouse+embryos"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSonn%26aufirst%3DS.%26aulast%3DJeong%26aufirst%3DY.%26aulast%3DRhee%26aufirst%3DK.%26atitle%3DNip2%252Fcentrobin%2520may%2520be%2520a%2520substrate%2520of%2520Nek2%2520that%2520is%2520required%2520for%2520proper%2520spindle%2520assembly%2520during%2520mitosis%2520in%2520early%2520mouse%2520embryos%26jtitle%3DMol.%2520Reprod.%2520Dev.%26date%3D2009%26volume%3D76%26spage%3D587%26epage%3D592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Fry, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nigg, E. A.</span><span> </span><span class="NLM_article-title">Characterization of mammalian NIMA-related kinases</span> <span class="citation_source-journal">Methods Enzymol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1997</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">270</span><span class="NLM_x">–</span> <span class="NLM_lpage">282</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=1997&pages=270-282&author=A.+M.+Fryauthor=E.+A.+Nigg&title=Characterization+of+mammalian+NIMA-related+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DNigg%26aufirst%3DE.%2BA.%26atitle%3DCharacterization%2520of%2520mammalian%2520NIMA-related%2520kinases%26jtitle%3DMethods%2520Enzymol.%26date%3D1997%26volume%3D283%26spage%3D270%26epage%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Helps, N. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P. T.</span><span> </span><span class="NLM_article-title">NIMA-related kinase 2 (Nek2), a cell-cycle-regulated protein kinase localized to centrosomes, is complexed to protein phosphatase 1</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">349</span><span class="NLM_x">, </span> <span class="NLM_fpage">509</span><span class="NLM_x">–</span> <span class="NLM_lpage">518</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=349&publication_year=2000&pages=509-518&author=N.+R.+Helpsauthor=X.+Luoauthor=H.+M.+Barkerauthor=P.+T.+Cohen&title=NIMA-related+kinase+2+%28Nek2%29%2C+a+cell-cycle-regulated+protein+kinase+localized+to+centrosomes%2C+is+complexed+to+protein+phosphatase+1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHelps%26aufirst%3DN.%2BR.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DBarker%26aufirst%3DH.%2BM.%26aulast%3DCohen%26aufirst%3DP.%2BT.%26atitle%3DNIMA-related%2520kinase%25202%2520%2528Nek2%2529%252C%2520a%2520cell-cycle-regulated%2520protein%2520kinase%2520localized%2520to%2520centrosomes%252C%2520is%2520complexed%2520to%2520protein%2520phosphatase%25201%26jtitle%3DBiochem.%2520J.%26date%3D2000%26volume%3D349%26spage%3D509%26epage%3D518" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Meraldi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nigg, E. A.</span><span> </span><span class="NLM_article-title">Centrosome cohesion is regulated by a balance of kinase and phosphatase activities</span> <span class="citation_source-journal">J. Cell Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">3749</span><span class="NLM_x">–</span> <span class="NLM_lpage">3757</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=11707526" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD3MXot12nsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2001&pages=3749-3757&author=P.+Meraldiauthor=E.+A.+Nigg&title=Centrosome+cohesion+is+regulated+by+a+balance+of+kinase+and+phosphatase+activities"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Centrosome cohesion is regulated by a balance of kinase and phosphatase activities</span></div><div class="casAuthors">Meraldi, Patrick; Nigg, Erich A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">114</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3749-3757</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">Centrosome cohesion and sepn. are regulated throughout the cell cycle, but the underlying mechanisms are not well understood.  Since overexpression of a protein kinase, Nek2, is able to trigger centrosome splitting (the sepn. of parental centrioles), we have surveyed a panel of centrosome-assocd. kinases for their ability to induce a similar phenotype.  Cdk2, in assocn. with either cyclin A or E, was as effective as Nek2, but several other kinases tested did not significantly interfere with centrosome cohesion.  Centrosome splitting could also be triggered by inhibition of phosphatases, and protein phosphatase 1α (PP1α) was identified as a likely physiol. antagonist of Nek2.  Furthermore, we have revisited the role of the microtubule network in the control of centrosome cohesion.  We could confirm that microtubule depolymn. by nocodazole causes centrosome splitting.  Surprisingly, however, this drug-induced splitting also required kinase activity and could specifically be suppressed by a dominant-neg. mutant of Nek2.  These studies highlight the importance of protein phosphorylation in the control of centrosome cohesion, and they point to Nek2 and PP1α as crit. regulators of centrosome structure.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2MF69ghfWwrVg90H21EOLACvtfcHk0ljWiA3cBPsy8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXot12nsr0%253D&md5=7f44d5cbecf80b4669fa1a9f7f517f49</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeraldi%26aufirst%3DP.%26aulast%3DNigg%26aufirst%3DE.%2BA.%26atitle%3DCentrosome%2520cohesion%2520is%2520regulated%2520by%2520a%2520balance%2520of%2520kinase%2520and%2520phosphatase%2520activities%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2001%26volume%3D114%26spage%3D3749%26epage%3D3757" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Wai, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schramm, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korsching, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Valen, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ozaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boecker, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schweigerer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dockhorn-Dworniczak, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poremba, C.</span><span> </span><span class="NLM_article-title">Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=11836553" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVChurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2002&pages=441-451&author=D.+H.+Waiauthor=K.+L.+Schaeferauthor=A.+Schrammauthor=E.+Korschingauthor=F.+Van+Valenauthor=T.+Ozakiauthor=W.+Boeckerauthor=L.+Schweigererauthor=B.+Dockhorn-Dworniczakauthor=C.+Poremba&title=Expression+analysis+of+pediatric+solid+tumor+cell+lines+using+oligonucleotide+microarrays"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Expression analysis of pediatric solid tumor cell lines using oligonucleotide microarrays</span></div><div class="casAuthors">Wai, Daniel H.; Schaeffer, Karl-Ludwig; Schramm, Alexander; Korsching, Eberhard; Van Valen, Frans; Ozaki, Toshifumi; Boecker, Werner; Schweigerer, Lothar; Dockhorn-Dworniczak, Barbara; Poremba, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-451</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">The authors identified patterns of differentially-expressed genes in cell lines derived from several pediatric solid tumors.  Affymetrix Human Cancer G110 Arrays, carrying 1,700 cancer-assocd. genes, were applied to a panel of 11 cell lines originating from Ewing tumors (ETs), neuroblastomas, and malignant melanoma of soft parts.  Hierarchical clustering clearly differentiated these 3 entities and revealed groups of 75, 102, and 36 gene probe-sets exhibiting tumor-type specific up-regulation in these cell lines, resp.  Whereas ET lines demonstrated increased expression of microtubule-assocd. protein tau (MAPT), protein phosphatase 1 regulatory subunit 1A (PPPlRlA), NIMA (never in mitosis gene a)-related kinase 2 (NEK2), and cyclin D1 (CCNDl), neuroblastoma samples exhibited high expression of wingless-type mouse mammary tumor virus integration site family member 11 (WNT11), Drosophila frizzled homolog 2 (FZD2), and adenomatous polyposis coli (APC) which are involved in regulating free β-catenin levels.  These genes likely maintain tumor-specific characteristics and participate in key down-stream regulatory mechanisms.  The authors also correlated the expression levels of up-regulated genes in ETs with their chromosomal localization and compared these data to the comparative genomic hybridization profiles of the cell lines.  The authors demonstrate that gains of genetic material contribute essentially to differential gene expression.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdxN3dNcX0I7Vg90H21EOLACvtfcHk0ljWiA3cBPsy8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVChurY%253D&md5=24e904a9a5dbdc1c7a7776e4585536e3</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWai%26aufirst%3DD.%2BH.%26aulast%3DSchaefer%26aufirst%3DK.%2BL.%26aulast%3DSchramm%26aufirst%3DA.%26aulast%3DKorsching%26aufirst%3DE.%26aulast%3DVan%2BValen%26aufirst%3DF.%26aulast%3DOzaki%26aufirst%3DT.%26aulast%3DBoecker%26aufirst%3DW.%26aulast%3DSchweigerer%26aufirst%3DL.%26aulast%3DDockhorn-Dworniczak%26aufirst%3DB.%26aulast%3DPoremba%26aufirst%3DC.%26atitle%3DExpression%2520analysis%2520of%2520pediatric%2520solid%2520tumor%2520cell%2520lines%2520using%2520oligonucleotide%2520microarrays%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2002%26volume%3D20%26spage%3D441%26epage%3D451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Fukuhara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Variakojis, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golomb, H. M.</span><span> </span><span class="NLM_article-title">Chromosome abnormalities in poorly differentiated lymphocytic lymphoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1979</span><span class="NLM_x">, </span> <span class="NLM_volume">39</span><span class="NLM_x">, </span> <span class="NLM_fpage">3119</span><span class="NLM_x">–</span> <span class="NLM_lpage">3128</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=1979&pages=3119-3128&author=S.+Fukuharaauthor=J.+D.+Rowleyauthor=D.+Variakojisauthor=H.+M.+Golomb&title=Chromosome+abnormalities+in+poorly+differentiated+lymphocytic+lymphoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFukuhara%26aufirst%3DS.%26aulast%3DRowley%26aufirst%3DJ.%2BD.%26aulast%3DVariakojis%26aufirst%3DD.%26aulast%3DGolomb%26aufirst%3DH.%2BM.%26atitle%3DChromosome%2520abnormalities%2520in%2520poorly%2520differentiated%2520lymphocytic%2520lymphoma%26jtitle%3DCancer%2520Res.%26date%3D1979%26volume%3D39%26spage%3D3119%26epage%3D3128" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Kokuryo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, M.</span><span> </span><span class="NLM_article-title">Nek2 as an effective target for inhibition of tumorigenic growth and peritoneal dissemination of cholangiocarcinoma</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">9637</span><span class="NLM_x">–</span> <span class="NLM_lpage">9642</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=9637-9642&author=T.+Kokuryoauthor=T.+Sengaauthor=Y.+Yokoyamaauthor=M.+Naginoauthor=Y.+Nimuraauthor=M.+Hamaguchi&title=Nek2+as+an+effective+target+for+inhibition+of+tumorigenic+growth+and+peritoneal+dissemination+of+cholangiocarcinoma"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKokuryo%26aufirst%3DT.%26aulast%3DSenga%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DY.%26aulast%3DNagino%26aufirst%3DM.%26aulast%3DNimura%26aufirst%3DY.%26aulast%3DHamaguchi%26aufirst%3DM.%26atitle%3DNek2%2520as%2520an%2520effective%2520target%2520for%2520inhibition%2520of%2520tumorigenic%2520growth%2520and%2520peritoneal%2520dissemination%2520of%2520cholangiocarcinoma%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D9637%26epage%3D9642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Tsunoda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kokuryo, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Senga, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yokoyama, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nimura, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamaguchi, M.</span><span> </span><span class="NLM_article-title">Nek2 as a novel molecular target for the treatment of breast carcinoma</span> <span class="citation_source-journal">Cancer Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">100</span><span class="NLM_x">, </span> <span class="NLM_fpage">111</span><span class="NLM_x">–</span> <span class="NLM_lpage">116</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1111%2Fj.1349-7006.2008.01007.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=19038001" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtlGns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2009&pages=111-116&author=N.+Tsunodaauthor=T.+Kokuryoauthor=K.+Odaauthor=T.+Sengaauthor=Y.+Yokoyamaauthor=M.+Naginoauthor=Y.+Nimuraauthor=M.+Hamaguchi&title=Nek2+as+a+novel+molecular+target+for+the+treatment+of+breast+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Nek2 as a novel molecular target for the treatment of breast carcinoma</span></div><div class="casAuthors">Tsunoda, Nobuyuki; Kokuryo, Toshio; Oda, Koji; Senga, Takeshi; Yokoyama, Yukihiro; Nagino, Masato; Nimura, Yuji; Hamaguchi, Michinari</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-116</span>CODEN:
                <span class="NLM_cas:coden">CSACCM</span>;
        ISSN:<span class="NLM_cas:issn">1347-9032</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The role of Nek2, a member of the serine-threonine kinase family, was investigated in the tumorigenic growth of breast carcinoma.  Increased expression of Nek2 was obsd. in all breast carcinoma cell lines examd. (BT20, BT474, Hs578T, MCF7, MDA-MB-231, T47D, and ZR-75-1) by immunoblotting.  By treatment with Nek2 short interfering RNA (siRNA), expression of Nek2 was clearly decreased in both estrogen receptor (ER)-pos. (MCF7) and ER-neg. (MDA-MB-231) breast carcinoma cell lines.  Cell growth, colony formation in soft agar, and in vitro invasiveness of these cell lines were substantially suppressed by Nek2 siRNA treatment.  In a xenograft nude mouse model with s.c. implantation of MCF7 or MDA-MB-231, s.c. injection of Nek2 siRNA around the tumor nodules resulted in a redn. of tumor size compared with those of control siRNA injection.  Taken together, Nek2 appears to play a pivotal role in tumorigenic growth of breast carcinoma cells, and could be a useful therapeutic mol. target for the treatment of breast carcinoma both in ER-pos. and ER-neg. cases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTBN0t3kO2frVg90H21EOLACvtfcHk0ljdd8bWno4l3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtlGns7g%253D&md5=360ba1082e73540e4a42642e16f52cc8</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1111%2Fj.1349-7006.2008.01007.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1349-7006.2008.01007.x%26sid%3Dliteratum%253Aachs%26aulast%3DTsunoda%26aufirst%3DN.%26aulast%3DKokuryo%26aufirst%3DT.%26aulast%3DOda%26aufirst%3DK.%26aulast%3DSenga%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DY.%26aulast%3DNagino%26aufirst%3DM.%26aulast%3DNimura%26aufirst%3DY.%26aulast%3DHamaguchi%26aufirst%3DM.%26atitle%3DNek2%2520as%2520a%2520novel%2520molecular%2520target%2520for%2520the%2520treatment%2520of%2520breast%2520carcinoma%26jtitle%3DCancer%2520Sci.%26date%3D2009%26volume%3D100%26spage%3D111%26epage%3D116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Cappello, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blaser, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gorrini, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elia, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wakeham, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haider, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutros, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mason, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Youngson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Done, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mak, T. W.</span><span> </span><span class="NLM_article-title">Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">10</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&pages=1-10&author=P.+Cappelloauthor=H.+Blaserauthor=C.+Gorriniauthor=D.+C.+Linauthor=A.+J.+Eliaauthor=A.+Wakehamauthor=S.+Haiderauthor=P.+C.+Boutrosauthor=J.+M.+Masonauthor=N.+A.+Millerauthor=B.+Youngsonauthor=S.+J.+Doneauthor=T.+W.+Mak&title=Role+of+Nek2+on+centrosome+duplication+and+aneuploidy+in+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DCappello%26aufirst%3DP.%26aulast%3DBlaser%26aufirst%3DH.%26aulast%3DGorrini%26aufirst%3DC.%26aulast%3DLin%26aufirst%3DD.%2BC.%26aulast%3DElia%26aufirst%3DA.%2BJ.%26aulast%3DWakeham%26aufirst%3DA.%26aulast%3DHaider%26aufirst%3DS.%26aulast%3DBoutros%26aufirst%3DP.%2BC.%26aulast%3DMason%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DN.%2BA.%26aulast%3DYoungson%26aufirst%3DB.%26aulast%3DDone%26aufirst%3DS.%2BJ.%26aulast%3DMak%26aufirst%3DT.%2BW.%26atitle%3DRole%2520of%2520Nek2%2520on%2520centrosome%2520duplication%2520and%2520aneuploidy%2520in%2520breast%2520cancer%2520cells%26jtitle%3DOncogene%26date%3D2013%26spage%3D1%26epage%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gollahon, L.</span><span> </span><span class="NLM_article-title">Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple-negative breast cancer cells</span> <span class="citation_source-journal">Int. J. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">42</span><span class="NLM_x">, </span> <span class="NLM_fpage">839</span><span class="NLM_x">–</span> <span class="NLM_lpage">847</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=23340795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkt1Kiur0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2013&pages=839-847&author=J.+Leeauthor=L.+Gollahon&title=Nek2-targeted+ASO+or+siRNA+pretreatment+enhances+anticancer+drug+sensitivity+in+triple-negative+breast+cancer+cells"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Nek2-targeted ASO or siRNA pretreatment enhances anticancer drug sensitivity in triple-negative breast cancer cells</span></div><div class="casAuthors">Lee, Jaehyung; Gollahon, Lauren</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">839-847</span>CODEN:
                <span class="NLM_cas:coden">IJONES</span>;
        ISSN:<span class="NLM_cas:issn">1019-6439</span>.
    
            (<span class="NLM_cas:orgname">International Journal of Oncology</span>)
        </div><div class="casAbstract">Although the anticancer drugs paclitaxel and doxorubicin are commonly used to treat many solid tumors, their effectiveness is highly variable due to tumor cell resistance.  Therefore, it is important to find mechanisms that can be targeted to increase the sensitivity of cancer cells to current chemotherapeutic agents.  NIMA-related kinase 2 (Nek2), a serine/threonine kinase is emerging as an important oncogene because of its regulatory role in mitosis.  Thus, regulation of the Nek2 expression levels may prove important as a target for cancer treatment.  The purpose of our study was to det. whether drug sensitivity was increased in the triple neg. breast cancer cell lines MDA-MB-231 and MDA-MB-468 by using small interfering RNA (siRNA) and antisense oligonucleotides (ASOs) against Nek2.  To this end, MDA-MB-231 and MDA-MB-468 breast cancer cells transfected with Nek2 siRNA or ASO were exposed to various concns. of paclitaxel and doxorubicin.  Cell viability, cell cycle distribution and apoptosis were evaluated.  We obsd. that drug susceptibility in these transfected cells was dramatically increased compared with either agent alone.  FACS results showed that apoptosis was induced in siRNA- and ASO-transfected cells as expected due to the regulatory function of Nek2 in centrosome duplication.  Interestingly, the cell cycle was not arrested in transfected cells.  We found that siRNA and ASO against Nek2 worked synergistically with paclitaxel and doxorubicin by promoting cell apoptosis.  Our results suggest that these drugs in combination with Nek2 siRNA or ASO treatment may improve the sensitivity of cancer cells during chemotherapy treatments.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozgctIypcsZrVg90H21EOLACvtfcHk0ljjnTor9kzi8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkt1Kiur0%253D&md5=a796bd4185e8cda988701a414aa53182</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DGollahon%26aufirst%3DL.%26atitle%3DNek2-targeted%2520ASO%2520or%2520siRNA%2520pretreatment%2520enhances%2520anticancer%2520drug%2520sensitivity%2520in%2520triple-negative%2520breast%2520cancer%2520cells%26jtitle%3DInt.%2520J.%2520Oncol.%26date%3D2013%26volume%3D42%26spage%3D839%26epage%3D847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Lage, H.</span><span> </span><span class="NLM_article-title">ABC-transporters: implications on drug resistance from microorganisms to human cancers</span> <span class="citation_source-journal">Int. J. Antimicrob. Agents</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">188</span><span class="NLM_x">–</span> <span class="NLM_lpage">199</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1016%2FS0924-8579%2803%2900203-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=13678820" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1yqur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2003&pages=188-199&author=H.+Lage&title=ABC-transporters%3A+implications+on+drug+resistance+from+microorganisms+to+human+cancers"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">ABC-transporters: implications on drug resistance from microorganisms to human cancers</span></div><div class="casAuthors">Lage, Hermann</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Antimicrobial Agents</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">188-199</span>CODEN:
                <span class="NLM_cas:coden">IAAGEA</span>;
        ISSN:<span class="NLM_cas:issn">0924-8579</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Resistance to chemotherapy is a common clin. problem in patients with infectious diseases as well as in patients with cancer.  During treatment of infections or malignant tumors, the drug targets of prokaryotic or eukaryotic microorganisms and neoplastic cells are often found to be refractory to a variety of drugs that have different structures and functions.  This phenomenon was termed multidrug resistance (MDR).  The mechanisms leading to MDR are frequently caused by trans-membrane xenobiotic transport mols. belonging to the superfamily of ATP-binding cassette (ABC) transporters.  There is an urgent need to understand the structure-function relationships of these efflux pumps that underlie their transport mechanism and drug selectivity.  This knowledge may allow the rational design of new drugs that can inhibit or circumvent the activity of these MDR transport mols.  Furthermore, the development of such chemosensitizing agents would help us learn more about the physiol. functions and substrates of these pump proteins.  This review will discuss the current state of knowledge of the functional and structural similarities among ABC-transporters in prokaryotic and eukaryotic cells and their impact on MDR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqNtyU0p9Si4bVg90H21EOLACvtfcHk0ljjnTor9kzi8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1yqur4%253D&md5=907a548d672092a967504876967f1c5d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1016%2FS0924-8579%2803%2900203-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0924-8579%252803%252900203-6%26sid%3Dliteratum%253Aachs%26aulast%3DLage%26aufirst%3DH.%26atitle%3DABC-transporters%253A%2520implications%2520on%2520drug%2520resistance%2520from%2520microorganisms%2520to%2520human%2520cancers%26jtitle%3DInt.%2520J.%2520Antimicrob.%2520Agents%26date%3D2003%26volume%3D22%26spage%3D188%26epage%3D199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Bell, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerlach, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kartner, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buick, R. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ling, V.</span><span> </span><span class="NLM_article-title">Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1985</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">311</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=2857774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A280%3ADyaL2M7jtlOluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1985&pages=311-315&author=D.+R.+Bellauthor=J.+H.+Gerlachauthor=N.+Kartnerauthor=R.+N.+Buickauthor=V.+Ling&title=Detection+of+P-glycoprotein+in+ovarian+cancer%3A+a+molecular+marker+associated+with+multidrug+resistance"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Detection of P-glycoprotein in ovarian cancer: a molecular marker associated with multidrug resistance</span></div><div class="casAuthors">Bell D R; Gerlach J H; Kartner N; Buick R N; Ling V</div><div class="citationInfo"><span class="NLM_cas:title">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</span>
        (<span class="NLM_cas:date">1985</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">311-5</span>
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    </div><div class="casAbstract">A multidrug resistance phenotype is frequently observed in animal and human cell lines selected for in vitro resistance to a single chemotherapeutic agent.  Overexpression of a highly conserved cell-surface glycoprotein (P-glycoprotein) is consistently associated with this phenotype in these mutant lines.  A monoclonal antibody against P-glycoprotein was used to examine tumor samples from five patients with advanced ovarian cancer for evidence of P-glycoprotein overexpression.  High levels of P-glycoprotein were detected in samples from two patients suggesting that a multidrug resistance mutation may also occur in ovarian cancer.  This finding has broad implications for the understanding of nonresponse to chemotherapy in a variety of human neoplasms, and may provide a rational explanation for failure of chemotherapy in treatment of advanced ovarian cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTQQORUaC65AO3MPKNEWB5RfW6udTcc2ebHrNnCvj_lmLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2M7jtlOluw%253D%253D&md5=b14e36ba83450af03787beb760a5c420</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBell%26aufirst%3DD.%2BR.%26aulast%3DGerlach%26aufirst%3DJ.%2BH.%26aulast%3DKartner%26aufirst%3DN.%26aulast%3DBuick%26aufirst%3DR.%2BN.%26aulast%3DLing%26aufirst%3DV.%26atitle%3DDetection%2520of%2520P-glycoprotein%2520in%2520ovarian%2520cancer%253A%2520a%2520molecular%2520marker%2520associated%2520with%2520multidrug%2520resistance%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1985%26volume%3D3%26spage%3D311%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Burger, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foekens, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Look, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer-van Gelder, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klijn, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiemer, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoter, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nooter, K.</span><span> </span><span class="NLM_article-title">RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">827</span><span class="NLM_x">–</span> <span class="NLM_lpage">836</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=12576456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVKksbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=827-836&author=H.+Burgerauthor=J.+A.+Foekensauthor=M.+P.+Lookauthor=M.+E.+Meijer-van+Gelderauthor=J.+G.+Klijnauthor=E.+A.+Wiemerauthor=G.+Stoterauthor=K.+Nooter&title=RNA+expression+of+breast+cancer+resistance+protein%2C+lung+resistance-related+protein%2C+multidrug+resistance-associated+proteins+1+and+2%2C+and+multidrug+resistance+gene+1+in+breast+cancer%3A+correlation+with+chemotherapeutic+response"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: Correlation with chemotherapeutic response</span></div><div class="casAuthors">Burger, Herman; Foekens, John A.; Look, Maxime P.; Meijer-van Gelder, Marion E.; Klijn, Jan G. M.; Wiemer, Erik A. C.; Stoter, Gerrit; Nooter, Kees</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">827-836</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The aim of this study was to investigate whether expression of particular drug resistance genes in primary operable breast cancer correlates with response to first-line chemotherapy in advanced disease.  We detd. mRNA levels of BCRP, LRP, MRP1, MRP2, and MDR1 in 59 primary breast tumor specimens of patients who received chemotherapy as first-line systemic treatment after diagnosis of advanced disease.  The relative expression levels were measured by quant. real-time reverse transcription-PCR and subsequently analyzed in relation to the type of response to chemotherapy, the length of progression-free survival (PFS), and post-relapse overall survival.  For each of these drug resistance genes, a large variation in expression level was obsd. among the tumors of the different patients.  When analyzing mRNA expression in relation to overall response, it was found that the median expression level of these five drug resistance genes in the responding tumors, as compared with nonresponding tumors, was markedly lower.  Classification of tumors as high vs. low with respect to the expression level of these genes showed that the overall response in the MDR1-high subset (17%), as compared with the MDR1-low subset (68%), was significantly lower (P = 0.005).  Although similar differences in response rate were found for subsets of tumors stratified by the expression level of the other drug resistance genes, none of the obsd. differences were statistically significant.  However, in the subgroup of patients treated with anthracycline-based chemotherapy (5-fluorouracil, Adriamycin/epirubicin, and cyclophosphamide), a correlation between response and the expression of BCRP and MRP1 (only PFS) was found, whereas such an assocn. was not present in the cyclophosphamide, methotrexate, and 5-fluorouracil-treated group of patients.  Furthermore, high expression of LRP as well as MDR1 was found to be significantly assocd. with a poor PFS (P = 0.04 and P < 0.001, resp.).  For lung resistance-related protein, this assocn. was limited to 5-fluorouracil, Adriamycin/epirubicin, and cyclophosphamide.  Expression levels of BCRP, MRP1, or MRP2 were not related with the length of PFS.  Furthermore, no correlation between the expression level of these drug resistance genes and post-relapse overall survival was found.  In this pilot study, MDR1 expression in primary breast tumors was inversely related with the efficacy of first-line chemotherapy, and high expression level was a significant predictor of poor prognosis for patients with advanced disease.  Apart from MDR1, the expression levels of BCRP, LRP, and MRP1 might have some addnl. predictive value for clin. outcome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKQvPviASlqbVg90H21EOLACvtfcHk0ljGUR8yMSYGOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVKksbc%253D&md5=66a680552d3bed21d24fc42b12c36452</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBurger%26aufirst%3DH.%26aulast%3DFoekens%26aufirst%3DJ.%2BA.%26aulast%3DLook%26aufirst%3DM.%2BP.%26aulast%3DMeijer-van%2BGelder%26aufirst%3DM.%2BE.%26aulast%3DKlijn%26aufirst%3DJ.%2BG.%26aulast%3DWiemer%26aufirst%3DE.%2BA.%26aulast%3DStoter%26aufirst%3DG.%26aulast%3DNooter%26aufirst%3DK.%26atitle%3DRNA%2520expression%2520of%2520breast%2520cancer%2520resistance%2520protein%252C%2520lung%2520resistance-related%2520protein%252C%2520multidrug%2520resistance-associated%2520proteins%25201%2520and%25202%252C%2520and%2520multidrug%2520resistance%2520gene%25201%2520in%2520breast%2520cancer%253A%2520correlation%2520with%2520chemotherapeutic%2520response%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2003%26volume%3D9%26spage%3D827%26epage%3D836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Ro, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ro, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fritsche, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blick, M.</span><span> </span><span class="NLM_article-title">Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer</span> <span class="citation_source-journal">Hum. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">787</span><span class="NLM_x">–</span> <span class="NLM_lpage">791</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1016%2F0046-8177%2890%2990046-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=1974874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A280%3ADyaK3czltl2htA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1990&pages=787-791&author=J.+Roauthor=A.+Sahinauthor=J.+Y.+Roauthor=H.+Fritscheauthor=G.+Hortobagyiauthor=M.+Blick&title=Immunohistochemical+analysis+of+P-glycoprotein+expression+correlated+with+chemotherapy+resistance+in+locally+advanced+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Immunohistochemical analysis of P-glycoprotein expression correlated with chemotherapy resistance in locally advanced breast cancer</span></div><div class="casAuthors">Ro J; Sahin A; Ro J Y; Fritsche H; Hortobagyi G; Blick M</div><div class="citationInfo"><span class="NLM_cas:title">Human pathology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">787-91</span>
        ISSN:<span class="NLM_cas:issn">0046-8177</span>.
    </div><div class="casAbstract">We analyzed the expression of P-glycoprotein in samples from 48 patients with locally advanced breast cancer.  Tumor samples from 40 patients were obtained at mastectomy, which was performed after three cycles of induction chemotherapy consisting of doxorubicin, cyclophosphamide, vincristine, and prednisone.  P-glycoprotein expression distributed focally was observed in 20 tumors by the immunoperoxidase method using the anti-p170-monoclonal antibody C219.  The percentage of the tumor cell population expressing P-glycoprotein varied from less than 5% to greater than 30%; expression was observed significantly more often in tumors that showed less than partial response to the preoperative chemotherapy.  Furthermore, P-glycoprotein was not expressed in eight tumor specimens obtained at the time of diagnosis, prior to chemotherapy, from patients who subsequently had pathologic complete responses.  A comparative study of P-glycoprotein expression before and after chemotherapy and upon recurrence of tumor was done on a limited number of samples.  No significant differences in P-glycoprotein expression were found.  Therefore, it is possible that an intrinsic, rather than acquired, drug resistance may play a role in the failure of induction chemotherapy for locally advanced breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRTZvWaWpZH_5WtyewyzkyLfW6udTcc2eZkFdBq1NfoK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3czltl2htA%253D%253D&md5=61c4a7686a67a7aee9ae3e132a0f8504</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1016%2F0046-8177%2890%2990046-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0046-8177%252890%252990046-8%26sid%3Dliteratum%253Aachs%26aulast%3DRo%26aufirst%3DJ.%26aulast%3DSahin%26aufirst%3DA.%26aulast%3DRo%26aufirst%3DJ.%2BY.%26aulast%3DFritsche%26aufirst%3DH.%26aulast%3DHortobagyi%26aufirst%3DG.%26aulast%3DBlick%26aufirst%3DM.%26atitle%3DImmunohistochemical%2520analysis%2520of%2520P-glycoprotein%2520expression%2520correlated%2520with%2520chemotherapy%2520resistance%2520in%2520locally%2520advanced%2520breast%2520cancer%26jtitle%3DHum.%2520Pathol.%26date%3D1990%26volume%3D21%26spage%3D787%26epage%3D791" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Mi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brautigan, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larner, J. M.</span><span> </span><span class="NLM_article-title">Protein phosphatase-1alpha regulates centrosome splitting through Nek2</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">1082</span><span class="NLM_x">–</span> <span class="NLM_lpage">1089</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=1082-1089&author=J.+Miauthor=C.+Guoauthor=D.+L.+Brautiganauthor=J.+M.+Larner&title=Protein+phosphatase-1alpha+regulates+centrosome+splitting+through+Nek2"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMi%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DBrautigan%26aufirst%3DD.%2BL.%26aulast%3DLarner%26aufirst%3DJ.%2BM.%26atitle%3DProtein%2520phosphatase-1alpha%2520regulates%2520centrosome%2520splitting%2520through%2520Nek2%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D1082%26epage%3D1089" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Xiao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, X. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, X. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, H. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, J. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiao, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D. W.</span><span> </span><span class="NLM_article-title">Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation</span> <span class="citation_source-journal">Cell Death Differ.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1448</span><span class="NLM_x">–</span> <span class="NLM_lpage">1462</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1038%2Fcdd.2010.16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=20186153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVantr7E" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2010&pages=1448-1462&author=L.+Xiaoauthor=L.+L.+Gongauthor=D.+Yuanauthor=M.+Dengauthor=X.+M.+Zengauthor=L.+L.+Chenauthor=L.+Zhangauthor=Q.+Yanauthor=J.+P.+Liuauthor=X.+H.+Huauthor=S.+M.+Sunauthor=J.+Liuauthor=H.+L.+Maauthor=C.+B.+Zhengauthor=H.+Fuauthor=P.+C.+Chenauthor=J.+Q.+Zhaoauthor=S.+S.+Xieauthor=L.+J.+Zouauthor=Y.+M.+Xiaoauthor=W.+B.+Liuauthor=J.+Zhangauthor=Y.+Liuauthor=D.+W.+Li&title=Protein+phosphatase-1+regulates+Akt1+signal+transduction+pathway+to+control+gene+expression%2C+cell+survival+and+differentiation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Protein phosphatase-1 regulates Akt1 signal transduction pathway to control gene expression, cell survival and differentiation</span></div><div class="casAuthors">Xiao, L.; Gong, L.-L.; Yuan, D.; Deng, M.; Zeng, X.-M.; Chen, L.-L.; Zhang, L.; Yan, Qin; Liu, J.-P.; Hu, X.-H.; Sun, S.-M.; Liu, J.; Ma, H.-L.; Zheng, C.-B.; Fu, H.; Chen, P.-C.; Zhao, J.-Q.; Xie, S.-S.; Zou, L.-J.; Xiao, Y.-M.; Liu, W.-B.; Zhang, J.; Liu, Y.; Li, D. W.-C.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death and Differentiation</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1448-1462</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">AKT pathway has a crit. role in mediating signaling transductions for cell proliferation, differentiation and survival.  Previous studies have shown that AKT activation is achieved through a series of phosphorylation steps: first, AKT is phosphorylated at Thr-450 by JNK kinases to prime its activation; then, phosphoinositide-dependent kinase 1 phosphorylates AKT at Thr-308 to expose the Ser-473 residue; and finally, AKT is phosphorylated at Ser-473 by several kinases (PKD2 and others) to achieve its full activation.  For its inactivation, the PH-domain contg. phosphatases dephosphorylate AKT at Ser-473, and protein serine/threonine phosphatase-2A (PP-2A) dephosphorylates it at Thr-308.  However, it remains unknown regarding which phosphatase dephosphorylates AKT at Thr-450 during its inactivation.  In this study, we present both in vitro and in vivo evidence to show that protein serine/threonine phosphatase-1 (PP-1) is a major phosphatase that directly dephosphorylates AKT to modulate its activation.  First, purified PP-1 directly dephosphorylates AKT in vitro.  Second, immunopptn. and immunocolocalization showed that PP-1 interacts with AKT.  Third, stable knock down of PP-1α or PP-1β but not PP-1γ, PP-2Aα or PP-2Aβ by shRNA leads to enhanced phosphorylation of AKT at Thr-450.  Finally, overexpression of PP-1α or PP-1β but not PP-1γ, PP-2Aα or PP-2Aβ results in attenuated phosphorylation of AKT at Thr-450.  Moreover, our results also show that dephosphorylation of AKT by PP-1 significantly modulates its functions in regulating the expression of downstream genes, promoting cell survival and modulating differentiation.  These results show that PP-1 acts as a major phosphatase to dephosphorylate AKT at Thr-450 and thus modulate its functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBKgabJTpywrVg90H21EOLACvtfcHk0ljGUR8yMSYGOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVantr7E&md5=d6f6b03e2bbad10a250809f52cf9e721</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1038%2Fcdd.2010.16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fcdd.2010.16%26sid%3Dliteratum%253Aachs%26aulast%3DXiao%26aufirst%3DL.%26aulast%3DGong%26aufirst%3DL.%2BL.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DDeng%26aufirst%3DM.%26aulast%3DZeng%26aufirst%3DX.%2BM.%26aulast%3DChen%26aufirst%3DL.%2BL.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DYan%26aufirst%3DQ.%26aulast%3DLiu%26aufirst%3DJ.%2BP.%26aulast%3DHu%26aufirst%3DX.%2BH.%26aulast%3DSun%26aufirst%3DS.%2BM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DH.%2BL.%26aulast%3DZheng%26aufirst%3DC.%2BB.%26aulast%3DFu%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DP.%2BC.%26aulast%3DZhao%26aufirst%3DJ.%2BQ.%26aulast%3DXie%26aufirst%3DS.%2BS.%26aulast%3DZou%26aufirst%3DL.%2BJ.%26aulast%3DXiao%26aufirst%3DY.%2BM.%26aulast%3DLiu%26aufirst%3DW.%2BB.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DD.%2BW.%26atitle%3DProtein%2520phosphatase-1%2520regulates%2520Akt1%2520signal%2520transduction%2520pathway%2520to%2520control%2520gene%2520expression%252C%2520cell%2520survival%2520and%2520differentiation%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2010%26volume%3D17%26spage%3D1448%26epage%3D1462" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fearen, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olmos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadopoulos, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baird, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delgado, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lupinacci, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riisnaes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pope, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heaton, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garrett, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tolcher, A. W.</span><span> </span><span class="NLM_article-title">First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">4688</span><span class="NLM_x">–</span> <span class="NLM_lpage">4695</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1200%2FJCO.2011.35.5263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=22025163" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlOnsLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=4688-4695&author=T.+A.+Yapauthor=L.+Yanauthor=A.+Patnaikauthor=I.+Fearenauthor=D.+Olmosauthor=K.+Papadopoulosauthor=R.+D.+Bairdauthor=L.+Delgadoauthor=A.+Taylorauthor=L.+Lupinacciauthor=R.+Riisnaesauthor=L.+L.+Popeauthor=S.+P.+Heatonauthor=G.+Thomasauthor=M.+D.+Garrettauthor=D.+M.+Sullivanauthor=J.+S.+de+Bonoauthor=A.+W.+Tolcher&title=First-in-man+clinical+trial+of+the+oral+pan-AKT+inhibitor+MK-2206+in+patients+with+advanced+solid+tumors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors</span></div><div class="casAuthors">Yap, Timothy A.; Yan, Li; Patnaik, Amita; Fearen, Ivy; Olmos, David; Papadopoulos, Kyriakos; Baird, Richard D.; Delgado, Liliana; Taylor, Adekemi; Lupinacci, Lisa; Riisnaes, Ruth; Pope, Lorna L.; Heaton, Simon P.; Thomas, George; Garrett, Michelle D.; Sullivan, Daniel M.; de Bono, Johann S.; Tolcher, Anthony W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">4688-4695</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose AKT signaling is frequently deregulated in human cancers.  MK-2206 is a potent, oral allosteric inhibitor of all AKT isoforms with antitumor activity in preclin. models.  A phase I study of MK-2206 was conducted to investigate its safety, max.-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics (PDs), and preliminary antitumor efficacy.  Patients and Methods Patients with advanced solid tumors received MK-2206 on alternate days.  Paired tumor biopsies were mandated at the MTD for biomarker studies.  PD studies incorporated tumor and hair follicle analyses, and putative predictive biomarker studies included tumor somatic mutation analyses and immunohistochem. for phosphatase and tensin homolog (PTEN) loss.  Results Thirty-three patients received MK-2206 at 30, 60, 75, or 90 mg on alternate days.  Dose-limiting toxicities included skin rash and stomatitis, establishing the MTD at 60 mg.  Drug-related toxicities included skin rash (51.5%), nausea (36.4%), pruritus (24.2%), hyperglycemia (21.2%), and diarrhea (21.2%).  PKs (area under the concn.-time curve from 0 to 48 h and max. measured plasma concn.) were dose proportional.  Phosphorylated serine 473 AKT declined in all tumor biopsies assessed (P = .015), and phosphorylated threonine 246 proline-rich AKT substrate 40 was suppressed in hair follicles at 6 h (P = .008), on days 7 (P = .028) and 15 (P = .025) with MK-2206; reversible hyperglycemia and increases in insulin c-peptide were also obsd., confirming target modulation.  A patient with pancreatic adenocarcinoma (PTEN loss; KRAS G12D mutation) treated at 60 mg on alternate days experienced a decrease of approx. 60% in cancer antigen 19-9 levels and 23% shrinkage in tumor measurements.  Two patients with pancreatic neuroendocrine tumors had minor tumor responses.  Conclusion MK-2206 was well tolerated, with evidence of AKT signaling blockade.  Rational combination trials are ongoing to maximize clin. benefit with this therapeutic strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdHD9mhSwVT7Vg90H21EOLACvtfcHk0lhlD7P9XHDs-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlOnsLw%253D&md5=2ee8b8985e337a161807b9c862b573d2</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1200%2FJCO.2011.35.5263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2011.35.5263%26sid%3Dliteratum%253Aachs%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DFearen%26aufirst%3DI.%26aulast%3DOlmos%26aufirst%3DD.%26aulast%3DPapadopoulos%26aufirst%3DK.%26aulast%3DBaird%26aufirst%3DR.%2BD.%26aulast%3DDelgado%26aufirst%3DL.%26aulast%3DTaylor%26aufirst%3DA.%26aulast%3DLupinacci%26aufirst%3DL.%26aulast%3DRiisnaes%26aufirst%3DR.%26aulast%3DPope%26aufirst%3DL.%2BL.%26aulast%3DHeaton%26aufirst%3DS.%2BP.%26aulast%3DThomas%26aufirst%3DG.%26aulast%3DGarrett%26aufirst%3DM.%2BD.%26aulast%3DSullivan%26aufirst%3DD.%2BM.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DFirst-in-man%2520clinical%2520trial%2520of%2520the%2520oral%2520pan-AKT%2520inhibitor%2520MK-2206%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D29%26spage%3D4688%26epage%3D4695" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Rellos, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ivins, F. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pike, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nott, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parkinson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howell, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fedorov, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, Q. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smerdon, S. J.</span><span> </span><span class="NLM_article-title">Structure and regulation of the human Nek2 centrosomal kinase</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">6833</span><span class="NLM_x">–</span> <span class="NLM_lpage">6842</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=6833-6842&author=P.+Rellosauthor=F.+J.+Ivinsauthor=J.+E.+Baxterauthor=A.+Pikeauthor=T.+J.+Nottauthor=D.+M.+Parkinsonauthor=S.+Dasauthor=S.+Howellauthor=O.+Fedorovauthor=Q.+Y.+Shenauthor=A.+M.+Fryauthor=S.+Knappauthor=S.+J.+Smerdon&title=Structure+and+regulation+of+the+human+Nek2+centrosomal+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRellos%26aufirst%3DP.%26aulast%3DIvins%26aufirst%3DF.%2BJ.%26aulast%3DBaxter%26aufirst%3DJ.%2BE.%26aulast%3DPike%26aufirst%3DA.%26aulast%3DNott%26aufirst%3DT.%2BJ.%26aulast%3DParkinson%26aufirst%3DD.%2BM.%26aulast%3DDas%26aufirst%3DS.%26aulast%3DHowell%26aufirst%3DS.%26aulast%3DFedorov%26aufirst%3DO.%26aulast%3DShen%26aufirst%3DQ.%2BY.%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DSmerdon%26aufirst%3DS.%2BJ.%26atitle%3DStructure%2520and%2520regulation%2520of%2520the%2520human%2520Nek2%2520centrosomal%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D6833%26epage%3D6842" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Henise, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Irreversible Nek2 kinase inhibitors with cellular activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4133</span><span class="NLM_x">–</span> <span class="NLM_lpage">4146</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm200222m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4133-4146&author=J.+C.+Heniseauthor=J.+Taunton&title=Irreversible+Nek2+kinase+inhibitors+with+cellular+activity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Nek2 Kinase Inhibitors with Cellular Activity</span></div><div class="casAuthors">Henise, Jeffrey C.; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4133-4146</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A structure-based approach was used to design irreversible, cysteine-targeted inhibitors of the human centrosomal kinase, Nek2.  Potent inhibition of Nek2 kinase activity in biochem. and cell-based assays required a noncatalytic cysteine residue (Cys22), located near the glycine-rich loop in a subset of human kinases.  Elaboration of an oxindole scaffold led to our most selective compd., oxindole propynamide 16 (JH295).  Propynamide 16 irreversibly inhibited cellular Nek2 without affecting the mitotic kinases, Cdk1, Aurora B, or Plk1.  Moreover, 16 did not perturb bipolar spindle assembly or the spindle assembly checkpoint.  To our knowledge, 16 is the first small mol. shown to inactivate Nek2 kinase activity in cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq8mOvaT5BPbVg90H21EOLACvtfcHk0lhlD7P9XHDs-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmslGlsb4%253D&md5=35277e74fc346501e4847bba6586f9d0</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1021%2Fjm200222m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200222m%26sid%3Dliteratum%253Aachs%26aulast%3DHenise%26aufirst%3DJ.%2BC.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DIrreversible%2520Nek2%2520kinase%2520inhibitors%2520with%2520cellular%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4133%26epage%3D4146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Emmitte, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adjabeng, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alberti, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bambal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chamberlain, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis-Ward, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hassler, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hornberger, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuntz, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lansing, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nailor, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pobanz, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sung, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, M.</span><span> </span><span class="NLM_article-title">Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1694</span><span class="NLM_x">–</span> <span class="NLM_lpage">1697</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1016%2Fj.bmcl.2009.01.094" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=19237286" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXjtVSltrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1694-1697&author=K.+A.+Emmitteauthor=G.+M.+Adjabengauthor=C.+W.+Andrewsauthor=J.+G.+Albertiauthor=R.+Bambalauthor=S.+D.+Chamberlainauthor=R.+G.+Davis-Wardauthor=H.+D.+Dicksonauthor=D.+F.+Hasslerauthor=K.+R.+Hornbergerauthor=J.+R.+Jacksonauthor=K.+W.+Kuntzauthor=T.+J.+Lansingauthor=R.+A.+Mookauthor=K.+E.+Nailorauthor=M.+A.+Pobanzauthor=S.+C.+Smithauthor=C.+M.+Sungauthor=M.+Cheung&title=Design+of+potent+thiophene+inhibitors+of+polo-like+kinase+1+with+improved+solubility+and+reduced+protein+binding"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding</span></div><div class="casAuthors">Emmitte, Kyle A.; Adjebang, George M.; Andrews, C. Webb; Badiang-Alberti, Jennifer G.; Bambal, Ramesh; Chamberlain, Stanley D.; Davis-Ward, Ronda G.; Dickson, Hamilton D.; Hassler, Daniel F.; Hornberger, Keith R.; Jackson, Jeffrey R.; Kuntz, Kevin W.; Lansing, Timothy J.; Mook, Robert A.; Nailor, Kristen E.; Pobanz, Mark A.; Smith, Stephon C.; Sung, Chiu-Mei; Cheung, Mui</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1694-1697</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A series of thiophene PLK1 inhibitors was optimized for increased soly. and reduced protein binding through the appendage of basic amine functionality.  Interesting selectivity between PLK1 and PLK3 was also obtained through these modifications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLrXXbB1J4-rVg90H21EOLACvtfcHk0lgjD957P3NQOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXjtVSltrY%253D&md5=30831c589bae973ca9267dfea68971e1</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.01.094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.01.094%26sid%3Dliteratum%253Aachs%26aulast%3DEmmitte%26aufirst%3DK.%2BA.%26aulast%3DAdjabeng%26aufirst%3DG.%2BM.%26aulast%3DAndrews%26aufirst%3DC.%2BW.%26aulast%3DAlberti%26aufirst%3DJ.%2BG.%26aulast%3DBambal%26aufirst%3DR.%26aulast%3DChamberlain%26aufirst%3DS.%2BD.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DDickson%26aufirst%3DH.%2BD.%26aulast%3DHassler%26aufirst%3DD.%2BF.%26aulast%3DHornberger%26aufirst%3DK.%2BR.%26aulast%3DJackson%26aufirst%3DJ.%2BR.%26aulast%3DKuntz%26aufirst%3DK.%2BW.%26aulast%3DLansing%26aufirst%3DT.%2BJ.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNailor%26aufirst%3DK.%2BE.%26aulast%3DPobanz%26aufirst%3DM.%2BA.%26aulast%3DSmith%26aufirst%3DS.%2BC.%26aulast%3DSung%26aufirst%3DC.%2BM.%26aulast%3DCheung%26aufirst%3DM.%26atitle%3DDesign%2520of%2520potent%2520thiophene%2520inhibitors%2520of%2520polo-like%2520kinase%25201%2520with%2520improved%2520solubility%2520and%2520reduced%2520protein%2520binding%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1694%26epage%3D1697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Olmos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunetto, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yap, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taegtmeyer, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barriuso, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Degenhardt, Y. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allred, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lampkin, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dar, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Bono, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blagden, S. P.</span><span> </span><span class="NLM_article-title">Phase I study of GSK461364, a specific and competitive polo-like kinase 1 inhibitor, in patients with advanced solid malignancies</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">3420</span><span class="NLM_x">–</span> <span class="NLM_lpage">3430</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1158%2F1078-0432.CCR-10-2946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=21459796" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtVGit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2011&pages=3420-3430&author=D.+Olmosauthor=D.+Barkerauthor=R.+Sharmaauthor=A.+T.+Brunettoauthor=T.+A.+Yapauthor=A.+B.+Taegtmeyerauthor=J.+Barriusoauthor=H.+Medaniauthor=Y.+Y.+Degenhardtauthor=A.+J.+Allredauthor=D.+A.+Smithauthor=S.+C.+Murrayauthor=T.+A.+Lampkinauthor=M.+M.+Darauthor=R.+Wilsonauthor=J.+S.+de+Bonoauthor=S.+P.+Blagden&title=Phase+I+study+of+GSK461364%2C+a+specific+and+competitive+polo-like+kinase+1+inhibitor%2C+in+patients+with+advanced+solid+malignancies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid Malignancies</span></div><div class="casAuthors">Olmos, David; Barker, Douglas; Sharma, Rohini; Brunetto, Andre T.; Yap, Timothy A.; Taegtmeyer, Anne B.; Barriuso, Jorge; Medani, Hanine; Degenhardt, Yan Y.; Allred, Alicia J.; Smith, Deborah A.; Murray, Sharon C.; Lampkin, Thomas A.; Dar, Mohammed M.; Wilson, Richard; de Bono, Johann S.; Blagden, Sarah P.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3420-3430</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: GSK461364 is an ATP-competitive inhibitor of polo-like kinase 1 (Plk1).  A phase I study of two schedules of i.v. GSK461364 was conducted.  Exptl. Design: GSK461364 was administered in escalating doses to patients with solid malignancies by two schedules, either on days 1, 8, and 15 of 28-day cycles (schedule A) or on days 1, 2, 8, 9, 15, and 16 of 28-day cycles (schedule B).  Assessments included pharmacokinetic and pharmacodynamic profiles, as well as marker expression studies in pretreatment tumor biopsies.  RESULTS: Forty patients received GSK461364: 23 patients in schedule A and 17 in schedule B. Dose-limiting toxicities (DLT) in schedule A at 300 mg (2 of 7 patients) and 225 mg (1 of 8 patients) cohorts included grade 4 neutropenia and/or grade 3-4 thrombocytopenia.  In schedule B, DLTs of grade 4 pulmonary emboli and grade 4 neutropenia occurred at 7 or more days at 100 mg dose level.  Venous thrombotic emboli (VTE) and myelosuppression were the most common grade 3-4, drug-related events.  Pharmacokinetic data indicated that AUC (area under the curve) and Cmax (max. concn.) were proportional across doses, with a half-life of 9 to 13 h.  Pharmacodynamic studies in circulating tumor cells revealed an increase in phosphorylated histone H3 (pHH3) following drug administration.  A best response of prolonged stable disease of more than 16 wk occurred in 6 (15%) patients, including 4 esophageal cancer patients.  Those with prolonged stable disease had greater expression of Ki-67, pHH3, and Plk1 in archived tumor biopsies.  CONCLUSIONS: The final recommended phase II dose for GSK461364 was 225 mg administered i.v. in schedule A. Because of the high incidence (20%) of VTE, for further clin. evaluation, GSK461364 should involve coadministration of prophylactic anticoagulation.  Clin Cancer Res; 17(10); 3420-30.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOJ4inVI09-rVg90H21EOLACvtfcHk0lgjD957P3NQOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtVGit7c%253D&md5=3cf3213934f3a34aaeee469dc9cb6529</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-2946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-2946%26sid%3Dliteratum%253Aachs%26aulast%3DOlmos%26aufirst%3DD.%26aulast%3DBarker%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DBrunetto%26aufirst%3DA.%2BT.%26aulast%3DYap%26aufirst%3DT.%2BA.%26aulast%3DTaegtmeyer%26aufirst%3DA.%2BB.%26aulast%3DBarriuso%26aufirst%3DJ.%26aulast%3DMedani%26aufirst%3DH.%26aulast%3DDegenhardt%26aufirst%3DY.%2BY.%26aulast%3DAllred%26aufirst%3DA.%2BJ.%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DMurray%26aufirst%3DS.%2BC.%26aulast%3DLampkin%26aufirst%3DT.%2BA.%26aulast%3DDar%26aufirst%3DM.%2BM.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3Dde%2BBono%26aufirst%3DJ.%2BS.%26aulast%3DBlagden%26aufirst%3DS.%2BP.%26atitle%3DPhase%2520I%2520study%2520of%2520GSK461364%252C%2520a%2520specific%2520and%2520competitive%2520polo-like%2520kinase%25201%2520inhibitor%252C%2520in%2520patients%2520with%2520advanced%2520solid%2520malignancies%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2011%26volume%3D17%26spage%3D3420%26epage%3D3430" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Whelligan, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomson, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mas-Droux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barillari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burns, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grummitt, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayliss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span> </span><span class="NLM_article-title">Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">53</span><span class="NLM_x">, </span> <span class="NLM_fpage">7682</span><span class="NLM_x">–</span> <span class="NLM_lpage">7698</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1008727" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1Krs7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7682-7698&author=D.+K.+Whelliganauthor=S.+Solankiauthor=D.+Taylorauthor=D.+W.+Thomsonauthor=K.+M.+Cheungauthor=K.+Boxallauthor=C.+Mas-Drouxauthor=C.+Barillariauthor=S.+Burnsauthor=C.+G.+Grummittauthor=I.+Collinsauthor=R.+L.+van+Montfortauthor=G.+W.+Aherneauthor=R.+Baylissauthor=S.+Hoelder&title=Aminopyrazine+inhibitors+binding+to+an+unusual+inactive+conformation+of+the+mitotic+kinase+Nek2%3A+SAR+and+structural+characterization"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Aminopyrazine Inhibitors Binding to an Unusual Inactive Conformation of the Mitotic Kinase Nek2: SAR and Structural Characterization</span></div><div class="casAuthors">Whelligan, Daniel K.; Solanki, Savade; Taylor, Dawn; Thomson, Douglas W.; Cheung, Kwai-Ming J.; Boxall, Kathy; Mas-Droux, Corine; Barillari, Caterina; Burns, Samantha; Grummitt, Charles G.; Collins, Ian; van Montfort, Rob L. M.; Aherne, G. Wynne; Bayliss, Richard; Hoelder, Swen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">7682-7698</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We report herein the first systematic exploration of inhibitors of the mitotic kinase Nek2.  Starting from HTS hit aminopyrazine I, compds. with improved activity were identified using structure-based design.  Our structural biol. investigations reveal two notable observations.  First, I and related compds. bind to an unusual, inactive conformation of the kinase which to the best of our knowledge has not been reported for other types of kinase inhibitors.  Second, a phenylalanine residue at the center of the ATP pocket strongly affects the ability of the inhibitor to bind to the protein.  The implications of these observations are discussed, and the work described here defines key features for potent and selective Nek2 inhibition, which will aid the identification of more advanced inhibitors of Nek2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrhzgVaRXbQkrVg90H21EOLACvtfcHk0ljry5Je_sBPiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1Krs7nI&md5=d1a4af6869319bed0a340e8ff7db4397</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm1008727&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1008727%26sid%3Dliteratum%253Aachs%26aulast%3DWhelligan%26aufirst%3DD.%2BK.%26aulast%3DSolanki%26aufirst%3DS.%26aulast%3DTaylor%26aufirst%3DD.%26aulast%3DThomson%26aufirst%3DD.%2BW.%26aulast%3DCheung%26aufirst%3DK.%2BM.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DMas-Droux%26aufirst%3DC.%26aulast%3DBarillari%26aufirst%3DC.%26aulast%3DBurns%26aufirst%3DS.%26aulast%3DGrummitt%26aufirst%3DC.%2BG.%26aulast%3DCollins%26aufirst%3DI.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DBayliss%26aufirst%3DR.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DAminopyrazine%2520inhibitors%2520binding%2520to%2520an%2520unusual%2520inactive%2520conformation%2520of%2520the%2520mitotic%2520kinase%2520Nek2%253A%2520SAR%2520and%2520structural%2520characterization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7682%26epage%3D7698" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Solanki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Innocenti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mas-Droux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barillari, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Montfort, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayliss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span> </span><span class="NLM_article-title">Benzimidazole inhibitors induce a DFG-out conformation of never in mitosis gene A-related kinase 2 (Nek2) without binding to the back pocket and reveal a nonlinear structure–activity relationship</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">1626</span><span class="NLM_x">–</span> <span class="NLM_lpage">1639</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm1011726" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=1626-1639&author=S.+Solankiauthor=P.+Innocentiauthor=C.+Mas-Drouxauthor=K.+Boxallauthor=C.+Barillariauthor=R.+L.+van+Montfortauthor=G.+W.+Aherneauthor=R.+Baylissauthor=S.+Hoelder&title=Benzimidazole+inhibitors+induce+a+DFG-out+conformation+of+never+in+mitosis+gene+A-related+kinase+2+%28Nek2%29+without+binding+to+the+back+pocket+and+reveal+a+nonlinear+structure%E2%80%93activity+relationship"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1021%2Fjm1011726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm1011726%26sid%3Dliteratum%253Aachs%26aulast%3DSolanki%26aufirst%3DS.%26aulast%3DInnocenti%26aufirst%3DP.%26aulast%3DMas-Droux%26aufirst%3DC.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DBarillari%26aufirst%3DC.%26aulast%3Dvan%2BMontfort%26aufirst%3DR.%2BL.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DBayliss%26aufirst%3DR.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DBenzimidazole%2520inhibitors%2520induce%2520a%2520DFG-out%2520conformation%2520of%2520never%2520in%2520mitosis%2520gene%2520A-related%2520kinase%25202%2520%2528Nek2%2529%2520without%2520binding%2520to%2520the%2520back%2520pocket%2520and%2520reveal%2520a%2520nonlinear%2520structure%25E2%2580%2593activity%2520relationship%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D1626%26epage%3D1639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group">Innocenti, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, K. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solanki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mas-Droux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowan, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yeoh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boxall, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlake, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hardy, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aherne, G. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bayliss, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hoelder, S.</span><span> </span><span class="NLM_article-title">Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure–activity relationship, structural biology, and cellular activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3228</span><span class="NLM_x">–</span> <span class="NLM_lpage">3241</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201683b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3228-3241&author=P.+Innocentiauthor=K.+M.+Cheungauthor=S.+Solankiauthor=C.+Mas-Drouxauthor=F.+Rowanauthor=S.+Yeohauthor=K.+Boxallauthor=M.+Westlakeauthor=L.+Pickardauthor=T.+Hardyauthor=J.+E.+Baxterauthor=G.+W.+Aherneauthor=R.+Baylissauthor=A.+M.+Fryauthor=S.+Hoelder&title=Design+of+potent+and+selective+hybrid+inhibitors+of+the+mitotic+kinase+Nek2%3A+structure%E2%80%93activity+relationship%2C+structural+biology%2C+and+cellular+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm201683b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201683b%26sid%3Dliteratum%253Aachs%26aulast%3DInnocenti%26aufirst%3DP.%26aulast%3DCheung%26aufirst%3DK.%2BM.%26aulast%3DSolanki%26aufirst%3DS.%26aulast%3DMas-Droux%26aufirst%3DC.%26aulast%3DRowan%26aufirst%3DF.%26aulast%3DYeoh%26aufirst%3DS.%26aulast%3DBoxall%26aufirst%3DK.%26aulast%3DWestlake%26aufirst%3DM.%26aulast%3DPickard%26aufirst%3DL.%26aulast%3DHardy%26aufirst%3DT.%26aulast%3DBaxter%26aufirst%3DJ.%2BE.%26aulast%3DAherne%26aufirst%3DG.%2BW.%26aulast%3DBayliss%26aufirst%3DR.%26aulast%3DFry%26aufirst%3DA.%2BM.%26aulast%3DHoelder%26aufirst%3DS.%26atitle%3DDesign%2520of%2520potent%2520and%2520selective%2520hybrid%2520inhibitors%2520of%2520the%2520mitotic%2520kinase%2520Nek2%253A%2520structure%25E2%2580%2593activity%2520relationship%252C%2520structural%2520biology%252C%2520and%2520cellular%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3228%26epage%3D3241" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Torrance, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jackson, P. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montgomery, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinzler, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vogelstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nunes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frost, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span> </span><span class="NLM_article-title">Combinatorial chemoprevention of intestinal neoplasia</span> <span class="citation_source-journal">Nat. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1024</span><span class="NLM_x">–</span> <span class="NLM_lpage">1028</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1038%2F79534" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=10973323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmslSju7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2000&pages=1024-1028&author=C.+J.+Torranceauthor=P.+E.+Jacksonauthor=E.+Montgomeryauthor=K.+W.+Kinzlerauthor=B.+Vogelsteinauthor=A.+Wissnerauthor=M.+Nunesauthor=P.+Frostauthor=C.+M.+Discafani&title=Combinatorial+chemoprevention+of+intestinal+neoplasia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Combinatorial chemoprevention of intestinal neoplasia</span></div><div class="casAuthors">Torrance, Christopher J.; Jackson, Peta E.; Montgomery, Elizabeth; Kinzler, Kenneth W.; Vogelstein, Bert; Wissner, Allan; Nunes, Maria; Frost, Philip; Discafani, Carolyn M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York)</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1024-1028</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature America Inc.</span>)
        </div><div class="casAbstract">A combination of two drugs afforded remarkable protection from intestinal neoplasia in APCMin/+ mice, a murine model of human familial adenomatous polyposis (FAP).  One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventive activity.  The second drug was EKB569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase.  Although 100% of the untreated APCMin/+ mice developed -20 polyps, nearly half the mice treated with these two agents developed no polyps at all.  These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoysAYwWewtCrVg90H21EOLACvtfcHk0ljry5Je_sBPiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmslSju7g%253D&md5=2b1da2bdcd72fec51856ff25643efd4c</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1038%2F79534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F79534%26sid%3Dliteratum%253Aachs%26aulast%3DTorrance%26aufirst%3DC.%2BJ.%26aulast%3DJackson%26aufirst%3DP.%2BE.%26aulast%3DMontgomery%26aufirst%3DE.%26aulast%3DKinzler%26aufirst%3DK.%2BW.%26aulast%3DVogelstein%26aufirst%3DB.%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DNunes%26aufirst%3DM.%26aulast%3DFrost%26aufirst%3DP.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26atitle%3DCombinatorial%2520chemoprevention%2520of%2520intestinal%2520neoplasia%26jtitle%3DNat.%2520Med.%26date%3D2000%26volume%3D6%26spage%3D1024%26epage%3D1028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Rabindran, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosfjord, E. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baxter, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Golas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallett, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Overbeek, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsou, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">3958</span><span class="NLM_x">–</span> <span class="NLM_lpage">3965</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1158%2F0008-5472.CAN-03-2868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=15173008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=3958-3965&author=S.+K.+Rabindranauthor=C.+M.+Discafaniauthor=E.+C.+Rosfjordauthor=M.+Baxterauthor=M.+B.+Floydauthor=J.+Golasauthor=W.+A.+Hallettauthor=B.+D.+Johnsonauthor=R.+Nilakantanauthor=E.+Overbeekauthor=M.+F.+Reichauthor=R.+Shenauthor=X.+Shiauthor=H.+R.+Tsouauthor=Y.+F.+Wangauthor=A.+Wissner&title=Antitumor+activity+of+HKI-272%2C+an+orally+active%2C+irreversible+inhibitor+of+the+HER-2+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase</span></div><div class="casAuthors">Rabindran, Sridhar K.; Discafani, Carolyn M.; Rosfjord, Edward C.; Baxter, Michelle; Floyd, M. Brawner; Golas, Jonathan; Hallett, William A.; Johnson, Bernard D.; Nilakantan, Ramaswamy; Overbeek, Elsebe; Reich, Marvin F.; Shen, Ru; Shi, Xiaoqing; Tsou, Hwei-Ru; Wang, Yu-Fen; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3958-3965</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER-2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of cancers.  Overexpression of HER-2 is seen in 25-30% of breast cancer patients and predicts a poor outcome in patients with primary disease.  Trastuzumab (Herceptin), a monoclonal antibody to HER-2, is specifically approved for HER-2-pos. breast cancer but is active only in a subset of these tumors.  Blocking HER-2 function by a small mol. kinase inhibitor, therefore, represents an attractive alternate strategy to inhibit the growth of HER-2-pos. tumors.  HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro.  It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.  HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor.  In agreement with the predicted effects of HER-2 inactivation, HKI-272 treatment of cells results in inhibition of downstream signal transduction events and cell cycle regulatory pathways.  This leads to arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle, ultimately resulting in decreased cell proliferation.  In vivo, HKI-272 is active in HER-2- and EGFR-dependent tumor xenograft models when dosed orally on a once daily schedule.  On the basis of its favorable preclin. pharmacol. profile, HKI-272 has been selected as a candidate for addnl. development as an antitumor agent in breast and other HER-2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2xeLXlAwWvbVg90H21EOLACvtfcHk0ljwev6RSmCNBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D&md5=60accd0599b7c489e4c3753d4f39cab4</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2868%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DBaxter%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DAntitumor%2520activity%2520of%2520HKI-272%252C%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520HER-2%2520tyrosine%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D3958%26epage%3D3965" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Trott, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olson, A. J.</span><span> </span><span class="NLM_article-title">AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">455</span><span class="NLM_x">–</span> <span class="NLM_lpage">461</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1002%2Fjcc.21334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=19499576" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2010&pages=455-461&author=O.+Trottauthor=A.+J.+Olson&title=AutoDock+Vina%3A+improving+the+speed+and+accuracy+of+docking+with+a+new+scoring+function%2C+efficient+optimization%2C+and+multithreading"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</span></div><div class="casAuthors">Trott, Oleg; Olson, Arthur J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Computational Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">455-461</span>CODEN:
                <span class="NLM_cas:coden">JCCHDD</span>;
        ISSN:<span class="NLM_cas:issn">0192-8651</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">AutoDock Vina, a new program for mol. docking and virtual screening, is presented.  AutoDock Vina achieves an approx. 2 orders of magnitude speed-up compared with the mol. docking software previously developed in the authors' lab (AutoDock 4), while also significantly improving the accuracy of the binding mode predictions, judging by the authors' tests on the training set used in AutoDock 4 development.  Further speed-up is achieved from parallelism, by using multithreading on multicore machines.  AutoDock Vina automatically calcs. the grid maps and clusters the results in a way transparent to the user.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpLecOIkUxIlrVg90H21EOLACvtfcHk0ljwev6RSmCNBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsFGnur3O&md5=c6974af8a1235f7aa09918d3e6f70dc4</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fjcc.21334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcc.21334%26sid%3Dliteratum%253Aachs%26aulast%3DTrott%26aufirst%3DO.%26aulast%3DOlson%26aufirst%3DA.%2BJ.%26atitle%3DAutoDock%2520Vina%253A%2520improving%2520the%2520speed%2520and%2520accuracy%2520of%2520docking%2520with%2520a%2520new%2520scoring%2520function%252C%2520efficient%2520optimization%252C%2520and%2520multithreading%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D2010%26volume%3D31%26spage%3D455%26epage%3D461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Nie, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feher, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Natala, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McBride, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiryanov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaldor, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stafford, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hikami, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchiyama, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hikichi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumoto, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amano, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosfield, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skene, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ichikawa, T.</span><span> </span><span class="NLM_article-title">Discovery of TAK-960: an orally available small molecule inhibitor of polo-like kinase 1 (PLK1)</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">3662</span><span class="NLM_x">–</span> <span class="NLM_lpage">3666</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Fjm401719n&amp;key=10.1016%2Fj.bmcl.2013.02.083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Fjm401719n&amp;key=23664874" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Fjm401719n&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnsVyksr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2013&pages=3662-3666&author=Z.+Nieauthor=V.+Feherauthor=S.+Natalaauthor=C.+McBrideauthor=A.+Kiryanovauthor=B.+Jonesauthor=B.+Lamauthor=Y.+Liuauthor=S.+Kaldorauthor=J.+Staffordauthor=K.+Hikamiauthor=N.+Uchiyamaauthor=T.+Kawamotoauthor=Y.+Hikichiauthor=S.+Matsumotoauthor=N.+Amanoauthor=L.+Zhangauthor=D.+Hosfieldauthor=R.+Skeneauthor=H.+Zouauthor=X.+Caoauthor=T.+Ichikawa&title=Discovery+of+TAK-960%3A+an+orally+available+small+molecule+inhibitor+of+polo-like+kinase+1+%28PLK1%29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of TAK-960: An orally available small molecule inhibitor of polo-like kinase 1 (PLK1)</span></div><div class="casAuthors">Nie, Zhe; Feher, Victoria; Natala, Srinivasa; McBride, Christopher; Kiryanov, Andre; Jones, Benjamin; Lam, Betty; Liu, Yan; Kaldor, Stephen; Stafford, Jeffrey; Hikami, Kouki; Uchiyama, Noriko; Kawamoto, Tomohiro; Hikichi, Yuichi; Matsumoto, Shin-ichi; Amano, Nobuyuki; Zhang, Lilly; Hosfield, David; Skene, Robert; Zou, Hua; Cao, Xiaodong; Ichikawa, Takashi</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3662-3666</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Using structure-based drug design, the authors identified and optimized a novel series of pyrimidodiazepinone PLK1 inhibitors resulting in the selection of the development candidate TAK-960 (I).  TAK-960 is currently undergoing Phase I evaluation in adult patients with advanced solid malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo06c_HY-gD-LVg90H21EOLACvtfcHk0ljwev6RSmCNBg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnsVyksr0%253D&md5=25dca079405c47098fd261a77ceccf53</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2013.02.083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2013.02.083%26sid%3Dliteratum%253Aachs%26aulast%3DNie%26aufirst%3DZ.%26aulast%3DFeher%26aufirst%3DV.%26aulast%3DNatala%26aufirst%3DS.%26aulast%3DMcBride%26aufirst%3DC.%26aulast%3DKiryanov%26aufirst%3DA.%26aulast%3DJones%26aufirst%3DB.%26aulast%3DLam%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKaldor%26aufirst%3DS.%26aulast%3DStafford%26aufirst%3DJ.%26aulast%3DHikami%26aufirst%3DK.%26aulast%3DUchiyama%26aufirst%3DN.%26aulast%3DKawamoto%26aufirst%3DT.%26aulast%3DHikichi%26aufirst%3DY.%26aulast%3DMatsumoto%26aufirst%3DS.%26aulast%3DAmano%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DHosfield%26aufirst%3DD.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DCao%26aufirst%3DX.%26aulast%3DIchikawa%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520TAK-960%253A%2520an%2520orally%2520available%2520small%2520molecule%2520inhibitor%2520of%2520polo-like%2520kinase%25201%2520%2528PLK1%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D23%26spage%3D3662%26epage%3D3666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm401719n&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2014.57.issue-14%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Fjm401719n%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm401719n" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a8bd148893c46","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
